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1. Histamine and its receptors 
 
1.1 Histamine 
Histamine1 (2-(1H-imidazol-4-yl)ethanamine), is a biogenic amine formed from L-
histidine by the enzyme called histidine decarboxylase or an ubiquitous L-amino acid 
decarboxylase. Histamine is present in many plants and found in nearly all animal tissues 
where it was detected in different cell types including mast cells, basophils, platelets, 
endothelial and neuronal cells.2 Highest concentration of histamine is found in lungs, skin, 
and the gastrointestinal tract. Histamine plays a role as chemical messenger and transfers 
signals from one cell to another. As such histamine is also able to induce numerous 
physiological and pathophysiological effects like contraction of smooth muscle, stimulation of 
hormone release, modulation of immune responses, gastric acid secretion, induction of sleep 
and cognitive processes. 
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Figure 1.1 Tautomeric forms of histamine 
 
Histamine exists in two tautomeric forms, termed NτH and NpiH (Fig. 1.1). The ratio 
between the tautomers, NτH and NpiH is approximately 4:1 in an aqueous environment. 
Histamine is basic and the pKa of the α-amino group and the imidazole moiety is 9.7 and 5.9 
respectively. Therefore histamine can exist as a dication whereby stabilizing protonated 
moieties through the delocalization of the positive charge. At physiological pH only the 
primary amino group is protonated. 
 
1.2 Metabolism of histamine 
The histamine N-methyltransferase (HNMT) plays an important role in metabolism of 
histamine within the human airways and gut. It is the only enzyme responsible for the 
termination of neurotransmitter actions.3 The HNMT inactivates histamine by transferring a 
methyl group from S-adenosyl-L-methionine to the imidazole ring. Inactive Nτ-
methylhistamine is excreted in urine or can be further oxidized by diamine oxidase (DAO) or 
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monoamine oxidase (MAO) into Nτ-methyl-imidazole-aldehyde, which can be further 
oxidized into its corresponding acid (Fig. 1.2). The histamine metabolism pathway starting 
with DAO is only relevant in Peripheral Nervous System (PNS). 
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Figure 1.2 Metabolism of histamine 
 
1.3 Classification of ligands 
Ligands can be classified mainly into agonists, partial agonists, antagonists and 
inverse agonists based on the biological response they provoke. 
Agonists: An agonist is a substance that binds to a receptor and triggers a response in the cell. 
Partial agonists: Partial agonists are compounds that have a submaximal tissue response 
even if they fully occupy the receptor. 
Antagonists: A ligand that binds to a receptor without causing activation but impending 
agonist binding has been termed as antagonist. 
Inverse agonists: Inverse agonists are ligands that reduce the constitutive or basal activity.  
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Figure 1.3 Two state receptor activation model of receptors 
 
Figure 1.3 represents the classical two-state receptor model, however currently this 
model is discussed controversially, as there is evidence for different coexisting receptor 
conformations.  
 
1.4 Histamine H1-Receptors  
 
Table 1.1 A short overview on histamine H1-Receptors (H1Rs) 
 
Family G-protein coupled receptors (GPCRs) 
Protein sequence 487 aa (human), 486 (rat), 489 (mouse) 
Homology to other 
receptors 
hH2R (40% in TM domains), hH3R (20%), hH4R (20%) 
Molecular functions Contraction of smooth muscles in ileum, bronchi and uterus  
Increase in the permeability of the capillaries 
Stimulation of hormone release (adrenal medulla) 
Vasoconstriction via receptors at vascular smooth muscles 
Vasodilation via NO release from endothelial cells. 
CNS: regulation of wakefulness. 
Potential therapeutic 
applications  
Agonists: Therapeutic applications for agonists have not yet 
been established, are potential diagnostic tools 
Antagonists: Play a prominent role in the symptomatic 
treatment of allergy, motion sickness and vertigo and can also 
be used as mild sedatives. 
Isoforms No isoforms known so far 
Species differences Marked differences in the potency of antagonists for species 
homologues of the H1R 
Signal transduction The primary mechanism by which H1 receptors produce 
functional responses is via Gq/11-mediated activation of 
phospholipase C (PLC) and Ca2+ mobilization 
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Histamine exerts its pharmacological effects via four different receptor subtypes H1-
H4.4,5 Dale and Laidlaw in 1910 observed the stimulation of the smooth muscles and 
vasodilation by histamine.6 Later, Ash and Schild in 1966 identified this receptor and named 
as histamine H1R.7 The H1Rs, located on chromosome 3 of human genome are coupled via 
Gq/11 proteins. In the CNS, H1Rs are expressed in the thalamus, hippocampus, cortex, 
amygdala, and the basal forebrain. Outside the CNS, the H1Rs are widely expressed in tissue 
such as ileum, smooth muscles of airways and vasculature, and heart. A short overview on 
histamine H1R is given in Table 1.1, for detailed information see chapter 2.1. 
 
1.5 Histamine H2-Receptor 
Histamine H2-Receptor (H2R)8 was pharmacologically characterized by Black et al. in 
1972. H2R is widely distributed in the brain; highest densities are found in basal ganglia, 
hippocampus, amygdala and cerebral cortex.9 It is also found with lower densities in 
cerebellum and hypothalamus.9 In the periphery H2R was found in gastric cells, cardiac tissue, 
airway, uterine and the vascular smooth muscle.4 The important features of histamine H2R are 
given in Table 1.2. 
 
Table 1.2 A short overview on histamine H2-Receptors (H2Rs) 
 
Family G-protein coupled receptors (GPCRs) 
Protein sequence 359 aa (human, mouse) 358 (rat)  
Homology to other 
receptors 
hH1R (41% in TM domains), hH3R (22%), hH4R (20%)  
Molecular functions Stimulation of gastric acid secretion 
Positive inotropic and chronotropic effects on the heart 
Vasodilation 
Stimulation of adenylyl cyclase activity in guinea-pig 
hippocampal membranes 
Cardiac stimulation (increase of rate and output of heart action) 
Potential therapeutic 
applications  
Agonists: Congestive heart failure 
Antagonist: Treatment of gastric and duodenal ulcer 
Isoforms No isoforms known so far 
Species differences Significant differences in the potency of antagonists for species 
homologues of the H1R 
Signal transduction Coupled positively to adenylyl cyclase via Gs, leading to the 
formation of cAMP which is responsible for other effects like 
activation of H+/K+ -ATPase in the cytosole of the parietal cell 
resulting in the stimulation of gastric acid secretion.  
 
Histamine and its receptor  
 
5
 
1.6 Histamine H3-Receptor s 
The discovery of a third receptor subtype came in 1983 when Arrang et al. found that 
the histamine inhibits its own release from the depolarized slices of rat cerebral cortex by an 
action mediated by another receptor subtype which is pharmacologically different from the H1 
and H2 receptors. This novel receptor was named H3R,10 subsequently characterized11 in 1987 
and recently cloned12 in 1999 by Lovenberg et al. A short overview on histamine H3-Receptor 
(H3R) is given in Table 1.3, detailed information is given in chapter 3.1. 
 
Table 1.3 A short overview on histamine H3-Receptors (H3Rs) 
 
Family G-protein coupled receptors (GPCRs) 
Protein sequence 445 aa (human H3R) 
Homology to other 
receptors 
hH1R (20%), hH2R (22%), hH4R (37%, 58% in TM-domains) 
and other biogenic aminergic receptors (20-27%) 
Gene organization Most likely three exons and two introns. 
Histamine affinity pKi = 7.8 (human H3R) 
Molecular functions Autoreceptor: Inhibition of histamine synthesis 
Heteroreceptor: In CNS, modulation of release of dopamine, 
noradrenaline, serotonin, GABA, glutamate 
In peripheral nervous system, acetylcholine, neuropeptides. 
Potential therapeutic 
applications  
Agonists: Insomnia, antinociceptive, myocardial ischaemic 
arrhythmias (via modulation of noradrenaline liberation) 
Antagonists: In the treatment of obesity, narcolepsy, attention 
deficient hyperactivity disorder (ADHD), schizophrenia, 
Alzheimer’s disease, and nasal congestion (in combination with 
H1R antagonists). 
Splice variants More than 20 isoforms known in four different parts of receptor 
gene. 
With a shortened amino terminal end. 
With a partial deletion of TM2 and E1loop. 
With a variable length of E3 loop and finally 
With an elongated C-terminal end. 
Species differences More than 92% sequence conservation in human, mouse, rat, 
guinea-pig and monkey H3Rs. 
Comparable profiles for agonists but different pharmacological 
profile for inverse agonists/antagonists. 
Signal transduction Coupling to Gi/o and inhibition of adenylyl cyclase → cAMP ↓  
Other probable pathways include MAP kinase via βγ subunits, 
modulation of Ca2+ levels (agonists → Ca2+ ↓ → 
neurotransmitter release↓) 
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1.7 Histamine H4-Receptor s 
The histamine H4-Receptor (H4R)13 is less widely expressed than other histamine 
receptors. In CNS, H4R is found mainly in the cerebellum and at much lower levels in the 
hippocampus.14 Outside the CNS H4R is found in medullary and peripheral hematopoetic cells 
such as eosinophils, neutrophils, and CD4+ T-cells, suggesting an important role for the H4R 
in the immune system. A short overview on histamine H4R is given in Table 1.4. 
 
Table 1.4 A short overview on histamine H4 receptor (H4R) 
 
Family G-protein coupled receptors (GPCRs) 
Protein sequence 390 amino acids (human H4R) 
Homology to other 
receptors 
hH1R (20%, 26% in TM-domains), hH2R (20%, 27% in TM-
domains), hH3R (37%, 58% in TM-domains)  
Histamine affinity pKi = 7.8 - 8.4 
Gene organization Contains two introns and three exons. 
Molecular functions Involved in various brain functions. 
Chemotaxis of eosinophils of mast cells to histamine; control 
of IL-16 release from CD8+ T-cells 
It can play a role in inflammatory response. 
Potential therapeutic 
applications 
Antiinflammatory, allergic rhinitis (via mast cells), asthma 
(via mast cells, eosinophils and T-cells) atopic dermatitis. 
Autoimmune diseases like rheumatoid arthritis, multiple 
sclerosis, type I diabetes and systemic lupus erythematous 
(via dendritic or T-cells.) 
Splice variants No splice variants known so far. 
Species differences Has been cloned from different species including, rat, mouse, 
pig and guinea-pig and share only 65-72% homology 
Similar expression patterns but pharmacological profiles and 
signal transduction responses are dissimilar. 
Signal transduction Coupling to Gi/o and inhibition of adenylyl cyclase →    
cAMP ↓  
In mast cells probably linked to PLC → release of Ca2+ from 
ER 
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2. Side-chain modified analogues of histaprodifen: Asymmetric 
synthesis and histamine H1-Receptor activity 
 
2.1 Introduction  
Histamine1 is known to exert its pharmacological effects via four different receptor 
subtypes, H1-H4 receptors.4,15 Dale and Laidlaw described the stimulation of smooth muscles 
and vasodilation by histamine for the first time in 1910.6 Later in 1966, Ash and Schild 
identified the histamine H1-Receptor (H1R).7 The H1R is widely distributed in different 
mammalian tissues including brain, smooth muscles from airways, gastrointestinal tract, 
genitourinary system, the cardiovascular system, adrenal medulla, endothelial cells and 
lymphocytes.2 H1R antagonists have been used in the therapy of many allergic diseases, 
including urticaria, allergic rhinitis, pollenosis, and bronchial asthma. Nowadays H1R 
antagonists play a prominent role in the symptomatic treatment of allergies, motion sickness, 
and vertigo, and are also used as mild sedatives.16 On the other hand therapeutic applications 
for H1R agonists have not yet been established. There are different reasons responsible for 
this, mainly that H1Rs are involved in pathological processes and knowledge of H1R mediated 
physiological and pathophysiological functions is still limited, especially in the central 
nervous system (CNS). Until recently, highly potent and selective H1R agonists were not 
available. To review the most promising aspects of receptor activations, the development of 
potent and selective H1R agonists is highly demanding. 
 
2.1.1 Molecular architecture of histamine H1Rs 
The histamine H1R belongs to the super family of G-protein coupled receptors. 
Identification of H1R came in 1966 when Ash and Schild7 found the specific antagonism of 
some actions of histamine by low concentrations of antihistamine drugs. The human 
histamine H1R protein consists of 487 amino acids and is predicted to have seven 
transmembrane (TM) domains along with a helix VIII (Fig. 2.1.1), which is supposed to be 
perpendicular to the TM domains. Histamine H1Rs possess a large third intracellular loop 
(197 amino acids) and a short carboxyl terminal, which are common characteristics among 
Ca2+-mobilizing receptors.17 The genomic cloning of H1Rs from cattle,18 rats,19 guinea-pig20,21 
and human22 has led to valuable knowledge regarding the pharmacochemistry of the H1R. 
Overall, homology among the different H1Rs is more than 60%. Moreover, in TM domains it 
is more than 90%. The residue Asp 107 in TM-III is one of the most crucial amino acids for 
the binding of H1R agonists and antagonists.23,24 Other binding sites include Asp 73 in TM-II, 
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Asp 124 and Arg 125 as cationic and anionic sites, respectively, at the cytoplasmic border of 
TM-III and the ten amino acid residues Leu 455 to Pro 464 in the seventh TM domain. 
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Figure 2.1.1 Snake plot of human histamine H1R protein 
 
Amino acids represented in gray circles belong to the intra and extracellular loop of 
the receptor protein. Amino acids shown in black bold circles point to the head groups of the 
lipids and belong to the TM domains. Blue circles represent the amino acids that point to the 
lipid and belong to the TM domains. Amino acids pointing inside the binding crevice are 
shown with red circles and also belong to the TM domain. Amino acids with gray background 
represent the most conserved amino acids. Amino acids designated with red letters represent 
the potential binding sites. 
 
2.1.2 Signal transduction pathways for histamine H1Rs  
The histamine H1Rs are coupled to G-proteins in the region of the second and third 
intracellular loop (Fig. 2.2.2). On activation with H1R agonists, the receptor subsequently 
stimulates the connected phospholipase C (PLPC) in the cytoplasmic membrane.25 The PLPC 
catalyzes the inositol-phosphate-cycle leading to the formation of inositol 1,4,5-trisphospate 
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(IP3) and 1,2-diacylglycerol (DAG).26 IP3 interacts with its own receptors and releases Ca2+ 
into the cytosole under participation of ion channels.27 Free Ca2+ ions bind to the calmodulin 
(CaM) and stimulate the NO synthesis (NOS)28 leading to the enzymatic nitric oxide 
production29 and subsequently to the stimulation of guanylylcyclase (GC) and thus to the 
formation of cGMP from GTP.30 Ca2+ ions also activate phosphorylase which leads to the 
glycogenic response. Significantly H1R stimulation is connected with an influx of 
extracellular Ca2+ ions.31 The possible mechanisms for this effect are the opening of voltage-
dependent Ca2+-chanals (VDC) or receptor-operated Ca2+-channels (ROC). 
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Figure 2.1.2 Signal transduction pathways for histamine H1R  
 
2.1.3 Histamine H1-Receptor agonists 
Since the identification of histamine H1R by Ash and Schild,7 histamine H1R agonists 
have gained significant importance for the investigation of H1R mediated effects, such as 
neuroregulation of arousal,32-34 allergy, modulation of cardiovascular parameters,35,36 and 
release of endothelium derived relaxing factor.35,37,38 Studies of these effects have always 
been hampered by the lack of highly potent and selective histamine H1R agonists. In contrast, 
for the histamine H2 and H3 receptors, highly potent agonists have been described which 
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exceed the potency of the endogenous ligand histamine by a factor of 10 to 100.11,39-41 The use 
of the endogenous ligand histamine is not helpful because it often requires the concomitant 
presence of H2 and H3 receptor blockers, as histamine is able to activate H2 and H3 receptors. 
The search for the potent and high affinity H1R agonists has been an arduous task for several 
decades.4,42 
 
2.1.4 Developments in histamine H1R agonists 
Since the first chemical synthesis of histamine1 by Windaus et al. in early 1900’s, 
numerous derivatives were synthesized, possessing the imidazole as a common feature. The 
year 1941 can be considered as the “year of the birth of H1R agonists” when Walter et al.43 
synthesized a series of pyridylalkanamines and recognized that 2-(pyridine-2-yl)ethanamine 
(17) possesses H1-histaminergic effects. Since then numerous heterocyclic analogues of 
histamine have been synthesized and screened for histamine H1R agonist activity.44 
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Figure 2.1.3 Five-membered heterocyclic analogues of histamine 
 
Pharmacological data of some five membered heterocyclic analogues of histamine are 
summarized in Figure 2.1.3. Among five membered heterocyclic analogues 3, 4 and 5 were 
able to stimulate H1R and showed very weak agonism.45 Triazole analogues like 7 and 8 were 
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weak agonists but 9 and 10 were inactive. Heterocyclic analogues 12, 15 and 16 with two 
hetero atoms were relatively more potent H1R agonists.46 But histamine derivative 2 with 
ethylamine side chain connected to imidazole nitrogen was found to be inactive.47 
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Figure 2.1.4 Six-membered heterocyclic analogues of histamine 
 
Replacement of the imidazole ring with six membered nitrogen heterocycles did not 
increase the agonistic activity. Compounds 17 and 21 in which the ethylamine side chain is 
attached to the ortho position to a heterocyclic nitrogen atom elicit histaminergic response.46 
From the data obtained from five and six membered heterocyclic analogues it can be 
concluded that replacing the 4-sustituted imidazole by other azole, di- or triazole, isoxazole, 
or six membered heterocycles, such as azine, diazine or by benzene nuclei reduces H1R 
agonistic potency. However, these data also indicate that imidazole nucleus is not compulsory 
for the H1R agonistic activity. 
 
2.1.5 Search for selective H1R agonists 
From the historical perspective the work on methylated histamines is very 
significant.48,49 Further improvement of the selectivity for one of the three receptor subtypes 
was possible by methylation (Fig. 2.1.5). Durant et al.49 carried out the methylation of 
histamine at different positions. Methylation at C2 position of histamine led to 2-
methylhistamine (27, Fig. 2.1.6), which is a selective H1R agonist. On the other hand, 
methylation at the C5 position of histamine led to 5-methylhistamine (32),10 which is a 
selective agonist for the histamine H2R. Later, in 1987 Arrang et al.11 found that the α-
methylhistamine is a very selective agonists for the histamine H3R. Looking at this trend, the 
development of selective agonist for the newly found histamine H4R could also be achieved50 
by incorporating the methyl group at specific positions of histamine. 
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Figure 2.1.5 Methylhistamines, selective keys for single locks 
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Figure 2.1.6 Methyl substituents in histamine 
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Incorporation of methyl groups at different positions of the histamine molecule 
yielded many different analogues10 and among them 2-substituted analogues were found to be 
H1 selective (Fig. 2.1.6). Nα-methyl analogue 25 was equipotent with histamine but was not 
H1 selective, however compound 28 showed quite good activity and selectivity. 
Unfortunately, none of the compounds showed more activity than histamine itself. Table 2.1.1 
elaborates in details the effect of methyl group on H1R agonistic activity of histamine. 
 
Table 2.1.1 Effect of methyl group on H1R agonistic activity of histamine 
 
Comp. Position of 
methyl group 
Rel. Pot. 
(Emax) Comp. 
Position of 
methyl group 
Rel. Pot. 
(Emax) 
30 pi inactive 37 5, Να 0.2-1 % 
31 τ 0.5 % 38 5, α 0.1 % 
32 5 0.2-1 % 39 β, β inactive 
33 α 0.4 % 40 α, α - 
34 β 0.8 % 41 α Να 0.7 % 
35 2, 5 0.3 % 42 5, Να, Να 0.1 % 
36 τ, Να 0.7 % 43 Να, Να, Να 1 % 
 
Methylation at C2 and C5 led to the selective agonists for H1 and H2 receptors 
respectively, and these properties remain unchanged in the case of mono- (28) and 
dimethylation (29) of the Nα-atom of 27. Methylation at other positions in histamine did not 
increase H1-agonistic activity (Table 2.1.1). Moreover ring methylation led to a significant 
loss of activity in the case of Nτ-methylhistamine (31), the main metabolite of histamine, and 
complete loss of activity in the case of Npi-methylhistamine (30). 
 
2.1.6 Histamine derivatives modified at C2 position 
Inspired from the results of 2-methylated histamines, many derivatives having a 
variety of substituents were synthesized and screened for histamine H1-agonistic activity 
(Table 2.1.2). Introduction of polar groups such as -OH (44), -SH (45) or –NH2 (46) at the C2 
position of histamine led to inactive or very weakly active compounds. Efforts were also 
made towards compounds having longer alkyl chains in C2 position resulting in the synthesis 
of many compounds such as 49-55, but only compound 54 with lipophilic substituents 
showed moderate activity. Compounds with ring systems like cyclopropane (58) or 
cyclopentane (59) were found to be also very weak agonists. 2-Phenyl histamine (61) was 
proved to be relatively potent but increasing the distance between the phenyl ring and the 
imidazole moiety lowers the agonist activity significantly, as compounds 71-73 were weak 
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antagonists. In spite of the vast structural diversity none of the compounds showed more 
activity than histamine. Only 2-phenyl histamine (61) proved to be relatively potent and was 
consequently selected for further exploration of structure activity relationships (SARs). 
 
Table 2.1.2 SARs of 2-substituted histamine derivatives 
 
N
N
H
NH2
R
 
Comp. R Rel. Pot. (Emax) Comp. R 
Rel. Pot. 
(Emax) 
1 H 100% (100) 59 (CH2)2−
 
3% (65) 
44 OH inactive (0) 60 (CH2)2−
 
pA2 5.3 (0) 
45 SH inactive (0) 61 Ph- 31% (100) 
46 NH2 2% (100) 62 PhCH2- 2.5% (90) 
47 CH3 15% (100) 63 H3COCH2- 20% (100) 
48 CF3 7% (100) 64 H3CSCH2- <0.4% (60) 
49 C2H5 7% (100) 65 PhOCH2- 1.4% (100) 
50 C3H7 0.5% (80) 66 PhSCH2- 19% (100) 
51 C4H9 0.5% (100) 67 SCH2−H3C
 
13% (100) 
52 (CH3)2CH- 0.6% (90) 68 PhCH3CH- 1.5% (80) 
53 (CH2)2−
H3C
H3C
 
2.4% (100) 69 Ph(CH2)2- 3.2% (90) 
54 (CH2)2−
H3C
H3C
H3C
 
19% (100) 70 Ph(CH2)3- 1.2 (44) 
55 (CH2)3−
H3C
H3C
 
0.8% (53) 71 Ph(CH2)4- pA2 4.9 (0) 
56 (CH2)2−
H3C
Ph
 
7.6% (96) 72 Ph(CH2)5- pA2 5.1 (0) 
57 (CH2)2−
C2H5
Ph
 
7.4% (76) 73 Ph(CH2)6- pA2 5.6 (0) 
58 CH2−
 
5% (98) 74 CH2
 
pA2 5.7 (10) 
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2.1.7 SARs of 2-phenyl histamines 
From the SARs of 2-phenyl histamine (61), it is observed that the majority of the 
derivatives possess moderate to strong H1R agonist activity (Table 2.1.3). Substitution in 
ortho-position seems to be unfavorable for agonistic activity as ortho substituted analogues 75 
and 76 lead to a decrease in H1R agonist activity. Among para-substituted compounds only 
the fluoro (89) and the hydroxyl derivative (93) possess more than 10% of potency of 
histamine. Bulkier groups at para-position lead to a drastic decrease of H1R agonist activity. 
Interestingly, meta-substitution of the phenyl ring leads to a remarkable improvement of the 
histaminergic potency at H1R. Most of the meta-substituted compounds show full intrinsic 
activity (Emax) with moderate to strong agonistic activity. Independent of the electronical 
features, the substituents in meta-position are well tolerated. The compounds with high 
agonist potency are 77-81. Among halogenated derivatives, the bromo compound (79) is the 
most potent H1R agonist. Compound 81 with trifluoromethyl substitution at meta position was 
found to be the most potent H1R agonist in this series. 
 
Table 2.1.3 SARs of 2-phenyl histamine derivatives 
N
N
H
NH2
R
 
Comp. R Rel. Pot. (Emax) Comp. R Rel. Pot. (Emax) 
61 H 31% (100) 84 3-OC2H5 1%(70) 
75 2-Cl 2% (90) 85 3-OCF3 54%(100) 
76 2-CF3 1% (30) 86 3-OH 6%(100) 
77 3-F 85% (100) 87 3-NH2 7% (100) 
78 3-Cl 96% (100) 88 3-NO2 40% (100) 
79 3-Br 112% (100) 89 4-F 14% (100) 
80 3-I 96% (100) 90 4-Cl 0.5% (100) 
81 3-CF3 128% (100) 91 4-CF3 0.7% (100) 
82 3-CH3 15% (100) 92 2-CH3 0.4% (100) 
83 3-OCH3 42%( 100) 93 2-OH 16% (100) 
 
Further studies of the most potent 2-phenyl histamine derivative 81 was carried out  
with different alkyl groups on the primary amine (Table 2.1.4). Mono-methylation of 81 
produced compound 94 with even better potency than the parent compound. Using bigger 
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alkyl groups led to the compounds 96 and 97 with decrease in the agonistic as well as intrinsic 
activity. Di-methylated analogue 95 was found to be equipotent with histamine. 
 
Table 2.1.4 Effect of Nα-substitution on H1R agonistic potency 
 
N
N
H
N
F3C
R1
R2
 
Comp. R1 R2 Rel. Pot. (Emax) 
81 H H 128% (100) 
94 H CH3 174% (97) 
95 CH3 CH3 95% (88) 
96 H C2H5 30% (63) 
97 H 
 
28% (36) 
 
Table 2.1.5 Effect of heterocyclic moieties at C2 position on H1R agonistic potency 
 
N
N
H
NH2
Het
 
Comp. Heterocycle Rel. Pot. (Emax) Comp. Heterocycle Rel. Pot. (Emax) 
98 
O
 
47% (100) 103 
N
 
1% (78) 
99 N
H
 
14% (93) 104 
N
 
11% (100) 
100 
S
 
46% (100) 105 N
 
9% (85) 
101 S
 
66% (100) 106 
N
Br
 
70% (100) 
102 
S
Br
 
26% (100)    
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2.1.8 Effect of heterocyclic moieties at C2 position on H1R agonistic potency 
Studies were also carried out involving different heterocyclic moieties at C2 position 
of histamine (Table 2.1.5). With five membered heterocycles, such as furan, pyrrole or 
thiophen, only weak to moderate H1R agonistic activity was observed. Even using the 
pyridine heterocycle attached at ortho, meta or para position did not led to the good activity. 
Only the compound with a bromo substituent (106) on the pyridine ring showed moderate 
activity. 
 
2.1.9 The discovery of histaprodifens 
 
Table 2.1.6 Effect of lipophilic moieties at C2 position on H1R agonistic potency 
N
N
H
R
(CH2)X NH2
 
Comp. R n x Rel. Pot. (Emax) 
107 0 2 8% (28) 
108 1 2 0.5% (50) 
109 2 2 111% (100) 
110 3 2 pA2 5.9 (2) 
111 4 2 pA2 6.2 (0) 
112 
 
(CH2)n
 
4 3 pA2 4.5 (0) 
113 1 2 pA2 4.5 (0) 
114 
(CH2)n
 
2 2 8% (26) 
115 1 2 pA2 5.9 (0) 
116 
(CH2)2n(H2C)
 
2 2 pA2 6.2 (0) 
117 N (CH2)2
 
- 2 2.5% (34) 
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The discovery of histaprodifen51 came very recently while attempting to get more 
potent and selective histamine H1R agonists. The design of histaprodifen had its origin in the 
idea to attach a hydrophobic moiety at the C2 position of histamine. Moreover a diphenylalkyl 
substituent is a common feature of therapeutically used high affinity H1R antagonists such as 
diphenydramine, oxatomide, cetirizine, and fexofenadine. It has been thought that the high 
affinity might be provided by the two phenyl rings and efficacy by the histamine moiety. 
 
2.1.10 SAR of histaprodifen analogues 
Attachment of large lipophilic substituents at the 2-position of the imidazole ring of 
histamine was investigated (Table 2.1.6). The attachment of a diphenylmethyl or a 
diphenylethyl group as in 107 and 108 resulted in weak partial agonism of low efficacy. 
Compounds such as 110 and 111 with increased distance between the diphenyl and imidazole 
moiety led to the low affinity antagonists. Moreover, increasing the distance between the 
imidazole moiety and the basic amino group also led to an antagonist with low affinity (112). 
In contrast, using a diphenylpropyl substituent yielded a potent H1R agonist, histaprodifen 
(109). Histaprodifen was found to be more potent than histamine and behaved as a full agonist 
in guinea-pig ileum tissues. Efforts to increase the potency by increasing the distance between 
the two phenyl moieties were unsuccessful as it led to compounds with partial agonism (114) 
or weak antagonism (113). Introducing rigidity in the diphenyl part did not help as 
compounds 115 and 116 were found to be weak antagonists. Compound 117 with the nitrogen 
linker to the diphenyl group was also found to be an agonist with weak intrinsic activity. From 
these data it can be concluded that the diphenylpropyl moiety with ethylamine side chains is 
optimal for the H1R agonistic potency. 
Like in 2-phenyl histamine (62), histaprodifen (109) was chosen for further SARs 
studies, and it was of special interest to see the effect of halogen substituents on the phenyl 
moieties along with Nα-methyl substitution in the ethylamine side chain. Many compounds 
with different substituents on the phenyl rings were synthesized along with heterocyclic 
analogues with five and six membered rings and screened for histamine H1R agonistic 
activity. Table 2.1.7 explains the detailed SARs of these classes of compounds. 
Unlike the trend observed for 2-phenylhistamines, substitution of one of the phenyl 
ring with halogens did not improve agonistic activity, and in some cases it dropped 
drastically. Trifluoromethyl substitution had produced the most potent agonists 81 and 94 in 
the 2-phenylhistamine series but applying the same strategy in 109 was not successful as it 
yielded the compound 129 with very weak agonistic activity. Changing one of the phenyl 
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rings by heterocycles also did not improve the activity; only compound 133 with a 2-thienyl 
heterocycle showed moderate activity and was a full agonist. In contrast, Nα-methyl 
substitution led to the methylhistaprodifen (118) with higher potency. Moreover, the di-
methylated analogue 119 was also found to be potent. 3-Fluoro substitution of 
methylhistaprodifen led to the most potent analogue 122 which exceeded the potency of the 
endogenous ligand histamine by a factor of 5. 
 
Table 2.1.7 SARs of histaprodifen analogues 
 
N
N
H
N
X
R2
R1
R
 
Comp. X R R1 R2 Rel. Pot. (Emax) 
109 Ph H H H 111% (100) 
118 Ph H H CH3 343% (100) 
119 Ph H CH3 CH3 242% (100) 
120 Ph 2-F H H 9% (86) 
121 Ph 3-F H H 92% (98) 
122 Ph 3-F H CH3 522% (100) 
123 Ph 4-F H H 43% (85) 
124 Ph 2-Cl H H 30% (89) 
125 Ph 3-Cl H H 89% (93) 
126 Ph 4-Cl H H 10% (58) 
127 Ph 3-Br H H 52% (87) 
128 Ph 3-CH3 H H 20% (88) 
129 Ph 3-CF3 H H 4% (62) 
130 2-Pyridyl H H H 8% (89) 
131 3-Pyridyl H H H 18% (100) 
132 4-Pyridyl H H H 5% (77) 
133 2-Thienyl H H H 63% (100) 
134 3-Thienyl H H H 51% (97) 
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2.1.11 Molecular dynamic simulation of histaprodifens 
Histaprodifens possess high agonist activity and enhanced receptor affinity compared 
with histamine. The common feature of these compounds is a space filling substituent in the 
C2 position of imidazole ring. For a better understanding of SARs, interaction of 109 within 
the TM domains of the human histamine H1R were studied by Elz et al. using molecular 
dynamic (MD) simulations. The complex of 109 and the TM region of human H1R is shown 
in Figure 2.1.7. The carboxyl oxygen of the Asn 198 side chain is able to form two hydrogen 
bonds with the NτH-atom of the imidazole moiety and the hydroxyl group of Tyr 108 and at 
the same time NpiH-atom of imidazole forms the stable hydrogen bond with Tyr 431. The 
imidazole ring of 109 is located near Phe-435 and Tyr-108. Phenyl rings are located in a deep 
hydrophobic pocket built by Phe-199, Pro-202, Phe-432, Trp-428, Trp-158, Ile-115 and Tyr-
108. Both phenyl rings fill out the space of receptor pocket, and no space is available for the 
substituents on the ring. This observation is well supported by the experimental fact that 
efforts to increase the potency of 109 by benzyl substitution failed52 (Table 2.1.7). 
 
 
 
Figure 2.1.6 Binding model of histaprodifen 
 
2.1.11 SAR of suprahistaprodifen analogues 
Histaprodifen (109) has been a lead structure for the development of potent H1R 
agonists. For a long time now, interest has focused on the structural modification of the 
diphenyl part of the 109. Structural modification of the ethylamine side chain, specially 
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attaching different polar groups with the help of methylene linkers led to the discovery of 
suprahistaprodifen (136). 
 
Table 2.1.8 SARs of suprahistaprodifen analogues 
 
N
N
H
H
N
N
H
N
136
Suprahistaprodifen
N
N
H
H
N (CH2)n R
 
Comp. R n Rel. Pot. (Emax) 
135 H2N
 
2 n.d. (19) 
136 
N
HN
 
2 3630% (96) 
137 
N
 
2 923% (92) 
138 
O
 
2 pA2 6.4 (0) 
139 
HN
 
2 pA2 5.9 (0) 
140 H2N
 
3 6% (81) 
141 O
 
3 251% (47) 
142 
H
N
 
4 148% (45) 
143 H2N
 
4 6% (87) 
144 
 
4 955% (49) 
145 
N
 
4 2856% (89) 
146 S
 
4 433% (43) 
147 
S
 
4 1016% (52) 
148 
NO2
 
4 130% (43) 
149 O2N
 
4 91% (57) 
150 H2N
 
4 779% (49) 
151 H2N
 
5 14% (92) 
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Suprahistaprodifen (136) shows extremely high potency in guinea-pig ileum and is the 
most potent H1R agonists known so far. Efforts were also made to further improve the 
agonistic activity. Replacement of imidazole moiety with pyridine as in 137 leads to an 
agonist with moderate activity. With the exception of compounds 138 and 139, which were 
found to be weak antagonists, all other compounds showed moderate to very good activity but 
most of the compounds were partial agonists. Compound 147 with pyridine heterocycle also 
showed very high activity but replacement with other heterocycles 147-151 led to moderate to 
good activity. 
Many potent and relatively selective H1R agonists have been developed by academic 
research groups. Histaprodifen and suprahistaprodifen class of compounds are still the most 
potent H1R agonists in guinea-pig ileum and are the lead structures for the development of 
highly potent H1R agonists. With increasing understanding of histamine H1R and the 
mediated effects, H1R agonist may become important “future drugs or diagnostic tools.” 
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2.2 Aim of the work 
 
Since the identification of the histamine H1-Receptor by Ash and Schild,7 histamine 
H1R agonists have gained significant importance for the investigation of H1R mediated 
effects, such as neuroregulation of arousal,32-34 allergy, modulation of cardiovascular 
parameters,35,36 and release of endothelium derived relaxing factor.35,37,38 The study of these 
effects has always been hampered by the lack of highly potent and selective histamine H1R 
agonists. The search for highly potent and subtype-selective H1R agonists has been an 
arduous task for several years,53 and many derivatives have arisen from the class of 2-
substituted histamines,54 which display improved potency and selectivity.55,56  
 
N
N
H
NHR
Ph
Ph
136 Suprahistaprodifen, R =
109 Histaprodifen, R = H
PEC50 = 6.74
N
N
H
N
N
H
NH2
1
Histamine
PEC50 = 6.70
 
 
Figure 2.2.1 
 
Recently histaprodifen (109, Fig. 2.2.1)57 has been identified as a potent and selective 
histamine H1R agonist offering a starting point for the systematic development of highly 
potent and selective histamine H1R agonists. The main aim of the present study was to 
develop analogues of 109 as shown in Figure 2.2.2 to get additional information about 
structure-activity relationships (SARs) of histamine H1R agonists. In particular, the effects of 
polar groups attached to ethylamine side-chain should also be investigated, posing the 
additional challenge to introduce such groups in a regio-, diastereo- and enantioselective 
manner. A general retrosynthetic approach is given in Figure 2.2.2. As a suitable starting 
material toward side-chain modified derivatives of 1 and 109, commercially available trans 
urocanic acid (162) and the 3,3-diphenyl propionic acid (170) were envisioned. The coupling 
of two fragments should give the desired substrates and the required amino group in β-
position to the imidazole moiety could be introduced via an asymmetric aminohydroxylation 
(AA) reaction. 
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Figure 2.2.2 General retrosynthetic approach 
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2.3 Synthesis of side-chain modified histaprodifen analogues 
 
2.3.1 Attempted AA reaction on imidazole derivatives 
As stated previously, AA reaction was envisoned as one of the key steps, which has 
proved to be especially effective with cinnamates as substrates. On the other hand the AA 
reaction is also known to be problematic in presence of nitrogen containing heterocycles. 
Indeed, it has been reported by Dong et al.58 that the various imidazole urocanic acid methyl 
esters (152-155) failed completely to give the AA reaction despite its structural similarity with 
cinnamic acid ester (Scheme 2.3.1). 
 
N
N
CO2Me
X
No 
reaction
AA152, X = H153, X = Tr
154, X = Cbz
155, X = Ts
 
 
Scheme 2.3.1 Attempted AA reaction on urocanic acid methyl esters by Dong et al.58 
 
The possible chelation of the imidazole with osmium (VIII) was assumed to be the 
reason for these failed attempts.59 Moreover competition studies were also performed to 
explore this assumption. Using equal equivalents of 4-benzyloxy methyl cinnamate along 
with compounds 152 and 154, desired products were not detected. In a separate experiment, 
when a reaction of 154 was conducted in the presence of a stoichiometric amount of osmium 
reagent, no consumption of the substrates was observed.  
A similar trend was earlier observed for pyridylacrylates.60 The direct AA reaction on 
pyridylacrylates 156(a-c) was unsuccessful (Scheme 2.3.2), the possible and again the 
chelation of the pyridine nitrogen with osmium (VIII) could be the reason for these failed 
attempts. However, N-oxides 159(a-c) with the blocked nitrogen functionalities readily 
underwent the AA reaction furnishing the regioisomers 160(a-c) and 161(a-c) (Scheme 2.3.2). 
A similar strategy was also envisioned for imidazole derivatives, and consequently N-oxide 
imidazole acrylate was synthesized (Scheme 2.3.3). Starting from trans urocanic acid (162), 
esterification61 and N-methylation62 was achieved by known procedures. Finally 163, on 
exposure to m-CPBA, N-oxide 164 was generated, nevertheless in low yield. On the other 
hand, attempts to utilize the N-oxide 164 for AA reaction, which in case of the 
pyridylacrylates proved to be the method of choice to achieve asymmetric amino- and 
dihydroxylations, were not successful. 
Synthesis part H1-Receptor 26 
  
N
CO2Et
N
CO2Et
N
CO2Et
AA
CbzHN
OR
RO
NHCbz+
N
CO2Et
N
CO2Et
N
CO2Et
AA
CbzHN
OR
RO
NHCbz+
O O O
156a - 156c
ortho, meta, para 157a - 157c 158a - 158c
159a - 159c
ortho, meta, para 160a - 160c 161a - 161c
 
 
Scheme 2.3.2 AA reaction of N-oxide pyridylacrylates by Reiser and co-workers60 
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Scheme 2.3.3 Attempted AD reaction on imidazole N-oxides.; Reagents and conditions: (a) 
MeOH, H2SO4 (cat), reflux, 30 h, 91%; (b) DMS, K2CO3, acetone, RT, 10 h, 38%; (c) m-
CPBA(75%), EtOAc, RT, 24 h, 12-15%. 
 
2.3.2 Successful asymmetric dihydroxylation reaction on imidazole derivatives 
In an important contribution from Pyne and coworkers (Scheme 2.3.4) it was 
demonstrated that N-protected urocanic ethers having an acetyl group in 2-position of 
imidazole moiety are amenable toward osmium-catalyzed asymmetric dihydroxylation 
(AD).63 Looking at the similarity between AD and AA reactions and keeping the side chain in 
2-position of histaprodifen in mind, novel 2-keto-substituted imidazole derivatives as a 
starting point for AA reaction were envisioned. 
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Scheme 2.3.4 AD reaction of 2-acyl imidazole derivatives reported by Pyne and co-workers63 
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Scheme 2.3.5 Reagents and conditions: (a) NaH, MEM-Cl, DMSO, 0-80 °C, 6 h, 86 % [90:10 
mixture of 171:172]; (b) SOCl2, reflux 3 h, 72 %; (c) C6H5N, CHCl3, 0 °C → RT, 16 h, 98 %. 
 
2.3.3 Synthesis of substrates for AA reaction 
Treatment of 152 with 2-methoxyethoxymethyl chloride (MEM-Cl) and NaH afforded 
a 90:10 mixture of N-alkylated regioisomers 171 and 172, from which 171 being the major 
product could be separated by careful column chromatography, while the minor isomer 172 
was difficult to isolate. The synthesis of acid chloride 173 was achieved from 3,3-
diphenylpropionic acid (170) by known procedures.64 Acid chloride 173, was treated with 
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N,O-dimethylhydroxylamine hydrochloride and pyridine in ethanol free chloroform65 to 
generate Weinreb amide 174 quantitatively (Scheme 2.3.5). 
 
N
N
CO2Me
MEM
N
OPh
Ph
O Me
Me
+
N
N
CO2Me
MEM
Ph
OPh
a)
+
N
N
MEM
Ph
OPh
CO2Me
N
N
MEM
CO2Me
171 175
176172
174
171 175
a)
174
+
 
 
Scheme 2.3.6 Reagents and conditions: (a) LDA, THF, 0 °C → RT, 2 h, 36-52 % 
 
Subsequently, metallation of 171 with LDA and trapping with the Weinreb amide 174 
gave rise to 175 in moderate yield (Scheme 2.3.6). To overcome the problems in the 
separation of regioisomers (Scheme 2.3.5), the LDA mediated coupling was performed with 
the mixture of regioisomers (171, 172). Metallation of mixture of 171 and 172 with LDA and 
trapping with the Weinreb amide 174 gave rise to a mixture of 175 and 176, readily separated 
by column chromatography. The structures of 175 and 176 were confirmed by X-ray 
crystallographic analysis (Fig. 2.3.3 and 2.3.4). 
 
 
 
 
 
 
 
 
 
 
 
     Figure 2.3.3 X-ray structure of 175                 Figure 2.3.4 X-ray structure of 176 
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Scheme 2.3.7 Reagents and conditions: (a) DIBAL-H, CH2Cl2, 0 °C → RT, 12 h, 86%; (b) 
NaH, Benzyl bromide, DMF, 0 °C → RT, 16 h, 82%; (c) n-BuLi, THF, -78 °C, 1 h, 174, 1 h, 
then, RT, 1 h, 67%. 
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Scheme 2.3.8 Reagents and conditions (a) TBDMS-Cl, imidazole, DMF, 0 °C → RT, 1 h, 
96%; (b) n-BuLi, THF, -78 °C, 1 h, 174, 1 h, then, RT, 1 h, 69%; (c) TBAF, THF, 0 °C → 
RT, 1 h, 91% 
 
The synthesis of substrate 179 for AA reaction is highlighted in Scheme 2.3.7. 
DIBAL-H reduction of 171 furnished the desired allyl alcohol 177 in 86% yield, which was 
subsequently treated with sodium hydride and benzyl bromide to furnish the benzyl ether 178 
in 85% yield. Finally, metallation of 178 with n-BuLi and trapping with Weinreb amide 174 
at -78 oC, afforded 179 in 67 % yield. Similarly TBDMS protection of allyl alcohol 177 
followed by subsequent metallation with n-BuLi and trapping with Weinreb amide 174 at -78 
oC, afforded 181 in 69 % yield. Finally TBDMS group was removed using TBAF to generate 
the allyl alcohol 182 in excellent yield (Scheme 2.3.8).  
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2.3.4 Asymmetric aminohydroxylation of imidazolyl derivatives 
 
Table 2.3.1 Asymmetric aminohydroxylation of imidazolyl derivativesa 
 
N
N
R
MEM
Ph
OPh
N
N
NHCbz
MEM
Ph
Ph
OH
R
N
N
OH
MEM
Ph
OPh
NHCbz
R+
A B
O
AA
175 R = CO2Me
179 R = CH2OBn
182 R = CH2OH
183 R = CO2Me
185 R = CH2OBn
187 R = CH2OH
184 R = CO2Me
186 R = CH2OBn
188 R = CH2OH
 
Entry Substrate Ligand Solvent Reaction time [h] 
Ratio of 
regioisomersb 
Yieldc 
[%] 
% eed 
A  B 
1 175 (DHQ)2PHAL n-PrOH/H2O (1.5:1) 30 
183:184 
1:3 52 56  53 
2 175 (DHQD)2AQN n-PrOH/H2O (1.5:1) 30 
183:184 
1:1 56 54  52 
3 175 (DHQD)2AQN MeCN/H2O (3:1) 4 
183:184 
1:1 72 75  87 
4 179 (DHQ)2PHAL n-PrOH/H2O (1.5:1) 1 
185:186 
1:3.3 56 nd  nd 
5 179 (DHQD)2AQN n-PrOH/H2O (1.5:1) 1 
185:186 
1:3 65 nd  nd 
6 179 (DHQD)2AQN MeCN/H2O (3:1) 1 
185:186 
1:1.5 67 48
e 
 nd 
7 182 (DHQD)2AQN MeCN/H2O (1.5:1) 1 
187:188 
1:3 63 0  nd 
 
a
 Reagents and conditions: K2OsO2(OH)4 (4 mol %), ligand (5 mol %), BnOC(O)NNaCl (5 
mol %) at 25 °C. 
b
 Ratio determined by 1H NMR, for substrate 179 and 182 ratio determined after N-Cbz to N-
Boc conversion. 
c
 Isolated yields as a mixture of regioisomers.  
d
 Determined by HPLC on ChiracelTM OD/ODH (nd, not determined) 
e
 Determined after conversion to 194 by HPLC on ChiracelTM OD/ODH 
 
Indeed, 175, 179 and 182 could be utilized as substrate for the osmium-catalyzed 
aminohydroxylation (Table 2.3.1) with moderate results, nevertheless, succeeding for the first 
time with imidazole derivatives in this transformation. In agreement with the general trend 
observed in AA reactions with aromatic substrate, in the presence of (DHQ)2PHAL the amino 
group is preferentially introduced in the benzylic position (regioisomers B, entries 1, 7). To 
obtain a better ratio of regioisomers with respect to the desired histamine analogues, the 
pseudoenantiomeric ligand (DHQD)2AQN was employed. Although the ratio of regioisomers 
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could not be reversed as it is known in the case of cinnamates, at least the formation of 
desired regioisomer A was somewhat improved (Table 2.3.1, entries 2, 3, and 7). 
Changing the solvent from n-propyl alcohol/water to acetonitrile/water considerably 
improved the yield of the reaction with 175, as well as the enantioselectivity of the products 
(Table 2.3.1, entries 2, 3). Surprisingly the allyl ether 178 and allyl alcohol 182 were 
considerably more reactive than the ester 175, however with the former substrate the 
undesired regioisomer was always favored, even when the AQN ligand was employed. 
Moreover, only racemic products were obtained with the allyl alcohol 182 (Table 2.3.1, entry 
7). Preparatively most useful appeared to be the formation of 183 and 184 mediated by 
(DHQD)2AQN (Table 2.3.1, entry 3), giving useful yields and selectivities that allowed to 
arrive at regio- and enantiomerically pure products at the next stage in the reaction sequence. 
 
2.3.5 Separation of regioisomers in AA reaction 
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N
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Ph
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Scheme 2.3.9 Reagents and conditions: (a) 10% Pd/C, H2, MeOH, (Boc)2O, RT, 3 h 96%; (b) 
i) Conc. HCl:MeOH:H20 (1:1:1), reflux, 1 h, ii) H2SO4(cat.), MeOH, reflux 30 h, 75% (over 
two steps). 
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One of the most common limitations in AA reaction is the separation of regioisomers. 
In the reaction sequence the regioisomers were very difficult to separate, and were separated 
using preparative column chromatography (183, 184) and in some cases were inseparable 
(185, 186 and 187, 188) by column chromatography. On the other hand single-step 
exchange66 of the nitrogen protecting group on the mixture of 183 and 184 from Cbz to Boc 
allowed the facile separation of desired isomer 183 by column chromatography, which was 
obtained enantiomerically pure in 40% yield after recrystallization (28% yield starting from 
175) along with the corresponding regioisomer being obtained in 48% yield.  
 
 
 
 
 
 
 
 
 
Figure 2.3.6 X-ray structure of 189 
 
The structure of 189 was confirmed by X-ray analysis (Fig. 2.3.6) and the absolute 
configuration (S, S) was assigned by an analogy to the Sharpless ligands. Finally deprotection 
of 189 was achieved by treatment with aqueous HCl in methanol (using ethanol as a solvent 
resulted in transesterification products), resulting also in partial cleavage of methyl ester, 
which was subsequently remedied by acid catalyzed reesterification with abs. MeOH to give 
rise to 191 (Scheme 2.3.9).  
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OPh
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N
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R = MEM, 183-a
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Scheme 2.3.10 Reagents and conditions: (a) 10% Pd/C, H2, MeOH, RT, 3 h 78%; (b) i) Conc. 
HCl:MeOH:H20 (1:1:1), reflux, 1 h, ii) H2SO4(cat.), MeOH, reflux 30 h, 75% (over two 
steps). 
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The synthesis of (rac)-191 was achieved by mixing the (S,S) and (R,R)-183 followed 
by the Cbz deprotection to form the amine 183-a. Finally MEM group was deprotected by 
refluxing (183-a) with aqueous HCl in methanol, resulting also in partial cleavage of methyl 
ester, which was subsequently remedied by acid catalyzed reesterification with abs. MeOH to 
give rise to (rac)-191 (Scheme 2.3.10). 
Similarly, the mixture of 185 and 186 was converted to the N-Boc derivatives 192 and 
193 (94% yield). The reaction was followed carefully as extended reaction time led to the O-
debenzylation in minor quantity. Moreover, O-debenzylation being very slow, one pot 
debenzylation and N-Cbz to N-Boc exchange was not possible. Even though the two 
regioisomers 192 and 193 were not separable by chromatography, nor could be the major 
isomer defined at this stage, we nevertheless proceded forward in the hope of achieving the 
separation in the later stage.  
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Scheme 2.3.11 Reagents and conditions: (a) 10% Pd/C, H2, MeOH, Boc2O, RT, 3 h, 94%; (b) 
10% Pd/C, H2, THF, 40 bar, 40 °C, 48 h, 62%; (c) i) NaIO4, 1,4-dioxane, H2O, RT, 2.5 h, 
87% based on 192; ii) concd. HCl:MeOH:H20 (1:1:1), reflux, 1 h, 95%. 
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Thus, debenzylation of the mixture 192 and 193, with Pd-C/H2 in THF led to the 
mixture of 1,2- and 1,3-diols 194 and 195 in 62% yield. In contrast, with EtOAc as a solvent 
the reaction yields were low and side-products were formed. In all attempts complete 
conversion of starting material was not observed. After the debenzylation, the mixture of 1,2 
and 1,3-diols was treated with NaIO4 to cleave the 1,2-diol in undesired regioisomer 195 
(Scheme 2.3.11). This way 194 could be obtained as single distereomer and hence it was 
possible to determine the enantiomeric excess (48% ee). Finally MEM and Boc protecting 
groups were removed under acidic condition in one pot reaction to leave 196 as a 
hydrochloride salt. 
Initially, it was thought that the major isomers in the AA reaction on 179 as well as 
182 were 185 and 187. Later chemical analysis based on the reaction of regioisomers 194 and 
195 with NaIO4, which reacted only with 1,2-diol leaving 1,3-diol unaffected, revealed that 
the major isomers were undesired 186 and 188. It is evident from the investigation of 1H 
NMR (Fig. 2.3.7). After 20 minutes the resonance of Boc group in the 1,2-diol 195 was found 
to be decreasing and vanished completely after 2.5 h (Fig. 2.3.7), suggesting that the major 
isomer was 1,2-diol and hence it was concluded that the major isomers in AA reaction on 179 
and 182 were 186 and 188 respectively (Table2.3.1 entries 4- 7) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          1H NMR before reaction            1H NMR after 20 minutes           1H NMR after 2.5 hours 
 
Figure 2.3.7 
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2.3.6 Synthesis of keto-histaprodifen 
As the missing link to allow a meaningful assessment of the influence of the modified 
ethylamine side chain in 191 and 196 with respect to 109, histaprodifen analogue 201 being 
acylated instead of alkylated was thought to be synthesized using Curtius reaction as a key 
step. Starting from acrylate 175, hydrogenation with Pd-C/H2 followed by saponification of 
the methyl ester afforded acid 198 in very good yield. Initially, attempts to utilize acid 198 for 
the corresponding acyl azide transformation using ethyl chloroformate and sodium azide were 
not satisfactory, giving very low yield of the acyl azide. On the other hand, acid activation 
with oxalyl chloride followed by treatment with TMS-azide proved to be the method of 
choice. Subsequently, the azide was immediately subjected to the modified Curtius 
rearrangement, which proceeded well to furnish Cbz protected amine 199 in high yield 
(Scheme 2.3.12). The Cbz group was removed by hydrogenation and finally the MEM group 
was deprotected with HCl to give 201 as a dihydrochloride salt in 97% yield. 
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Scheme 2.3.12 Reagents and conditions: (a) 10% Pd/C, H2, MeOH, RT, 16 h, 96%; (b) LiOH, 
THF:MeOH:H2O (3:1:1) 0 °C → RT, 6 h, 95%; (c) i) (COCl)2, CH2Cl2, 0 °C → RT, 3 h; ii) 
TMS-N3, CH2Cl2, 0 °C → RT, 5 h; iii) BnOH, toluene, reflux, 18 h, 87% (over three steps); 
(d) 10% Pd/C, H2, MeOH, RT, 16 h, 86%; (e) Conc. HCl:MeOH:H20 (1:1:1), reflux, 1.5 h, 
97%. 
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Scheme 2.3.13 Reagents and conditions (a) i) (COCl)2, CH2Cl2, 0 °C → RT, 3 h; ii) TMS-N3, 
CH2Cl2, 0 °C → RT, 5 h; (b) H2O, toluene, reflux, 18 h; (c) Conc. HCl:MeOH:H20 (1:1:1), 
reflux, 1.5 h, 92%. 
 
In an attempt to achieve a direct conversion of 198 to the free amine 200, by the 
Curtius reaction, the intermediate isocyanate 202 was hydrolyzed using H2O, and 
interestingly, the urea derivative 201 was isolated. The possible attack of amine 200, which is 
formed by the partial hydrolysis of isocyanate 202 on the intermediate isocyanate itself, could 
be the reason for the formation of this interesting urea derivative 203 (Scheme 2.3.13). Later 
MEM group was removed under usual acidic condition followed by the basic work-up to 
obtain 204, a suprahistaprodifen type of compound as a free base. 
The minor isomer 176, obtained previously from the LDA mediated coupling (Scheme 
2.3.6) could be utilized for further transformations and would result to similar products as 
obtained from major isomers. With this in mind, building block 207 was synthesized in a 
straightforward way (Scheme 2.3.14) using similar routs used for the major isomer 199. 
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Scheme 2.3.14 Reagents and conditions: (a) 10% Pd/C, H2, MeOH, RT, 16 h, 92% (b) LiOH, 
THF:MeOH:H2O (3:1:1) 0 °C → RT, 6 h, 96 %; (c) i) (COCl)2, CH2Cl2, 0 °C → RT, 3 h; ii) 
TMS-N3, CH2Cl2, 0 °C → RT, 5 h; iii) BnOH, toluene, reflux, 18 h 78 % (over three steps); 
(d) 10% Pd/C, H2, MeOH, Boc2O, RT, 3 h, 89%. 
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Scheme2.3.15 Reagents and conditions: (a) NaBH4, IPA, 0 °C → RT, 16 h, 94%; (b) Conc. 
HCl:MeOH:H20 (1:1:1), reflux, 1.5 h, quantitative; (c) Ph3PCH2I, tBuOK, THF 24 h. 
 
For the synthesis of polar derivatives of histaprodifen, being one of the main aims of 
the present study, our attention was turned towards the hydroxyl derivative of keto-
histaprodifen (201). However, the attempts to utilize 208 were not as successful as 
anticipated. Sodium boro hydride reduction of 208 yielded alcohol 209 in 94% yields. 
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However, treatment of 209 under usual MEM deprotection condition led only to Boc 
deprotection, leaving MEM group intact (Scheme 2.3.15). Furthermore the effect of the polar 
carbonyl functionality should be compared with lipophilic moieties such as alkene, which has 
of more or less the same size. However, 208 did not undergo the Wittig transformation 
(Scheme 2.3.15). 
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Scheme 2.3.16 Reagents and conditions: (a) Ph3PCH2I, tBuOK, THF 0 °C → RT, 3 h 92%; 
(b) Ph3PCH2I, tBuOK, THF 0 °C → RT, 5 h 95 %. 
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Scheme 2.3.17 Reagents and conditions: (a) 10% Pd/C, H2, MeOH, RT, 16 h, 96%; (b) Conc. 
HCl, reflux, 16 h, quantitative; (c) Conc. HCl:MeOH:H20 (1:1:1), reflux, 1.5 h, (quantitative, 
crude). 
 
To verify the reason for this failed attempt, the Wittig reaction was performed on the 
similar substrate 197. Using 2 equivalents of Wittig reagent the ketone 197 underwent the 
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Wittig reaction successfully and gave rise to the alkene 211 in excellent yield. Also 212 was 
found to be amenable towards the Wittig reaction (Scheme 2.3.16), implying that in 208 steric 
factors could be the reasons for the failed Wittig reaction. 
 
2.3.7 Manipulation of carbonyl group  
Having accomplished the successful Wittig reaction on 212, the alkene 213 was 
hydrogenated with Pd-C/H2 to the methyl compound 214. On the other hand, NaBH4 
reduction of 213 generated corresponding alcohol 217 in excellent yield. Disappointingly, 
however in all compounds 213, 214 and 217, only deprotection of Boc protecting group was 
accomplished under strongly acidic conditions (6N HCl), leaving MEM group intact (Scheme 
2.3.15, 2.3.16 and 2.3.17). Moreover, upon refluxing 213 with concentrated HCl for 16 hours, 
the MEM group was not deprotected completely and compound 215 was obtained (Scheme 
2.3.17). So far, it has been observed that, MEM deprotection from imidazole derivatives is 
only possible for compounds having a 2-acyl moiety, suggesting the possible involvement of 
the carbonyl moiety during the acid catalyzed deprotection of MEM group. This unfortunate 
outcome has not been recognized before and requires further investigations. 
 
N
N
NHBoc
Ph
Ph O MEM
N
N
NHBoc
Ph
Ph OH MEM
N
N
NH2
Ph
Ph OH MEM
a)
b)
212 217
218
HCl
 
 
Scheme 2.3.18 Reagents and conditions: (a) NaBH4, IPA, 0 °C → RT, 10 h, 92 %; (b) Conc. 
HCl:MeOH:H20 (1:1:1), reflux, 1.5 h, quantitative. 
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Scheme 2.3.19 Reagents and conditions: (a) NaOH, (Boc)2O, RT, 30 min. 91%; (b) NaBH4, 
IPA, 0 °C → RT, 16 h, 96%; (c) Sat. HCl in ether 0 °C → RT, 16 h, quantitative. 
 
After facing these unexpected problems of MEM deprotection, another strategy for the 
synthesis of hydroxyl derivative 221 of histaprodifen was planed and carried out successfully 
(Scheme 2.3.19). Starting from dihydrochloride salt 201, the free amine functionality was 
selectively protected using (Boc)2O to achieve the required lipophilicity, which allowed the 
facile isolation of reduced product 220 after hydride treatment. Finally the Boc group was 
removed under acidic conditions to afford 221 as a hydrochloride salt. On the other hand, use 
of MEM deprotected building block 219 was not successful as 219 did not undergo a routine 
Wittig transformation even after refluxing in THF for 24 hours (Scheme 2.3.20). 
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Scheme 2.3.20 Reagents and conditions: (a) Ph3PCH2I, tBuOK, THF 0 °C → RT, 2 h, then 
reflux, 24 h. 
 
2.3.8 Attempted synthesis of the Nα-methylated analogue of keto-histaprodifen 
Nα-methylated analogues of histaprodifen are known to be more potent than the 
histaprodifen itself.51 To achieve a better potency, the synthesis of the Nα-methylated 
analogue of 201 was of a great interest. As a suitable starting material towards the Nα-
methylated analogue of 201, the Boc protected amine 208 was envisioned. However, on 
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treatment of 208 with methyl iodide and bases such as, NaH or tBuOK, along with Nα-
methylation, α-methylation to the carbonyl group was always observed (Scheme 2.3.21).  
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Scheme 2.3.21 Reagents and conditions: (a) NaH, MeI, 0 °C → RT, 2 h, 83%; (b) Conc. 
HCl:MeOH:H20 (1:1:1), reflux, 1.5 h, quantitative. 
 
Several attempts to achieve selective Nα-methylation were failed. Methylation of 208 
was faster when NaH was employed as a base, However, the reaction time was longer with 
tBuOK. In all attempts the only product formed was 223. Moreover using one equivalent of 
methyl iodide, mixture of products along with starting material 208 were observed and were 
not possible to separate by column chromatography. On the other hand, similar problem was 
observed when the methylation was performed with 212. Moreover, attempts to use protected 
carbonyl group were failed as silyl enol ether 225 was not found to be very stable and hence 
could not be utilized. Finally treatment of 223 with 6N HCl, the MEM and Boc protecting 
groups were removed in one pot reaction. Interestingly, this time the reaction proceeded in a 
usual manner (Scheme 2.3.21), making the argument stronger that MEM group deprotection 
on imidazole is amenable only in the presence of 2-acyl substituents under these conditions. 
An alternative strategy was employed to synthesize the Nα-methylated analogue of 
201, in which the crucial Nα-methylation step was envisioned before the base mediated 
coupling (Fig. 2.3.8). The synthon 234 was envisioned to be obtained from 232 which in turn 
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should be easily accessible from 171 by hydrogenation, saponification followed by modified 
Curtius reaction. 
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Figure 2.3.8 Alternative retrosynthetic approach for N-methylated analogue 234 
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Scheme 2.3.22 Reagents and conditions: (a) LiOH, THF:MeOH:H2O (3:1:1) 0 °C → RT, 6 h, 
84%; (b) 10% Pd/C, H2, MeOH, RT, 16 h, 93%; (c) i) (COCl)2, CH2Cl2, 0 °C → RT, 3 h; ii) 
TMS-N3, CH2Cl2, 0 °C → RT, 5 h; iii) BnOH, toluene, reflux, 18 h, 72% (over three steps); 
(d) 10% Pd/C, H2, MeOH, Boc2O, RT, 3 h, 83% of 232. 
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As described in Figure 2.3.8, starting with the mixture of regioisomers 171 and 172, 
upon treatment of this mixture with LiOH in THF:H2O:MeOH mixture a white solid was 
obtained as a non-separable mixture of regioisomers 226 and 227. The regioisomers were not 
separable even after the recrystallization as both were crystallized together. Upon 
hydrogenation with 10% Pd-C, a mixture of regioisomers 228 and 229 was obtained. At this 
stage the regioisomers were still not separable. Subsequently the mixture of acids was 
subjected to a modified Curtius protocol (Scheme 2.3.11) to obtain the Cbz protected mixture 
of regioisomers 230 and 231. At this stage, the separation of regioisomers was still not 
possible. On the other hand single step exchange of the nitrogen protecting group on the 
mixture of 230 and 231 from Cbz to Boc allowed the facile separation of desired isomer 232 
by column chromatography (Scheme 2.3.22). However attempts to convert 232 into 234 were 
unsuccessful (Scheme 2.3.23), probably also leading to the ring methylation of imidazole 
nitrogen. 
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Scheme 2.3.23: Attempted Nα-methylation of 232 
 
2.4.2 Conclusion 
In the race toward the highly potent and selective histamine H1R agonists, the 
asymmetric aminohydroxylation was performed successfully for the first time on imidazolyl 
derivatives and many polar analogues of histaprodifen were synthesized, in some cases also in 
enantiopure form. A convenient and straightforward synthesis of a keto derivative of 109, a 
keto-histaprodifen (201) was developed using the Curtius reaction as a key step. Moreover 
along with 201, its racemic hydroxy derivative 221 was also synthesized in an efficient way. 
All newly synthesized compounds were screened in vitro for functional interaction with 
guinea-pig ileum and have enlarged the knowledge about SARs of histamine H1R agonists. 
Pharmacology H1-Receptor 44 
  
2.4 Pharmacology 
 
2.4.1 Histamine H1R agonist activity 
All newly synthesized compounds were screened in vitro for functional interaction 
with histamine H1Rs of guinea-pig ileum according to standard procedures (see 2.5 
pharmacological methods). Table 2.4.1 summarizes all the pharmacological data.  
 
Table 2.4.1 Interaction with histamine H1Rs (guinea-pig ileum)a 
 
 Agonism  Affinityb 
Comp. 
Emax ± SEM pEC50 ± SEM Rel. Pot. [%] pD´2 ± SEM 
Nc 
1 100 6.70 ± 0.02 100 - >95 
109 100 6.74 ± 0.02 111 6.04 ± 0.05d 34e 
(rac)-191 0 - - 3.80 ± 0.09 7 
191 0 - - 4.61 ± 0.12 9 
196 0 - - 4.08 ± 0.14 6 
200 0 - - 5.05 ± 0.12 4 
201 75 ± 3 5.78 ± 0.08 12 nd 9 
204 0 - - 6.04 ± 0.07 13 
221 66± 2 5.00 ± 0.09 2 4.03 ± 0.10d 7 
224 0 - - 4.18 ± 0.09 7 
Mepyraminef 0 - - 9.07 ±0.03g 34 
 
a
 Experimental protocol and definition of parameters see (2.5 pharmacological methods)  
b
 Determined at 10-100 µM unless otherwise indicated. 
c
 Number of experiments for agonism or affinity determination. 
d
 pKp value, determined at 3-30 µM (109) and 200 µM (221) 
e
 N = 12 for affinity measurement. 
f
 Data from Ref.57 
g
 pA2 value, determined at 0.3-100 µM. 
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Partial Agonism: 
pEC50 = 5.78 ± 0.08 (histamine: 6.70) 
Rel. Potency: 12% (8 – 19) 
Emax = 75 ± 3% (N = 7, 2 animals) 
 
Sensitivity vs Mepyramine: 
pA2 = 9.03 ± 0.18 (N = 3) 
 
 
Figure 2.4.1 Partial H1R Agonism of 201 (keto-histaprodifen): Contraction of guinea-pig 
ileum by histamine (1) (■, N = 9) and 201 in the absence (♦, Emax = 75 ± 3%, N = 9) and 
presence (◊, 47 ± 4%, N = 5) of mepyramine (2 nM). Rel. Pot. of 201 was 12% (95% conf 
limits 9-17%), pA2 of mepyramine was 9.08 ± 0.11. These data were obtained from three 
animals. For protocol, see Ref.57 
 
Neither (rac)-191 nor the enantiopure 191 showed any elicited ileal contractions 
(Table 2.4.1). Moreover, the diastereomerically pure 196 behaved similarly like 191. Only at 
higher concentrations (30-100 µM), these compounds depressed the effect of histamine (1) 
without producing a rightward shift of the agonist curve. Thus, in contrast to the potent 
reference antagonist mepyramine (nanomolar affinity, pA2 = 9.07), these compounds have to 
be classified as weak non-competitive H1R blockers (pD´2 < 5). 
Compared with the lead compound histaprodifen (109), the new compounds 191 and 
196 are endowed with several chemical modifications. It was of a special interest to 
understand the effect of the carbonyl group attached to C2 of imidazole, since 2-acyl 
histamine derivatives have never been studied so far. Moreover, several modifications at once 
in histaprodifen (109) led the new compounds to behave as weak H1R antagonists. Therefore 
the synthesis of 201 was sought and carried out in a straightforward way (Scheme 2.3.11). 
Surprisingly compound 201, a ´keto-histaprodifen` turned out to be a moderate partial H1R 
agonists, displaying approximately 12% relative potency compared with its parent compound 
109. The contractile effect was mediated by H1Rs since mepyramine (2 nM), a reference H1R 
antagonist, successfully blocked the effect of 201 (Fig. 2.4.1) with the expected nanomolar 
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affinity. However its Nτ-protected precursor 200 failed completely to stimulate the H1Rs 
which is well in agreement with the current concept of SARs of histamine H1R agonists.67  
The symmetric histaprodifen urea hybrid 204 did not stimulate the histamine H1Rs 
despite its structural similarity with potent histaprodifen dimer (3,3-Diphenylpropyl derivative 
of 136, Rel. Pot. = 1680, histamine = 100) and turned out to be weak antagonist (pD´2 = 6.04, 
Table 2.4.1). 
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Partial Agonism: 
pEC50 = 5.00 ± 0.09 (histamine: 6.70) 
Rel. Potency: 2.0% (1.1 – 3.5) 
Emax = 66 ± 2% (N = 7, 3 animals) 
Affinity: pKP = 4.03 ± 0.10 (N = 7) 
 
Sensitivity vs Mepyramine: 
Strong sensitivity (N = 4) 
 
 
 
Figure 2.4.2 Partial H1R Agonism of 221 (Hydroxy-histaprodifen): Contraction of guinea-
pig ileum by histamine (1) (■, N = 7) and 221 in the absence (♦, Emax = 66 ± 2%, N = 7) and 
presence (◊, 5 ± 3%, N = 4) of mepyramine (3 nM). Rel. Pot. of 221 was 2.0% (95% conf 
limits 1.1 – 3.5%), pA2 of mepyramine could not be calculated due to the strong depression of 
the 221-induced response. The affinity of 221 was estimated as pKP value by competition of 
200 µM 221 (incubation time 3 min) with histamine at the end of each single agonist 
experiment (curve not shown). All data were obtained from three animals. For protocol, see 
Ref.57 
As several modifications at once did not produce the desired effect, the focus was 
turned on one modification at a time. One of the first modifications was to convert the 
carbonyl to alcohol functionality, which was thought to be easily obtained either from 208 or 
212. However, because of problems in the MEM deprotection, the desired analogue 221 was 
obtained by an alternative strategy (Scheme 2.3.18). In addition, the compound 221, a 
hydroxyl analogue of keto-histaprodifen (201) also turned out to be a partial H1R agonist 
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displaying about 2 % potency compared with histamine (1). The contractile effect was 
mediated by H1Rs since mepyramine (2 nM), a reference H1R antagonist, successfully 
blocked the effect of 201 (Fig. 2.4.2) with the expected nanomolar affinity. 
Another modification was the Nα-methylation to have an analogue of methyl 
histaprodifen. However, because of competing reactions, it was not possible to obtain the 
desired isomer (234). On the other hand a compound having additional methyl substituent α-
to the carbonyl group (223) was synthesized and screened for H1R agonistic activity. 
Surprisingly, 223 was not able to stimulate the H1Rs and behaved as weak antagonist (Figure 
2.4.3). This behaviour indicates that even a small substituent is not tolerated in the diphenyl 
side-chain of the keto-histaprodifen (201). So far it has been observed that agonistic activity 
could be obtained by carrying out some modifications at the carbonyl position in the side-
chain of 201. On the other hand, all other positions seem to be very sensitive. 
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Figure 2.4.3 Nonsurmountable H1R Antagonism of Compound 223 (α-Methylketo-
histaprodifen): Contraction of guinea-pig ileum by histamine (1) in the absence (■, N = 5) 
and in the presence of 223 [µM]: 30 (◊, Emax = 67 ± 5%, N = 5) and 50 (♦, Emax = 48 ± 6%, N 
= 2). Incubation time was 10 min. The rightward shift of the histamine curves amounted to 
less than 0.3 log units (0.15 ± 0.07, P > 0.05 for 30 µM 223 (N = 5), and 0.23 ± 0.11 for 50 
µM 223 (N = 2). Therefore, affinity was calculated as pD’2 = 4.18 ± 0.09 (95% conf limits 
3.92 – 4.44, N = 7). All data were obtained from three animals. 
 
Considering this fact, attempts were also made to convert carbonyl into more 
lipophilic moieties, but because of deprotection problem of MEM protecting group, desired 
compounds were not obtained and compounds such as 215 and 216 were not screened for the 
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H1R activity.It is also clear from the fact that Nτ-protected histamine derivatives are not able 
to stimulate the H1Rs. Moreover, because of the similar reasons compounds such as 211 and 
218 were also not screened. 
 
2.4.2 Conclusion 
In is concluded that the lack of H1R agonist activity observed for aminohydroxylated 
products structurally related to 109 [(rac)-191, 191, 196] is due to the additional oxygen-
containing polar functionalities attached to ethylamine side chain of 109. The keto derivative 
201 is the first 2-acyl derivative of 1 reported so far. This finding may be of importance since 
2-acyl congeners of histamine (1) are available much more efficiently than their 2-alkyl 
counterparts. Moreover, agonistic activity of hydroxyl analogue 221 indicates that the 
carbonyl position in the side chain of keto-histaprodifen has potential for the further 
modifications. 
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2.5 Pharmacological methods 
2.5.1 Pharmacology, data handling and pharmacological parameters 
Data are presented as mean ± SEM or SE or with 95% confidence limits (cl) unless otherwise 
indicated. Agonist potencies are given in percent or are expressed as pEC50 values (negative 
decadic logarithm of the molar concentration of the agonist producing 50% of the maximal 
response) and were corrected according to the long term mean value of the reference agonist 
histamine in our laboratory (guinea-pig ileum (H1): pEC50 = 6.70 for histamine). Maximal 
responses are expressed as Emax values (percentage of the maximal response to a reference 
compound). Antagonist affinities are expressed as either an apparent pA2 or a full pA2 value. 
The apparent pA2 value was calculated from the following equation: pA2 = −log c(B) + log(r − 
1), where c(B) is the molar concentration of antagonist and r the ratio of agonist EC50 
measured in the presence and absence of antagonist.68 The full pA2 value was determined 
according to the method of Arunlakshana and Schild69 using antagonist concentrations over 1-
2 log units. Noncompetitive antagonists are characterized by estimation of a pD'2 value 
according to the equation: pD'2 = −log c(B) + log (100/Emax − 1).70 Partial agonist affinity was 
estimated according to the method of Marano and Kaumann.71 The equilibrium dissociation 
constant KP for the partial agonist/receptor complex was estimated by comparing equiactive 
molar concentrations of the full agonist A (histamine) in the absence and presence of the 
partial agonist P in the same tissue according to the equation c(A) = m·c(A)* + b with m = 1/[1 
+ (1 − εP/εA)·c(P)/KP], where c(A) is the molar concentration of A in the absence of P, c(A)* 
the molar concentration of A in the presence of P, m the slope of a weighted regression line of 
c(A) versus c(A)*, b the ordinate intercept, and c(P) the molar concentration of P. εA and εP 
represent the intrinsic efficacies of A and P, respectively. Weights were calculated according 
to Lit.71 If εP << εA, pKP = −log KP can be calculated from log[(1/m) − 1] = log c(P) − log KP. 
Where appropriate, differences between means were determined by Student's t-test, after 
checking the homogeneity of the variances; P values < 0.05 were considered to indicate a 
significant difference between the mean values being compared. 
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2.5.2 Histamine H1R assay on the isolated guinea-pig ileum 
Guinea-pigs of either sex (250-500 g) were stunned by a blow on the neck and 
exsanguinated. The ileum was rapidly removed, rinsed and cut into segments of 1.5-2 cm 
length. The tissues were mounted isotonically (preload of 5 mN) in a jacketed 20-mL organ 
bath that was filled with Tyrode's solution of the following composition [mM]: NaCl 137, 
KCl 2.7, CaCl2 1.8, MgCl2 1.0, NaH2PO4 0.4, NaHCO3 11.9, and glucose 5.0. The solution 
additionally contained atropine to block cholinergic M receptors at a concentration not 
affecting H1Rs (0.05 µM). The solution was aerated with 95% O2-5% CO2 and warmed to a 
constant temperature of 37 °C. During an equilibration period of 80 min, the tissues were 
stimulated three times with histamine (1 µM, then 10 µM) followed by washout. Full and 
partial agonists: Each preparation was used to establish a cumulative concentration-effect 
curve for histamine (0.01-30 µM) followed by a second curve for a new agonist either in the 
absence or presence of mepyramine (1-100 nM, incubation time 10-15 min). For the 
determination of pKP, the partial agonist was not washed out and incubated for a defined 
period of time. A final cumulative curve for histamine was then constructed. pEC50 
differences were not corrected since up to four successive curves for histamine were 
superimposable (n > 10). Antagonists: Up to four cumulative concentration-response curves 
were determined on each tissue: a first to histamine (0.01-30 µM), and the 2nd – 4th to 
histamine in the presence of increasing concentrations of antagonist (incubation time 10–15 
min). pEC50 differences were not corrected since four successive curves for histamine were 
superimposable (n > 10). 
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2.6 Experimental part 
 
2.6.1 General Remarks 
Where indicated, reactions were carried out under a dry, oxygen-free atmosphere of 
N2 using Schlenk-technique or under argon atmosphere. Commercially available reagents 
were used as received. DMF, CH3CN and CH2Cl2 were distilled over P4O10 and stored under 
N2 over molecular sieves 3Å. EtOH and MeOH were dried over Mg and stored under N2. 
THF and Et2O were distilled over Na and stored over Na wire under N2. EtOAc, petroleum 
ether (60/40), CHCl3, CH2Cl2, MeOH and hexane for chromatographic separations were 
distilled before use. 
Thin Layer Chromatography (TLC): Silica gel 60 F254 on aluminum sheets of Merck Co. 
Ltd., (layer thickness: 0.2 mm) was used. The UV-light (λ = 254 nm) was adopted for the 
detection, Mostain, Vanillin sulfuric acid, Molybdato phosphoric acid (5% in EtOH), and 
Iodine were further used for development. 
Column Chromatography: Silica gel Geduran SI 60 (70-230 mesh) or Flash silica gel 60 
(230-400 mesh) purchased from Merck. Each experimental procedure gives more detailed 
information about the eluents. 
1H-NMRs: were recorded on Bruker Avance 300 (300 MHz), Bruker Avance 400 (400 MHz) 
and Bruker Avance 600 (600 MHz). The chemical shift (δ) is referred in ppm, which was 
calibrated on CDCl3 (7.26 ppm), DMSO-d6 (2.50 ppm), CD3OD (3.31 ppm), or 
Tetramethylsilane (0.00 ppm) as internal standard. The coupling constant J are given in Hz. 
The abbreviations for spin-spin splitting patterns: s = singlet, bs = broad singlet, d = doublet, t 
= triplet, q = quartet, m = multiplet, dd = doublet of doublet, ddd = doublet of doublet of 
doublet, dt = doublet of triplet.  
13C-NMRs: were recorded on Bruker Avance 300 (75.5 MHz), Bruker Avance 400 (100.6 
MHz), Bruker ARX 400 (100.6 MHz), and Bruker Avance 600 (150.9 MHz). The chemical 
shifts are given in δ (ppm), were calibrated on CDCl3 (77.16 ppm), DMSO-d6 (39.52 ppm), 
CD3OD (49.00 ppm), or Tetramethylsilane (0.00 ppm) as internal standard. The coupling 
constant J are given in Hz and the abbreviations for spin-spin splitting patterns are similar as 
used for 1H-NMRs. The multiplicities of signals were assigned by DEPT 90 and 135 (DEPT; 
distortionless enhancement by polarization transfer), and the notations were allotted as follow: 
+ = primary and tertiary C-atoms (positive DEPT 135 signal; tertiary C-atoms: DEPT 90 
signal), - = secondary C-atoms (negative DEPT signal), quart = quarternary C-atoms (DEPT 
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signal intensity zero). In some cases the COSY, HSQC, HMBC, and NOESY signals were 
investigated for the exact assignment of the structure.  
Melting points: were measured using the Buchi 510 or Buchi SMP 20 and are uncorrected.  
IR spectra: were recorded on Bio-Rad Excalibur Series FT-IR or Mattson Genesis Series FT-
IR. 
Mass spectra: were measured by Thermoquest Finnigan TSQ 7000 at the Central Analytical 
Laboratory University of Regensburg. The percentage in the bracket referes to the relative 
intensity of the peak compared to base peak (I = 100 %). For HRMS, the theoretical 
molecular formula and weight were calculated by ChemDraw® software, the practical 
measured figures were accepted in having a range of ± 3 ppm accuracy.  
Optical Rotation: was measured by Perkin-Elmer 241 MC polarimeter using 1.0 dm or 0.1 
dm measuring cell with 589 nm wavelength of Na-D-Line as light source. The concentration 
was noted in [g/100ml] unit. 
X-ray analysis: was performed by the Crystallography Laboratory (University of 
Regensburg, M. Zabel, S. Stempfhuber). 
HPLC-measurement: was achieved by using Chiracel OD / OD-H RH. 
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2.6.2 Experimental procedures and analysis of spectral data 
 
(E)-methyl 3-(1H-Imidazol-4-yl)acrylate (152) 
 
N
N
H
CO2Me
 
 
Trans urocanic acid (42 g 304, 1 mmol) and anhydrous Na2SO4 (6.0 g) were added to 450 mL 
of anhydrous methanol. Concentrated sulfuric acid (24 mL) was added to the reaction 
mixture, which was heated at reflux for 30 h. The solid Na2SO4 was filtered off, and the 
solvent was removed in vacuo. The remaining white solid was dissolved in a small amount of 
water and neutralized with saturated aq. NaHCO3 until no gas was evolved. The cloudy 
aqueous solution was extracted with ethyl acetate (2 × 400 mL). The organic layer was dried 
over Na2SO4, and the solvent was removed in vacuo. A white solid remained (44.56 g, 96%). 
m.p. = 92-94 C. All data were consistent with literature.72 
 
(E)-methyl 3-(1-methyl-1H-imidazol-4-yl)acrylate (163): 
 
N
N
CO2Me
Me
 
 
Dimethyl sulfate (3.4 mL) was added slowly to a stirred solution of 152 (2.9 g) in dry acetone 
(170 mL) and anhydrous potassium carbonate (10.2 g) and the mixture stirred at RT for a 
further 10 h. Filtration and removal of the solvent from the filtrate gave a viscous oil which 
was purified by column chromatography (CHCl3/EtOH, 10:1) gave the ester 163 (1.2 g 38%) 
which was used further without any purification. All data were consistent with literature.62 
 
(E)-methyl 3-(1-methyl-1H-imidazol-4-yl)acrylate (164): 
 
N
N
CO2Me
Me
O
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To a solution of 163 (240 mg, 1.45 mmol) in EtOAc (10 mL) was added m-CPBA (299.3 mg, 
1.74 mmol). The reaction mixture was stirred at RT for 24 h. Water (10 mL) was added and 
the reaction mixture was extracted in ethyl acetate (4 10 mL). Organic phases were combined 
and washed with brine (10 mL) and dried over Na2SO4. Filtration and evaporation gave a 
crude solid which was purified by column chromatography (CH2Cl2/MeOH, 10:2) to obtain 
164 (45 mg, 17%). 
Rf (SiO2, CH2Cl2/MeOH, 8:2) = 0.17; 1H NMR (300 MHz CD3OD): δ 3.74 (s, 3 H, OCH3), 
3.75 (s, 3 H, NCH3), 6.91 (d, J = 16.26 Hz, 1 H, =CHCO2), 7.56 (d, J = 16.26 Hz, 1 H, =CH), 
7.54 (bs, 1 H, Imi-C5), 8.33 (bs, 1 H, Imi-C2); 13C NMR (75.4 MHz CD3OD): δ = 36.2 (+, 
NCH3), 66.9 (+, OCH3), 120.31 (+, =CHCO2Me), 121.2 (+, CH, Imi-C5), 129.3 (+, =CH), 
129.8 (+, Cquat, Imi-C4), 131.2 (+, CH, Imi-C2), 167.8 (+, Cquat, CO); MS (EI, 70 eV): m/z 
(%) = 182.1 (49.8) [M+•], 166.1, (66.5) [M - O], 151.1 (17.2), 135.1 (100), 123.1 (42.9), 111.1 
(34.5). 
 
(E)-methyl 3-(1-((2methoxyethoxy)methyl)1H-Imidazol-4-yl)acrylate (171): 
 
N
N
CO2Me
MEM
 
 
To a suspensation of NaH (5.8 g 144.6 mmol) in DMSO (40 mL) was added dropwise a 
solution of methyl urocanate (152) (20 g 131.5 mmol) at 0 °C. The reaction mixture was 
stirred at 80 °C until no gas evolved (Ca. 2 h). MEM-chloride (18 g 144.6 mmol) in DMSO 
(20 mL) was added dropwise and the solution was stirred for further 12 h at 80 °C, excess of 
DMSO was distilled under reduced pressure to leave black oil. 5% aqueous solution of 
NaHCO3 (300 mL) was added and extracted with 1:1 mixture of CH2Cl2:Et2O (3×300 mL). 
The combined extracts were dried and concentrated to leave a black oil which was purified by 
short path column chromatography (EtOAc/hexanes 9:1) to give a mixture of regioisomers 
(171:172) as brown oil (25 g 86 %) the ratio of 171 and 172 was 90:10 as determined by 1H 
NMR. The major isomer 171 could be separated by careful column chromatography (white 
solid, 72 %). 
Rf (SiO2, EtOAc) = 0.17; m.p. = 74-75 °C; 1H NMR (300 MHz CDCl3): δ 3.37 (s, 3 H 
OCH3), 3.50-3.58 (m, 4 H, OCH2CH2O), 3.77 (s, 3 H, CO2CH3), 5.36 (s, 2 H, NCH2O), 6.59 
(d, J = 15.6 Hz 1 H, =CHCO2), 7.25 (bs, 1 H, Imi-5H), 7.56 (d, J = 15.6 Hz 1 H, =CH), 7.64 
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(bs, 1 H, Imi-2H); 13C NMR (75.4 MHz CDCl3): δ = 51.4 (+, CO2CH3), 58.9 (+, OCH3), 67.8 
(-, CH2O), 71.5 (-, CH2O), 76.7 (-, NCH2O), 116.2 (+, CH, Imi-C5), 121.2 (+, CHCO2), 135.9 
(+, =CH), 138.7 (+, CH, Imi-C2), 138.8 (+, Cquat, Imi-C4), 167.8 (+, Cquat, CO); IR (KBr): ~ν  
= 3190, 2866, 2586, 1719, 1651, 1541, 1504, 1431, 1300, 1215, 1168, 1097, 852, 788, 740, 
618, 512 cm-1; MS (DCI, NH3): m/z (%) = 241.2 (100) [M + H+], 481.1, (0.52) [2 M + H+]; 
Elemental analysis calcd (%) for C11H16N2O4 (240.11) C 54.99, H 6.71, N 11.66; found C 
54.86, H 6.16, N 11.58. 
 
N-methoxy-N-methyl-3,3-diphenylpropanamide (174): 
 
O
NPh
Ph
O
 
 
To a solution of acid chloride (173)64 (11.63 g 47.5 mmol) and N,O-dimethylhydroxylamine 
hydrochloride (5.1 g 52.3 mmol) in CHCl3 (ethanol free)65 at 0 °C was added dropwise 
pyridine (8.5 mL 104.5 mmol). The reaction mixture was stirred at the same temperature for 
30 min. and then reacted overnight at ambient temperature. Evaporated to dryness, water (100 
mL) was added and aqueous phase was extracted in hexane (300 mL) washed with aqueous 
saturated NaHCO3 (100 mL) and brine (100 mL). Dried over MgSO4, Solvent was evaporated 
in rotary evaporator to leave oil, which was purified by column chromatography to obtain the 
product as white solid (98%). 
Rf (SiO2, hexanes/EtOAc 7:3) = 0.24; m.p. = 48-49 °C; 1H NMR (300 MHz CDCl3): δ 3.09 
(s, 3 H, NCH3), 3.18 (d, J = 7.68 Hz, 2 H, CH2CO), 3.55 (s, 3 H, OCH3), 4.68 (t, J = 7.68 Hz, 
1 H, CHCH2), 7.30-7.13 (m, 10 H, aromatic); 13C NMR (CDCl3): δ = 32.3 (+, NCH3), 38.0 (-
, CH2), 46.5 (+, CHCH2), 61.4 (+, OCH3), 126.4 (+, CH, aromatic), 128.0 (+, CH, aromatic), 
128.6 (+, CH, aromatic), 144.3 (+, Cquat, aromatic), 172.5 (+, Cquat, CO); IR (KBr): ~ν  = 3026, 
2966, 1663, 1491, 1460, 1412, 1381, 1172, 1078, 1029, 987, 952, 777, 754, 695 cm-1; MS 
(DCI, NH3): m/z (%) = 270.3 (100) [M + H+], 287.3, (66) [M + NH4+], 539.2, (6.7) [2 M + 
H+]; Elemental analysis calcd for C17H19NO2 (269.14), C 75.81, H 7.11, N 5.20; found C 
75.68, H 6.40, N 5.05. 
 
(E)-methyl3-(1-((2methoxyethoxy)methyl)-2-(3,3-diphenylpropanoyl)-1H-Imidazol-4-
yl)acrylate (175)  and (E)-methyl 3-(1-((2-methoxyethoxy)methyl)-2-(3,3-
diphenylpropanoyl)-1H-imidazol-5-yl)acrylate (176): 
Experimental part H1-Receptor 56 
  
N
N
CO2Me
Ph
Ph O MEM
N
N
Ph
Ph O MEM
CO2Me
175 176
 
 
A mixture of 171 (700 mg, 2.914 mmol) and Weinreb amide 174 (863 mg, 3.205 mmol) in 
dry THF (15 mL) was set to stir under N2 at 0 °C. LDA (2 equiv. 5.828 mmol) in THF (7 mL) 
was added slowly, dropwise over a period of 4-7 min. The reaction mixture was sired at the 
same temperature for 1 h and allowed to warm up to RT and stirred for further 30 min. H2O 
(xx mL) was added and mixture was extracted in CH2Cl2 (3 × 20 mL), washed with 5% 
aqueous NaHCO3 (10 mL), Brine (10 mL), dried and concentrated to give a brown oil. 
Purification of this oil by column chromatography (EtOAc/Hexanes 3/7) gave 175 as white 
solid (48%). Recrystallization from Ether/hexanes (1:2), 175 was dissolved in ether and 
hexane was added slowly until precipitation, warmed up to 40 °C and kept at RT. Crystals 
were grown in 2 days and were suitable for the X-ray analysis. A similar reaction can also be 
performed on the mixture of 171 and 172 to obtain the mixture of 175 and 176 in 51% yield. 
Data for 175; Rf (SiO2, hexanes/EtOAc 7:3) = 0.16; m.p. = 78-80 °C; 1H NMR (300 MHz 
CDCl3): δ 3.31 (s, 3 H OCH3), 3.36-3.42 (m, 4 H, OCH2CH2O), 3.80 (s, 3 H CO2CH3), 3,93 
(d, J = 7.8 Hz, 2 H, CHCH2), 4.79 (t, J = 7.8 Hz, 1 H, =CHCH2), 5.70 (s, 2 H, NCH2O), 6.70 
(d, J = 15.64 Hz, 1 H, CHCO2), 7.12-7.31 (m, 10 H, aromatic), 7.44 (bs, 1 H, Imi-5H), 7.57 
(d, J = 15.64 Hz 1 H, =CH); 13C NMR (75.5 MHz, CDCl3): δ = 45.0 (-, CHCH2), 46.4 (+, 
CHCH2), 51.7 (+, CO2CH3), 59.0 (+, OCH3), 68.6 (-, OCH2), 71.3 (-, OCH2), 77.6 (-, 
NCH2O), 118.2 (+, CH, Imi-C5), 125.9 (+, =CHCO2), 126.4 (+, CH, aromatic), 127.9 (+, CH, 
aromatic), 128.6 (+, CH, aromatic), 135.5 (+, =CH), 137.9 (+, Cquat, Imi-C4), 143.3 (+, Cquat, 
Imi-C2), 143.8 (+, Cquat, aromatic), 167.6 (+, Cquat, CO2CH3), 191.6 (+, Cquat, CO); IR (KBr): 
~ν  = 3122, 3026, 2941, 2883, 1718, 1676, 1650, 1456, 1377, 1296, 1240, 1195, 1163, 1082, 
1021, 817, 746, 727, 698, 650, 619, 575, 531 cm-1; MS (ESI, CH2Cl2/MeOH/NH4Ac): m/z 
(%) = 449.2 (100) [M + H+], 447.0 (100) [M - H+]; Elemental analysis calcd (%) for 
C26H28N2O5 (448.2): calc. C 69.63, H 6.29, N 6.25; found C 69.37, H 5.82, N 6.06. 
Data for 176; Rf  (SiO2, hexanes/EtOAc 7:3) = 0.18; m.p. = 104-105 °C; 1H NMR (300 MHz 
CDCl3): δ 3.29 (s, 3 H OCH3), 3.30-3.35 (m, 4 H, OCH2CH2O), 3.79 (s, 3 H CO2CH3), 3,92 
(d, J = 7.96 Hz, 2 H, CHCH2), 4.79 (t, J = 7.96 Hz, 1 H, =CHCH2), 5.88 (s, 2 H, NCH2O), 
6.48 (d, J = 16.19 Hz, 1 H, CHCO2), 7.11-7.16 (m, 2 H, aromatic), 7.21-7.31 (m, 2 H, 
aromatic), 7.53 (bs, 1 H, Imi-5H), 7.62 (d, J = 16.19 Hz 1 H, =CH); 13C NMR (75.5 MHz, 
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CDCl3): δ = 45.4 (-, CHCH2), 46.6 (+, CHCH2), 52.0 (+, CO2CH3), 59.0 (+, OCH3), 67.9 (-, 
OCH2), 71.3 (-, OCH2), 73.8 (-, NCH2O), 121.3 (+, CH, Imi-C4), 129.2 (+, =CHCO2), 126.5 
(+, CH, aromatic), 127.9 (+, CH, aromatic), 128.6 (+, CH, aromatic), 131.2 (+, =CH), 134.1 
(+, Cquat, Imi-C5), 143.7 (+, Cquat, aromatic), 144.7 (+, Cquat, Imi-C2), 166.5 (+, Cquat, 
CO2CH3), 191.6 (+, Cquat, CO); IR (KBr): ~ν  = 2882, 2828, 1701, 1679, 1644, 1492, 1439, 
1275, 1248, 1198, 1156, 1133, 1107, 1083, 1030, 851, 746, 704, 648 cm-1; MS (CI, NH3): m/z 
(%) = 449.3 (100) [M + H+], 359.2 (2.3) [M - MEM], 167.1 (3.04) [CHPh2], 165.1 (2.9). 
 
benzyl(1S,2S)-1-(methoxycarbonyl)-2-(1-((2-methoxyethoxy)methyl)-2-(3,3-
diphenylpropanoyl)-1H-imidazol-4-yl)-2-hydroxyethylcarbamate (183): 
benzyl(1R,2S)-2-(methoxycarbonyl)-1-(1-((2-methoxyethoxy)methyl)-2-(3,3-
diphenylpropanoyl)-1H-imidazol-4-yl)-2-hydroxyethylcarbamate (184): 
 
N
N
CO2Me
Ph
Ph O MEM
OH
NHCbz
N
N
CO2Me
Ph
Ph O MEM
NHCbz
OH
183 184
 
 
A procedure for asymmetric aminohydroxylation: A 25 mL round-bottomed flask was 
charged with benzyl carbamate (397 mg, 2.626 mmol) and CH3CN (4 mL). To this stirred 
solution was added a freshly prepared aqueous solution of NaOH (103.34 g, 2.583 mmol in 3 
mL water), followed by tert-butyl hypochlorite (0.30 mL 280.5 mg 2.583 mmol). After 5 min 
a solution of (DHQD)2AQN (13 mg 0.038 mmol 5 mol %) and acrylate 175 (380 mg, 0.847 
mmol) in CH3CN (5 mL) was added in one portion followed by K2OsO2(OH)4 (13 mg 0.034 
mmol 4 mol %). The reaction mixture was stirred at 25 °C for 4 hours. Ethyl acetate (10 mL) 
was added and reaction mixture was extracted (3×20 mL) washes with broine (20 mL) Dried 
over MgSO4, Solvent was evaporated in rotary evaporator to leave oil which was purified by 
column chromatography to obtain the mixture of regioisomers (72%). 
Data for 183; Rf (SiO2, hexanes/EtOAc 7:3) = 0.14; thick oil; [ ]α D20  = - 4.7 (c = 0.4, CHCl3) 
for 75% ee; 1H NMR (300 MHz CDCl3): δ = 3.30 (s, 3 H OCH3), 3.34-3.37 (m, 4 H, 
OCH2CH2O), 3.54 (bs, 1 H, OH), 3.77 (dd, J = 16.40, 7.93 Hz, 1 H, CHHCH), 3.79 (s, 3 H 
CO2CH3), 3.87 (dd, J = 16.40, 7.93 Hz, 1 H, CHHCH), 4.75 (t, J = 7.93 Hz, 1 H, CHCH2), 
4.79 (dd, J = 2.59, 9.30 Hz, 1 H, CHNH), 5.07 (s, 2 H, CH2, benzyl), 5.23 (bs, 1 H, CHOH), 
Experimental part H1-Receptor 58 
  
5.64 (dd, J = 14.03, 10.36 Hz, 2 H, NCH2O), 5.79 (d, J = 9.30 Hz, 1 H, NH), 7.10-7.17 (m, 2 
H, aromatic + Imi-5H), 720-7.29 (m, 14 H, aromatic); 13C NMR (75.5 MHz, CDCl3): δ = 
45.1 (-, CHCH2), 46.5 (+, CHCH2), 52.9 (+, CO2CH3), 58.0 (+, CHNH), 59.2 (+, OCH3), 67.2 
(-, CH2OCO), 68.4 (-, OCH2), 68.8 (+, CHOH), 71.4 (-, OCH2), 77.5 (-, NCH2O), 121.9 (+, 
CH, Imi-C5), 126.5 (+, CH, aromatic), 127.9 (+, CH, aromatic), 128.1 (+, CH, aromatic), 
128.3 (+, CH, aromatic), 128.6 (+, CH, aromatic), 136.2 (+, Cquat, Imi-C4), 141.5 (+, Cquat, 
aromatic), 141.9 (+, Cquat, aromatic), 143.8 (+, Cquat, Imi-C2), 156.4 (+, Cquat, NHCO2), 171.2 
(+, Cquat, CO2CH3), 191.1 (+, Cquat, CO); IR (Film): ~ν  = 3423, 3061, 3030, 2927, 1726, 1681, 
1599, 1516, 1455, 1339, 1213, 1056, 983, 909, 847, 736, 701 cm-1; MS (EI, 70 eV): m/z (%) 
= 615.0 (3.53) [M+•], 507.0 (7.2) 448.(3.2) 393.1 (100) [M - (MEM + Cbz)] 303 (12.5), 207 
(16.9), 167 (41.1), 165 (15.8), 108 (15.7), 91.0 (32.5), 89.0 (56.7), 59.0 (28.1); HRMS calcd 
for C34H37N23O8, 615.2581. Found 615.2579. 
Data for 184; Rf  (SiO2, hexanes/EtOAc 7:3) = 0.15; thick oil; [ ]α D20  = - 18.5 (c = 0.4, CHCl3) 
for 87% ee; 1H NMR (300 MHz CDCl3): δ = 3.26 (s, 3 H, OCH3), 3.30-3.39 (m, 4 H, 
OCH2CH2O), 3.68-384 (m, 5 H, CH2CH + COCH3), 4.63 (dd, J = 11.06, 5.50 Hz, 1 H, 
CHOH), 4.67 (t, J = 7.68 Hz, 1 H, CHCH2), 5.05 (s, 2 H, CH2, benzyl), 5.20 (dd, J = 1.95, 
9.33 Hz, 1 H, CHNH), 5.53-5.65 (m, 2 H, NCH2O), 5.70 (d, J = 9.43 Hz 1 H, NH), 7.07-7.28 
(m, 16 H, aromatic + Imi-5H); 13C NMR (75.5 MHz, CDCl3): δ = 45.1 (-, CHCH2), 46.5 (+, 
CHCH2), 51.4 (+, CHNH), 53.0 (+, CO2CH3), 59.1 (+, OCH3), 67.3 (-, CH2OCO), 68.6 (-, 
OCH2), 71.4 (-, OCH2), 72.5 (+, CHOH), 77.5 (-, NCH2O), 122.7 (+, CH, Imi-C5), 126.5 (+, 
CH, aromatic), 127.9 (+, CH, aromatic), 128.0 (+, CH, aromatic), 128.3 (+, CH, aromatic), 
128.3 (+, CH, aromatic), 128.4 (+, CH, aromatic), 128.6 (+, CH, aromatic), 128.7 (+, CH, 
aromatic), 136.3 (+, Cquat, Imi-C4), 142.4 (+, Cquat, aromatic), 143.8 (+, Cquat, Imi-C2), 143.8 
(+, Cquat, aromatic), 155.9 (+, Cquat, NHCO2), 172.7 (+, Cquat, CO2CH3), 191.1 (+, Cquat, CO); 
IR (Film): ~ν  = 3329 (broad), 3139, 3061, 3029, 2926, 1724, 1682, 1600, 1532, 1496, 1455, 
1397, 1253, 1107, 1049, 1027, 984, 918, 845, 753, 701 cm-1; MS (ESI, 
CH2Cl2/MeOH/NH4Ac): m/z = 616.2 [M + H+], 1231.6 [2M + H+], 1253.6 [2M + NH4+]. 
 
methyl 3-(1-((2-methoxyethoxy)methyl)-2-(3,3-diphenylpropanoyl)-1H-imidazol-4-yl)-2-
amino-3-hydroxypropanoate (183-a) 
 
N
N
CO2Me
Ph
Ph O MEM
OH
NH2
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To a solution of 183 (racemic) (80 mg 0.13 mmol) in ethanol (5 mL) was added Pd/C (8 mg, 
10% wt) and purged with the atmosphere of hydrogen via balloon and stirred for 3 h, filtered 
through a small pad of Celite, washed with MeOH (10 mL), concentrated and purified by 
column chromatography (MeOH/EtOAc) to obtain the pail yellow product as a thick oil. 
Rf (SiO2, MeOH/EtOAc 2:8) = 0.23; thick oil; 1H NMR (300 MHz CDCl3): δ = 1.74 (bs, 2 H, 
NH2 exchangeable with D2O), 3.31 (s, 3 H, OCH3), 3.38-3.40 (m, 4 H, OCH2CH2O), 3.78 (s, 
3 H CO2CH3), 3.86 (d, J = 7.86 Hz, 1 H, CHHCH), 4.05 (d, J = 3.16 Hz, 1 H, CHNH2), 4.76 
(t, J = 7.86 Hz, 1 H, CHCH2), 5.04 (d, J = 3.16, Hz, 1 H, CHOH), 5.68 (d, J = 10.39 Hz, 1 H, 
NCHHO), 5.73 (d, J = 10.39 Hz, 1 H, NCHHO), 7.12-7.18 (m, 2 H, aromatic), 721-7.30 (m, 
8 H, aromatic),7.31 (bs, 1 H, Imi-5H); 13C NMR (75.5 MHz, CDCl3): δ = 44.9 (-, CHCH2), 
46.6 (+, CHCH2), 52.6 (+, CO2CH3), 58.2 (+, CHNH2), 59.1 (+, OCH3), 68.5 (-, OCH2), 69.4 
(+, CHOH), 71.5 (-, OCH2), 77.4 (-, NCH2O), 122.9 (+, CH, Imi-C5), 126.5 (+, CH, 
aromatic), 128.0 (+, CH, aromatic), 128.1, (+, CH, aromatic), 128.6 (+, CH, aromatic), 128.6 
(+, CH, aromatic), 142.3 (+, Cquat, Imi-C4), 143.3 (+, Cquat, Imi-C2), 143.9 (+, Cquat, 
aromatic), 144.0 (+, Cquat, aromatic), 173.7 (+, Cquat, CO2CH3), 191.3 (+, Cquat, CO); IR 
(Film): ~ν  = 3400-3354 (broad), 3026, 2929, 2882, 1745, 1680, 1600, 1493, 1249, 1201, 1101, 
981, 848, 754, 702, 667 cm-1; MS (ESI, CH2Cl2/MeOH/NH4Ac): m/z (%) = 482.2 (100) [M + 
H+]; HRMS (EI, 70 eV) calcd for C26H31N3O6, 481.2291. Found 481.2284. 
 
tert-butyl (1S,2S)-1-(methoxycarbonyl)-2-(1-((2-methoxyethoxy)methyl)-2-(3,3-
diphenylpropanoyl)-1H-imidazol-4-yl)-2-hydroxyethylcarbamate (189): 
 
N
N
CO2Me
Ph
Ph O MEM
OH
NHBoc
 
 
To a solution of 183 (80 mg 0.13 mmol) and (Boc)2O (37 mg 0.17 mmol) in MeOH (6 mL) 
was added Pd/C (8 mg, 10 % wt) and purged with the atmosphere of hydrogen via balloon 
and stirred for 1 h, filtered through a small pad of Celite, washed with EtOAc (15 mL), 
concentrated and purified by column chromatography (hexanes/EtOAc 6:4) to obtain the pure 
product (96 %). The same reaction can also be performed on the mixture of regioisomers 183 
and 184 to yield the mixture of 189 and 190, which is readily separated by column 
chromatography. 
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Rf  (SiO2, hexanes/EtOAc 6:4) = 0.25; m.p. = 89-90 °C; [ ]α D20  = + 7.15 (c = 1, CHCl3) for 
99.9 % ee; 1H NMR (300 MHz CDCl3): δ = 1.40 (s, 9 H, NHCMe3), 3.31 (s, 3 H, OCH3), 
3.36-3.39 (m, 4 H, OCH2CH2O), 3.57 (bs, 1 H, OH), 3.80 (dd, J = 16.42, 7.92 Hz, 1 H, 
CHHCH), 3.78 (s, 3 H, CO2CH3), 3.90 (dd, J = 16.42, 7.92 Hz, 1 H, CHHCH), 4.70 (dd, J = 
3.05, 9.06 Hz, 1 H, CHNH), 4.76 (t, J = 7.92 Hz, 1 H, CHCH2), 5.19 (dd, 1 H, J = 3.05, 5.32 
Hz CHOH), 5.57 (d, J = 9.05 Hz, 1 H, NH), 5.66 (d, J = 10.56 Hz, 1 H, NCHHO), 5.70 (d, J = 
10.56 Hz, 1 H, NCHHO), 7.12-7.18 (m, 2 H, aromatic + Imi-5H), 722-7.29 (m, 10 H, 
aromatic + Imi-2H), 13C NMR (75.5 MHz, CDCl3): δ = 45.1 (-, CHCH2), 46.6 (+, CHCH2), 
52.8 (+, CO2CH3), 57.6 (+, CHNH), 59.1 (+, OCH3), 68.5 (-, OCH2), 68.9 (+, CHOH), 71.4 (-
, OCH2), 77.5 (-, NCH2O), 80.3 (+, Cquat, CMe3), 122.0 (+, CH, Imi-C5), 126.5 (+, CH, 
aromatic), 127.9 (+, CH, aromatic), 128.0, (+, CH, aromatic), 128.6 (+, CH, aromatic), 141.8 
(+, Cquat, Imi-C4), 142.0 (+, Cquat, Imi-C2), 143.8 (+, Cquat, aromatic), 143.9 (+, Cquat, 
aromatic), 155.9 (+, Cquat, NHCO2), 171.5 (+, Cquat, CO2CH3), 191.1 (+, Cquat, CO); IR 
(Film): ~ν  = 3400, 2930, 2890, 1724 1692, 1512, 1500, 1454, 1363, 1285, 1163, 1106, 1057, 
1017, 1000, 857, 784, 754, 729, 705, 615 cm-1; MS (EI, 70 eV): m/z (%) = 581.3 [M+•], 508.0 
(5.5), 448.(3.2) 393.2 (100) [M – (MEM + Boc)], 303 (3.9), 207 (8.9), 167 (41.1), 167 (49.7), 
133 (10.3), 89.1 (91.6), 59.0 (50.1); HRMS calcd for C31H39N3O8, 581.2737. Found 
581.2728. 
 
(2S,3S)-methyl3-(2-(3,3-diphenylpropanoyl)-1H-imidazol-4-yl)-2-amino-3 
hydroxypropanoatedihydrochloride (191): 
 
N
N
H
CO2Me
Ph
Ph
O
HO
NH2
.2HCl
 
 
To a solution of 189 (40 mg 0.069 mmol) in 1:1 mixture of MeOH:H2O (2 mL) was added 
conc. HCl (1 mL) and the reaction mixture was refluxed for 1.5 h, cooled to RT and excess of 
solvent was removed using rotary evaporator and remaining yellowish solid was kept under 
high vacuum for 3-4 hours at 60 °C. The solid was dissolved in dry MeOH (4 mL) and 
Na2SO4 (40 mg) was added. Concentrated sulfuric acid (2 drops) was added to the reaction 
mixture, which was heated at reflux for 30 h. The solid Na2SO4 was filtered off, and the 
solvent was removed in vacuo. Brine (5 mL) was added and the reaction mixture was 
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extracted in CH2Cl2 (4×7 mL) dried over Na2SO4. After evaporation of solvent the white solid 
was obtained (75% over two steps). 
Rf (SiO2, MeOH/EtOAc 3:7) = 0.16; white solid, m.p.  = 147-154 °C; [ ]α D20  = − 14.3 (c = 0.6, 
CH2Cl2); 1H NMR (300 MHz CD3OD): δ = 3.73 (s, 3 H, COCH3), 3.79 (dd, J = 1.89, 7.82 
Hz, 2 H, CH2CO), 3.87 (d, 1 H, J = 3.60 Hz, 1 H, CHNH2), 4.75 (t, J = 7.82 Hz, 1 H, 
CHCH2), 5.11 (dd, J = 0.72, 3.60 Hz, 1 H, CHOH), 7.09-7.31 (m, 10 H, aromatic + Imi-5H), 
13C NMR (75.5 MHz, CD3OD): δ = 44.5 (-, CHCH2), 47.6 (+, CHCH2), 52.8 (+, CO2CH3), 
60.3 (+, CHNH2), 70.3 (+, CHOH), 118.0 (+, CH, Imi-C5), 127.4 (+, CH, aromatic), 128.9 
(+, CH, aromatic), 129.0 (+, CH, aromatic), 129.5 (+, CH, aromatic), 145.5 (+, Cquat, Imi-
C4), 145.6 (+, Cquat, aromatic), 146.3 (+, Cquat, Imi-C2), 174.5 (+, Cquat, CO2CH3), 190.4 (+, 
Cquat, CO); IR (neat): ~ν  = 3300-2500 (broad), 1754, 1715, 1599, 1495, 1219, 1163, 1039, 
1017, 754, 698, 613 cm-1; MS (ESI, CH2Cl2/MeOH/NH4Ac): m/z = 394.1 [M + H+], 787.5 
[2M + H+]; HRMS (EI, 70 eV) calcd for C22H23N3O4, 393.1689. Found 393.1688. Elemental 
analysis calcd (%) for C22H25Cl2N3O4 (466.3576): calc. C, 56.66; H, 5.40; Cl, 15.20; N, 9.01; 
found C 56.71, H 5.68, N 8.60. 
 
(E)- 3-(1-((2-methoxyethoxy)methyl)-1H-Imidazol-4-yl)prop-2-en-1-ol (177): 
 
N
N
MEM
OH
 
 
Compound 171 (2 g, 8.32 mmol) was dissolved in CH2Cl2 (40 mL) under N2 and cooled to 0 
°C. DIBAL-H (1 M in CH2Cl2, 25.8 mL, 25.8 mmol) was added dropwise. The mixture was 
allowed to warm up to RT slowly and stirred further for 6-8 h and cooled to 0 °C again, H2O 
(9 mL) was added slowly, followed by NaOH (2N, 8 mL) and H2O (9 mL). The mixture was 
filtered through Celite and washed with CH2Cl2 several times. The organic layer of the filtrate 
was separated. Water phase was extracted with CH2Cl2 (8×30 mL). The combined organic 
phase was dried over MgSO4 and filtered. The filtrate was concentrated under reduced 
pressure and the residue was subjected to column chromatography (90/10, EtOAc/MeOH) to 
afford 177 as colorless thick oil (1.52 g 86%). 
Rf (SiO2, EtOAc/MeOH) = 0.29; thick oil; 1H NMR (300 MHz CDCl3): δ = 3.32 (s, 3 H 
OCH3), 3.44-3.51 (m, 4 H, OCH2CH2O), 3.73 (bs, 1 H, OH), 4.17-4.28 (m, 2 H, CH2OH), 
5.26 (s, 2 H, NCH2O), 6.42 (dd, J = 15.85, 3.74 Hz, 1 H, =CHCH2OH), 6.48 (dd, J = 15.85, 
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3.74 Hz 1 H, =CH), 6.94 (d, J = 1.17 Hz, 1 H, Imi-5H), 7.52 (d, J = 1.17 Hz, 1 H, Imi-2H); 
13C NMR (75.5 MHz, CDCl3): δ = 59.1 (+, OCH3), 63.1 (-, CH2OH), 67.7 (-, CH2O), 71.6 (-, 
CH2O), 76.7 (-, NCH2O), 116.2 (+, CH, Imi-C5), 121.8 (+, =CH), 128.7 (+, =CHCH2), 137.7 
(+, CH, Imi-C2), 140.8 (+, Cquat, Imi-C4); IR (Film): ~ν  = 3358-3262 (broad), 3126, 2924, 
2881, 1501, 1458, 1359, 1228, 1200, 1096, 1037, 969, 848, 775, 739, 628 cm-1; MS (EI, 70 
eV): m/z (%) = 212.1 (41.2) [M+•], 183.1, (84.6) [M+ - C2H5] 123.0 (45.2) [M+ - MEM], 89.1 
(33.1), 59.1 (100), 45.1 (7.33); HRMS (EI, 70 eV) calcd for C10H16N2O3, 212.1161. Found 
212.1162. 
 
1-((2-methoxyethoxy)methyl)-4-((E)- 3-(benzyloxy)prop-1-enyl)-1H-Imidazole (178): 
 
N
N
MEM
OBn
 
 
A round bottom flask charged with NaH (151 mg 60% dispersion 3.76 mmol), was added 
dropwise a solution of alcohol 177 in DMF (4 mL) at RT and the reaction mixture was stirred 
at RT for 1 h. Benzyl bromide (643 mg, 3.76 mmol, 0.48 mL) was added slowly and the 
reaction mixture was stirred at RT for 16 h. Water (10 mL) was added and the reaction 
mixture was extracted in ether (20 mL), washed with brine(10 mL) and dried (MgSO4). 
Filtration and evaporation of the solvent afforded the crude product which was purified by 
column chromatography (hexanes/EtOAc) (82%). 
Rf (SiO2, EtOAc) = 0.21 Thick oil; 1H NMR (300 MHz CDCl3): δ 3.35 (s, 3 H OCH3), 3.46-
3.53 (m, 4 H, OCH2CH2O), 4.17 (d, J = 4.80 Hz, 2 H, =CHCH2), 4.55 (s, 2 H, CH2O), 5.27 (s, 
2 H, NCH2O), 6.46 (dt, J = 4.84, 15.75 Hz, =CHCH2), 6.54 (d, J = 15.81 Hz, 1 H, =CH), 6.98 
(d, J = 0.95 Hz, 1 H, Imi-5H), 7.23-7.38 (m, 5 H, aromatic), 7.54 (d, J = 0.95 Hz, 1 H, Imi-
2H); 13C NMR (75.5 MHz, CDCl3): δ = 59.0 (+, OCH3), 67.6 (-, CH2O), 70.5 (-, CH2O), 71.5 
(-, CH2O), 71.8 (-, OCH2), 76.5 (-, NCH2O), 116.3 (+, CH, Imi-C5), 123.9 (+, =CH), 125.0 
(+, =CHCH2), 127.5 (+, CH, aromatic), 127.6 (+, CH, aromatic), 128.3 (+, CH, aromatic), 
137.6 (+, CH, Imi-C2), 138.4 (+, Cquat, aromatic), 140.8 (+, Cquat, Imi-C4); IR (film): ~ν  = 
3128, 2926, 2879, 1668, 1540, 1497, 1454, 1360, 1304, 1242, 1200, 1102, 1037, 970, 847, 
746, 700, 623 cm-1; MS (EI, 70 eV): m/z (%) = 302.1 (20.2) [M+•], 211.0 (24.8) [M – C7H7], 
183.1, (46.6) [M - (Bn + C2H5)] 107.0 (18.3), 89.1 (64.2), 59.1 (100), 31.1 (12.3); HRMS (EI, 
70 eV) calcd for C17H22N2O3, 302.1630. Found 302.1628. 
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1-(1-((2methoxyethoxy)methyl)4-((E)-3-(benzyloxy)prop-1-enyl)-1H-Imidazol -2-yl)3,3-
diphenylpropan-1-one (179): 
 
N
N
MEM
OBn
Ph
Ph O
 
 
To a solution of alkene (250 mg, 0.827 mmol) in THF (2 mL) at -78 °C  was added drop wise 
solution of  n-BuLi (0.62 mL 0.992 mmol,15% sol in n-hexane) and the black solution was 
stirred at the same temperature for 1 h.  Weinreb amide 174 (245 mg, 0.909 mmol) in THF (2 
mL) was added slowly at -78 °C  and reaction mixture was stirred at the same temperature for 
further 1 h and warmed up to RT and stirred for further 1.5 h. The mixture was diluted with 
CH2Cl2 (10 mL) washed with 5% aqueous Na2CO3 (5 mL) dried (MgSO4) filtration and 
evaporation gave the oil which was purified by column chromatography (EtOAc/hexanes 3:7) 
gave 179 as a tan oil (67-69%). 
Rf  (SiO2, hexanes/EtOAc 7:3) = 0.23; Thick oil; 1H NMR (300 MHz CDCl3): δ = 3.30 (s, 3 
H, OCH3), 3.32-3.38 (m, 4 H, OCH2CH2O), 3.92 (d, J = 7.89 Hz, 2 H, CH2CH), 4.20 (dd, J = 
1.97 Hz, =CHCH2O), 4.58 (s, 2 H, OCH2Ph), 4.80 (t, J = 7.89 Hz, 1 H, CH2CH), 5.68 (s, 2 H, 
NCH2O), 6.50-6.61 (m, 2 H, CH=CH), 7.10-7.40 (m, 16 H, aromatic + Imi-5H), 13C NMR 
(75.5 MHz, CDCl3): δ = 45.0 (-, CHCH2), 46.4 (+, CHCH2), 59.0 (+, OCH3), 68.2 (-, OCH2), 
70.4 (-, CH2OBn), 71.3 (-, OCH2), 72.3 (-, OCH2Ph), 77.2 (-, NCH2O), 122.3 (+, CH, Imi-
C5), 123.4 (+, =CH), 126.4 (+, CH, aromatic), 127.2 (+, =CHCH2), 127.7 (+, CH, aromatic), 
127.8 (+, CH, aromatic), 128.0 (+, CH, aromatic), 128.4 (+, CH, aromatic), 128.5 (+, CH, 
aromatic), 138.3 (+, Cquat, Imi-C4), 140.2 (+, Cquat, aromatic), 142.5 (+, Cquat, Imi-C2), 144.0 
(+, Cquat, aromatic), 191.4 (+, Cquat, CO); IR (Film): ~ν  = 3059, 3028, 2924, 2874, 1678, 1493, 
1454, 1427, 1361, 1303, 1245, 1200, 1105, 980, 847, 815, 733, 700, 608 cm-1; MS (ESI): m/z 
(%) = 511.2 (100) [M + H+]; HRMS (EI, 70 eV) calcd for C32H34N2O4, 510.2519. Found 
510.2518. 
 
Compound (180): 
 
N
N
MEM
OTBDMS
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To a solution of allyl alcohol 177 (1 g 4.72 mmol) and TBDMS-Cl (854 mg 5.66 mmol) in 
DMF (2 mL) was added imidazole (803 mg 11.8 mmol). The reaction mixture was stirred at 
RT for 1 h. Water (10 mL) was added and the reaction mixture was extracted in ether (2×20 
mL), washed with brine (10 mL) and dried (MgSO4). Filtration and evaporation of the solvent 
afforded the crude product which was purified by column chromatography (hexanes/EtOAc 
1:9) to obtain the product as thick oil (96%). 
Rf (SiO2, EtOAc) = 0.26; thick oil; 1H NMR (300 MHz CDCl3): δ = 0.08 (s, 6 H, SiMe2), 
0.91 (s, 9 H, SiCMe3), 3.35 (s, 3 H OCH3), 3.47-3.54 (m, 4 H, OCH2CH2O), 4.32 (d, J = 3.50 
Hz, 2 H, CH2O), 5.29 (s, 2 H, NCH2O), 6.41 (dt, J = 15.68, 4.12 Hz, 1 H, =CHCH2O), 6.48 
(d, J = 15.68 Hz 1 H, =CH), 6.95 (d, J = 0.92 Hz, 1 H, Imi-5H), 7.53 (d, J = 0.92 Hz, 1 H, 
Imi-2H); 13C NMR (CDCl3): δ = − 5.1 (+, SiMe2), 18.6 (+, Cquat, SiCMe3), 26.1 (+, SiCMe3), 
59.2 (+, OCH3), 63.7 (-, CH2O), 67.7 (-, CH2O), 71.7 (-, CH2O), 76.7 (-, NCH2O), 116.0 (+, 
CH, Imi-C5), 120.8 (+, =CH), 128.4 (+, =CHCH2), 137.6 (+, CH, Imi-C2), 141.2 (+, Cquat, 
Imi-C4); IR (neat): ~ν  = 2953, 2929, 2884, 2856, 1690, 1541, 1499, 1462, 1359, 1252, 1098, 
1061, 1040, 966, 834, 775, 625 cm-1; MS (EI, 70 eV): m/z (%) = 326.4 (78.8) [M+•], 311.3, 
(10.7) [M - CH4] 269.3 (35.3) [M - C4H10], 237.2 (100) [M+ - MEM], 193.2 (32.5), 119.1 
(41.7), 89.1 (40.7), 75.1 (38.9), 59.1 (77.8); HRMS (EI, 70 eV) calcd for C16H30N2SiO3, 
326.2026. Found 326.2025. 
 
Compound (181): 
 
N
N
MEM
OTBDMS
Ph
Ph O
 
 
To a solution of alkene 180 (760 mg, 2.33 mmol) in THF (5 mL) at -78 °C was added drop 
wise solution of n-BuLi (1.75 mL 2.80 mmol, 15% sol in n-hexane) and the black solution 
was stirred at the same temperature for 1 h. Weinreb amide 174 (690 mg, 2.5 mmol) in THF 
(5 mL) was added slowly at -78 °C and reaction mixture was stirred at the same temperature 
for further 1 h and warmed up to RT and stirred for further 1.5 h. The mixture was diluted 
with diethyl ether (20 mL) washed with 5% aqueous Na2CO3 (5 mL) dried (MgSO4) filtration 
and evaporation gave the oil which was purified by column chromatography (EtOAc/hexanes 
3/7) gave 181 (69%). 
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Rf  (SiO2, hexanes/EtOAc 7:3) = 0.25; m.p. = 56.57 °C; 1H NMR (300 MHz CDCl3): δ = 
0.12 (s, 6 H, SiMe2), 0.95 (s, 9 H, SiCMe3), 3.31 (s, 3 H OCH3), 3.34-3.40 (m, 4 H, 
OCH2CH2O), 3.93 (d, J = 7.86 Hz, 2 H, CHCH2), 4.31-4.42 (m, 2 H, CH2O), 4.81 (t, J = 7.86 
Hz, 1 H, CHCH2), 5.71 (s, 2 H, NCH2O), 6.41 (dt, J = 15.68, 4.12 Hz, 1 H, =CHCH2O), 6.47-
6.59 (m, 2 H, HC=CH), 7.12-7.32 (m, 11 H, aromatic + Imi-5H); 13C NMR (75.5 MHz, 
CDCl3): δ = − 5.1 (+, SiMe2), 18.6 (+, Cquat, SiCMe3), 26.1 (+, SiCMe3), 45.1 (-, CH2CH), 
46.4 (+, CH2CH), 59.1 (+, OCH3), 63.6 (-, CH2O), 68.2 (-, CH2O), 71.4 (-, CH2O), 77.2 (-, 
NCH2O), 120.4 (+, CH, Imi-C5), 122.0 (+, =CH), 126.4 (+, CH, aromatic), 128.1 (+, CH, 
aromatic), 128.6 (+, CH, aromatic), 130.5 (+, =CHCH2), 140.7 (+, Cquat, Imi-C4) 142.5 (+, 
Cquat, Imi-C2), 144.1 (+,Cquat, aromatic), 191.5 (+, Cquat, CO); IR (neat): ~ν  = 3119, 2927, 
2857, 2856, 1685, 1493, 1452, 1359, 1274, 1125, 1082, 1066, 1022, 1006, 943, 836, 810, 769, 
728, 698, 669 cm-1; MS (EI, 70 eV): m/z (%) = 534.4 (59.8) [M+•], 506.2 (12.4) [M - C2H6], 
479.4, (22.8), 447.4 (12.2), 313.3 (29.9), 207.2 (12.1), 181.2 (12.0), 167.2 (100), 89.1 (37.6), 
59.1 (54.2); HRMS (EI, 70 eV) calcd for C31H42N2SiO4, 534.2914. Found 534.2909. 
 
1-(1-((2-methoxyethoxy)methyl)-4-((E)-3-hydroxyprop-1-enyl)-1H-imidazol-2-yl)-3,3-
diphenylpropan-1-one (182): 
 
N
N
MEM
OH
Ph
Ph O
 
 
To a solution of 181 (200 mg 0.374 mmol) in THF (5 mL) at 0 °C was added TBAF (130 mg 
0.415 mmol) and the reaction mixture was stirred at RT for 1.5 h. Water (5 mL) was added 
and the reaction mixture was extracted with CH2Cl2 (2×20 mL) and dried over MgSO4. 
Filtration and evaporation of the solvent afforded the crude product which was purified by 
column chromatography (hexanes/EtOAc 3:7) to obtain the product as thick oil (91%). 
Rf (SiO2, hexanes/EtOAc 3:7) = 0.29; thick oil; 1H NMR (300 MHz CDCl3): δ = 1.60 (bs, 1 
H, OH), 3.31 (s, 3 H, OCH3), 3.35-3.40 (m, 4 H, OCH2CH2O), 3.93 (d, J = 7.89 Hz, 2 H, 
CHCH2), 4.34 (d, 2 H, J = 3.36 Hz, CH2O), 4.80 (t, J = 7.89 Hz, 1 H, CHCH2), 5.71 (s, 2 H, 
NCH2O), 6.51-6.66 (m, 2 H, HC=CH), 7.12-7.31 (m, 11 H, aromatic + Imi-5H); 13C NMR 
(75.5 MHz, CDCl3): δ = 45.1 (-, CH2CH), 46.4 (+,CH2CH), 59.1 (+, OCH3), 63.5 (-, CH2O), 
68.4 (-, CH2O), 71.5 (-, CH2O), 77.2 (-, NCH2O), 122.1 (+, CH, Imi-C5), 122.3 (+, =CH), 
126.5 (+, CH, aromatic), 128.1 (+, CH, aromatic), 128.6 (+, CH, aromatic), 129.9 (+, 
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=CHCH2), 140.2 (+, Cquat, Imi-C4) 142.6 (+, Cquat, Imi-C2), 144.0 (+, Cquat, aromatic), 191.5 
(+, Cquat, CO); IR (neat): ~ν  = 2923, 2856, 1674, 1493, 1451, 1426, 1301, 1198, 1082, 1089, 
1029, 979, 813, 750, 729, 699, 613 cm-1; MS (EI, 70 eV): m/z (%) = 420.4 (56.8) [M+•], 392.4 
(12.4) 331.3 [M − MEM], 301.3, (25.7), 253.2 (31.7), 211.2 (25.3), 207.2 (34.6), 167.2 (100), 
138.2 (56.7), 124.1 (25.2), 89.1 (25.1), 59.1 (55.6); HRMS (EI, 70 eV) calcd for C25H28N2O4, 
420.2049. Found 420.2050. 
 
Compounds 185 and 186 
 
N
N
MEM
OBn
Ph
Ph O
NHCbz
OH
N
N
MEM
OBn
Ph
Ph O
OH
NHCbz
185 186
 
 
Procedure for asymmetric aminohydroxylation: A 25 mL round-bottomed flask was 
charged with NaOH (49.22 mg, 1.23 mmol) in water (2 mL) and to the clear solution benzyl 
carbamate (189.03 mg, 1.25 mmol) was added followed by CH3CN (1.5 mL). At this stage the 
solution should be homogeneous. To this stirred solution was added a freshly prepared tert-
butyl hypochlorite (0.142 mL 133.6 mg 1.53 mmol). After 5 min a solution of (DHQD)2AQN 
(15.8 mg 0.021 mmol 5 mol %) and 179 (206 mg, 0.4034 mmol) in CH3CN (4 mL) was added 
in one portion followed by K2OsO2(OH)4 (5.95 mg 0.016 mmol 4 mol %). The reaction 
mixture was stirred at 25 °C for 1 h. Ethyl acetate (10 mL) and water (5 mL)was added and 
reaction mixture was extracted in EtOAc (3×10 mL) washed with brine (10 mL) and dried 
over MgSO4. Solvent was evaporated in rotary evaporator to leave oil which was purified by 
column chromatography (hexanes/EtOAc 1:1) to obtain the product as mixture of 
regioisomers (65-67%). The regioisomers were not separable and used as such for the next 
reaction. 
Rf (SiO2, hexanes/EtOAc 7:3) = 0.17; thick oil; MS (ESI, CH2Cl2/MeOH/NH4Ac): m/z = 
678.4 [M + H+], 712.3 [M + Cl−], 736.4 [M + CH3CO2−]. 
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Compounds 192 and 193:  
 
N
N
MEM
OBn
Ph
Ph O
NHBoc
OH
N
N
MEM
OBn
Ph
Ph O
OH
NHBoc
192 193
 
 
To a solution of mixture of regioisomers 185 and 186 (81 mg 0.12 mmol) and (Boc)2O (34 
mg 0.15 mmol) in MeOH (3 mL) was added Pd/C (8 mg, 10% wt) and purged with the 
atmosphere of hydrogen via balloon and stirred for 1 h, filtered through a small pad of Celite, 
washed with EtOAc (15 mL), concentrated and purified by column chromatography 
(hexanes/EtOAc 6:4) to obtain non-separable mixture of regioisomers (92%). 
Rf (SiO2, hexanes/EtOAc 7:3) = 0.19; thick oil.  
 
Compounds 194 and 195 
 
N
N
MEM
OH
Ph
Ph O
NHBoc
OH
N
N
MEM
OH
Ph
Ph O
OH
NHBoc
194 195
 
 
To a solution of mixture of regioisomers 192 and 193 (400 mg 0.621 mmol) in THF (15 mL) 
was added Pd/C (40 mg, 10% wt) and stirred under the atmosphere of hydrogen (40 bar 40 
°C) for 48 h, filtered through a small pad of Celite, washed with MeOH (30 mL), 
concentrated and purified by column chromatography (hexanes/EtOAc 8:2) to obtain non-
separable mixture of regioisomers (62%). 
Separation of regioisomers 194 and 195: To a solution of mixture of 1,3-(194) and 1,2-diol 
(195) (250 mg 0.45 mmol) in dioxane:water (3:1 42 mL) at RT was added solid NaIO4 (483 
mg 2.25 mmol) in portions over a period of 5 min. The reaction mixture was stirred at RT for 
2.5 h. Water (15 mL) was added and the reaction mixture was extracted in EtOAc (4×15 mL). 
The combined organic phase was washed with brine (10 mL), dried over MgSO4. Filtration 
and evaporation gave a mixture of aldehyde and unreacted 1,3-diol. 1,3-diol (194) was 
isolated by column chromatography (hexanes/EtOAc 8:2). 
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Compound 194: 
N
N
MEM
OH
Ph
Ph O
OH
NHBoc
 
 
Rf  (SiO2, EtOAc) = 0.26; thick oil; [ ]α D20  = − 2.18 (c = 0.55, CHCl3) for 48 % ee; 1H NMR 
(300 MHz CDCl3): δ = 1.34 (s, 9 H, NHCMe3), 3.24 (s, 3 H OCH3), 3.29-3.35 (m, 4 H, 
OCH2CH2O), 3.65-3.87 (m, 5 H, CHCH2, CH2OH, CHNH), 4.68 (t, J = 7.62 Hz, 1 H, 
CHCH2), 4.96 (d, 1 H, J = 3.12 Hz, CHOH), 5.42 (d, 1 H, J = 7.37 Hz, NHBoc), 5.63 (s, 2 H, 
NCH2O), 6.51-6.66 (m, 2 H, HC=CH), 7.05-7.10 (m, 2 H, aromatic), 7.15-7.23 (m, 8 H, 
aromatic), 7.26 (bs, 1 H, Imi-5H); 13C NMR (75.5 MHz, CDCl3): δ = 28.3 (+, CMe3), 45.0 (-, 
CH2CH), 46.6 (+,CHCH2), 56.0 (+, CHNH), 59.0 (+, OCH3), 63.4 (-, CH2OH), 68.4 (-, 
CH2O), 70.1 (+, CHOH), 71.4 (-, CH2O), 77.4 (-, NCH2O), 80.0 (+, Cquat, CMe3), 122.4 (+, 
CH, Imi-C5), 126.6 (+, CH, aromatic), 127.9 (+, CH, aromatic), 128.0 (+, CH, aromatic), 
128.5 (+, CH, aromatic), 142.0 (+, Cquat, Imi-C4), 142.7 (+, Cquat, Imi-C2), 143.7 (+, Cquat, 
aromatic), 143.8 (+, Cquat, aromatic), 156.7 (+, Cquat, NHCO), 191.0 (+, Cquat, CO); IR (neat): 
~ν  = 3400 (broad), 3000, 1720, 1682, 1494, 1454, 1366, 1249, 1165,  1103, 1050, 1030, 983, 
702, 682, 672 cm-1; MS (EI, 70 eV): m/z (%) = 554.4 [M + H+], 393.1 (37.7), 227.1, 167.0 
(34.9), 89.1 (100), 59.1 (94.2); HRMS (EI, 70 eV) calcd for C30H39N3O7, 533.2788. Found 
533.2789. 
 
1-(4-((1S,2R)-2-amino-1,3-dihydroxypropyl)-1H-imidazol-2-yl)3,3-diphenylpropan-1-
onedihydrochloride (196):  
 
N
N
H
OHPh
Ph
O
NH2
HO
2HCl
 
 
To a solution of 1,3-diol 194 (40 mg 0.072 mmol)in 1:1 mixture of MeOH:H2O (3 mL) was 
added concentrated HCl (1.5 mL) and refluxed for 1.5 h, evaporated to dryness on rotary 
evaporator and dried under high vacuum at 55 °C for 4 h to yield a glassy solid (97 %). 
Rf  (SiO2, CH2Cl2/MeOH/NH3. 7:3:0.2) = 0.27; m.p. = 122-127 °C; [ ]α D20  = -4.8 (c 0.6, 
MeOH); 1H NMR (600 MHz DMSO): δ = 3.43 (dd, J = 5.97, 11.10 Hz, 1 H, CHHOH), 3.47 
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(m, 1 H, CHNH3), 3.55 (dd, J = 3.93, 11.10 Hz, 1 H, CHHOH), 3.87 (dd, J = 7.77, 17.15 Hz, 
1 H, CHHCO), 3.93 (dd, J = 7.77, 17.15 Hz, 1 H, CHHCO), 4.68 (dd, J = 7.77, 7.77 Hz, 1 H, 
CHCH2), 4.85 (d, J = 6.98 Hz, 1 H, CHOH), 4.98 (s, very broad, 2 H, imidazole NH and 
CH2OH), 7.12-7.35 (m 10 H, aromatic), 7.51 (s 1 H, Imi-5H), 8.06 (bs, 3 H, CHNH3); 13C 
NMR (150.9 MHz, DMSO): δ = 43.2 (−, CH2CH), 45.4 (+, CHCH2), 56.5 (+, CHNH2), 58.3 
(CH2OH), 63.2 (+, CHOH), 121.0 (+, CH, Imi-C5, broad) 126.1 (+, CH, aromatic), 127.5 (+, 
CH, aromatic), 128.3 (+, CH, aromatic), 139.9 (+, Cquat, Imi-C4) 142.5 (+, Cquat, Imi-C2), 
144.0 (+, Cquat, aromatic), 187.2 (+, Cquat, CO); IR neat: ~ν  = 3400-3020 (broad), 2890, 1703, 
1676, 1599, 1493, 1396, 1223, 1044, 1022, 990, 731, 699, 613 cm-1; MS (EI, 70 eV): m/z (%) 
= 365.2 [M+•], 166.9 (18.6), 139.0 (65.0), 60.0 (12.0), 28.1 (100); HRMS: calcd for 
C21H23N3O3: 365.1739. Found: 365.1732. 
 
methyl3-(1-((2methoxyethoxy)methyl)-2-(3,3-diphenylpropanoyl)-1H-Imidazol-4 
yl)propanoate (197):  
 
N
N
CO2Me
Ph
Ph O MEM
 
 
A solution of 175 (610 mg 1.36 mmol) in MeOH (20 mL) was treated with 10 wt % Pd/C (61 
mg) and purged with a atmosphere of hydrogen followed by vigorous stirring in an 
atmosphere of hydrogen (via balloon) for 16 h. The reaction mixture was filtered through a 
pad of Celite, washed with MeOH (20 mL). The solvent was removed in vacuo to obtain 
quantitative yield of the product which was used for the next step without any purification. 
Rf  (SiO2, hexanes/EtOAc 7:3) = 0.16; thick oil; 1H NMR (300 MHz CDCl3): δ = 2.73 (t, J = 
7.39 Hz, 2 H, CH2CO), 2.94 (t, J = 7.39 Hz, 2 H, CH2CH2), 3.30 (s, 3 H, OCH3), 3.32-3.39 
(m, 4 H, OCH2CH2O), 3.68 (s, 3 H, CO2CH3), 3,87 (d, J = 7.86 Hz, 2 H, CHCH2), 4.78 (t, J = 
7.86 Hz, 1 H, CHCH2), 5.67 (s, 2 H, NCH2O), 7.05 (s, 1 H, Imi-5H), 7.10-7.16 (m, 2 H, 
aromatic), 7.21-7.30 (m, 8 H, aromatic); 13C NMR (75.5 MHz, CDCl3): δ = 23.5 (-, CH2CO), 
33.5 (-, CH2CH2), 44.9 (-, CHCH2), 46.5 (+, CHCH2), 51.7 (+, CO2CH3), 59.0 (+, OCH3), 
68.1 (-, OCH2), 71.4 (-, OCH2), 77.0 (-, NCH2O), 122.1 (+, CH, Imi-C5), 126.4 (+, CH, 
aromatic), 128.0 (+, CH, aromatic), 128.5 (+, CH, aromatic), 141.9 (+, Cquat, Imi-C4), 142.2 
(+, Cquat, Imi-C2), 144.0 (+, Cquat, aromatic), 173.4 (+, Cquat, CO2CH3), 191.2 (+, Cquat, CO); 
IR (Film): ~ν  = 3027, 2927, 2890, 1738, 1673, 1600, 1489, 1430, 1365, 1260, 1200, 1129, 
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1099, 753, 703 cm-1; MS (CI, NH3): m/z (%) = 451.3 (100) [M + H+], 422.2 (1.53), 167.1 
(2.12);  
 
3-(1-((2methoxyethoxy)methyl)-2-(3,3-diphenylpropanoyl)-1H-Imidazol-4-
yl)propanoicacid (198):  
 
N
N
CO2H
Ph
Ph O MEM
 
 
A solution of 197 (530 mg, 1.17 mmol) in THF-MeOH-H2O (3:1:1, 25 mL) at 0 °C was 
treated with 1 N LiOH (1.765 mmol) and the mixture was allowed to come to RT and stirred 
for 8 h. After most of the THF and MeOH were evaporated, the aqueous phase was acidified 
with the addition of 1 N HCl and extracted with CH2Cl2 (4×40 mL). Combined organic layers 
were washed with brine (20 mL), dried (MgSO4) filtration and evaporation gave the 
corresponding acid as thick oil. 
Rf  (SiO2, EtOAc ) = 0.17; thick oil; 1H NMR (300 MHz CDCl3): δ = 2.76 (t, J = 6.96 Hz, 2 
H, CH2CO), 2.94 (t, J = 6.96 Hz, 2 H, CH2CH2), 3.31 (s, 3 H, OCH3), 3.34-3.40 (m, 4 H, 
OCH2CH2O), 3,87 (d, J = 7.82 Hz, 2 H, CHCH2), 4.76 (t, J = 7.82 Hz, 1 H, CHCH2), 5.67 (s, 
2 H, NCH2O), 7.07 (s, 1 H, Imi-5H), 7.10-7.16 (m, 2 H, aromatic), 7.21-7.31 (m, 8 H, 
aromatic) 9.68 (bs; 1 H, CO2H); 13C NMR (75.5 MHz, CDCl3): δ = 23.0 (-, CH2CO), 33.8 (-, 
CH2CH2), 45.0 (-, CHCH2), 46.5 (+, CHCH2), 59.1 (+, OCH3), 68.3 (-, OCH2), 71.4 (-, 
OCH2), 77.2 (-, NCH2O), 122.0 (+, CH, Imi-C5), 126.4 (+, CH, aromatic), 128.0 (+, CH, 
aromatic), 128.6 (+, CH, aromatic), 141.6 (+, Cquat, Imi-C4), 141.9 (+, Cquat, Imi-C2), 143.9 
(+, Cquat, aromatic), 177.3 (+, Cquat, CO2H), 190.9 (+, Cquat, CO); IR (Film): ~ν  = 3325 (broad), 
3027, 2927, 1726, 1678, 1491, 1454, 1103, 984, 848, 751, 702 cm-1; MS (EI, 70 eV): m/z (%) 
= 436.1 (66.6) [M+•], 349.1 (45.8) [M+ - MEM], 269.1 (22.5), 179.1 (24.5), 154.0 (100)123.0 
(13.5), 89.0 (10.7), 59.0 (36.1); HRMS calcd for C25H28N2O5 436.1998. Found 436.1998. 
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benzyl2-(1-((2methoxyethoxy)methyl)-2-(3,3-diphenylpropanoyl)-1H-imidazol-4-
yl)ethylcarbamate (199):  
 
N
N
NHCbz
Ph
Ph O MEM
 
 
To a suspensation of acid 198 (300 mg, 687 mmol) in CH2Cl2 (4 mL) at 0 °C was slowly 
added Oxalyl chloride (175 mg, 1.37 mmol) and reaction mixture was stirred at room 
temperature for 3 h. N2 was bubbled to remove the excess of Oxalyl chloride. CH2Cl2 (4 mL) 
was added and evaporated by bobbling N2 and dried under high vacuum (30 min.) to remove 
any traces of Oxalyl chloride. Again CH2Cl2 (4 mL) was added followed by TMS-azide (159 
mg, 1.375 mmol) and the reaction mixture was stirred at room temperature for 4 h. N2 was 
bubbled and dried under high vacuum (30 min.) to leave the corresponding azide as a pale 
yellow oil which was used for the rearrangement without any further purification. 
Rearrangement: To a solution of azide in toluene (5 mL) was added benzyl alcohol (0.5 mL) 
and the reaction mixture was refluxed for 18 h. The solvent was removed in vacuo. The 
residue was purified by chromatography on silica (hexanes/EtOAc 1:1) to obtain 199 (86%). 
Rf  (SiO2, hexanes/EtOAc 1:1) = 0.27; thick oil; 1H NMR (300 MHz CDCl3): δ = 2.79 (t, J = 
6.38 Hz, 2 H, CH2CCH2), 3.29 (s, 3 H, OCH3), 3.35-3.37 (m, 4 H, OCH2CH2O), 3.52-3.59 
(m, 2 H, CH2NH), 3,86 (d, J = 7.96 Hz, 2 H, CHCH2), 4.76 (t, J = 7.96 Hz, 1 H, CHCH2), 
5.10 (s, 2 H, CH2OBn), 5.46 (t, J = 6.38 Hz, 1 H, NH), 5.66 (s, 2 H, NCH2O), 7.04 (s, 1 H, 
Imi-5H), 7.09-7.14 (m, 2 H, aromatic), 7.18-7.32 (m, 13 H, aromatic); 13C NMR (75.5 MHz, 
CDCl3): δ = 28.1 (-, CH2CH2), 33.8 (-, CH2NH), 44.9 (-, CHCH2), 46.6 (+, CHCH2), 59.0 (+, 
OCH3), 66.7 (-, CH2OCO), 68.3 (-, OCH2), 71.4 (-, OCH2), 77.1 (-, NCH2O), 122.5 (+, CH, 
Imi-C5), 126.4 (+, CH, aromatic), 128.0 (+, CH, aromatic), 128.2 (+, CH, aromatic), 128.5 
(+, CH, aromatic), 128.6 (+, CH, aromatic), 136.7 (+, Cquat, aromatic), 140.7 (+, Cquat, Imi-
C4), 142.4 (+, Cquat, Imi-C2), 143.9 (+, Cquat, aromatic), 156.4 (+, Cquat, CO2Bn), 191.1 (+, 
Cquat, CO); IR (Film): ~ν  = 3344 (broad), 3061, 3029, 2929, 1717, 1677, 1521, 1454, 1364, 
1249, 1132, 1103, 983, 910, 848, 733, 700 cm-1; MS (ESI,CH2Cl2/MeOH/NH4Ac): m/z = 
542.4 [M + H+]. 
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1-(1-((2methoxyethoxy)methyl)-4-(2-aminoethyl)-1H-Imidazolyl)-3,3-diphenylpropan-1-
one (200):  
 
N
N
NH2
Ph
Ph O MEM
 
 
A solution of the 199 (80 mg, 0.148 mmol) in MeOH (4 mL) was treated with 10 % Pd/C (8 
mg) and purged with hydrogen followed by vigorous stirring in an atmosphere of hydrogen 
(via balloon) for 2 h. The reaction mixture was filtered through a pad of Celite, washed with 
MeOH. The solvent was removed in vacuo. The residue was purified by chromatography on 
silica (CH2Cl2/MeOH/NH3 19:1:0.5). 
Rf (SiO2, CH2Cl2/MeOH 8:2:) = 0.32; thick oil; 1H NMR (300 MHz CDCl3): δ = 2.18 (bs, 2 
H, NH2), 2.83 (t, J = 6.48 Hz, 2 H, CH2CH2), 2.93-2.98 (m, 2 H, CH2NH2), 3.28-3.40 (m, 7 H, 
OCH3 + OCH2CH2O), 3.88 (d, J = 7.82 Hz, 2 H, CHCH2), 4.78 (t, J = 7.82 Hz, 1 H, CHCH2), 
5.69 (s, 2 H, NCH2O), 7.08 (s, 1 H, Imi-5H), 7.12-7.17 (m, 2 H, aromatic), 7.22-7.31 (m, 8 H, 
aromatic); 13C NMR (75.5 MHz, CDCl3): δ = 27.9 (-, CH2CH2), 45.0 (-, CHCH2), 46.6 (+, 
CHCH2), 51.0 (-, CH2NH), 59.1 (+, OCH3), 68.3 (-, OCH2), 71.5 (-, OCH2), 77.2 (-, NCH2O), 
122.5 (+, CH, Imi-C5), 126.5 (+, CH, aromatic), 128.1 (+, CH, aromatic), 128.6 (+, CH, 
aromatic), 141.4 (+, Cquat, Imi-C4), 142.4 (+, Cquat, Imi-C2), 144.0 (+, Cquat, aromatic), 191.2 
(+, Cquat, CO); IR (Film): ~ν  = 3381, 2925, 2819, 1674, 1599, 1550, 1454, 1247, 1199, 1101, 
948, 848, 797, 752, 703 cm-1; MS (CI, NH3) m/z (%) = 408.3 (5.9) [MH+], 360.2 (96.2), 346.2 
(100). 
 
1-(4-(2-aminoethyl)-1H-Imidazolyl)-3,3-diphenylpropan-1-onedihydrochloride (201):  
 
N
N
H
NH2
Ph
Ph O
2HCl
 
 
To a solution of 200 (60 mg, 0.147 mmol) in MeOH:H20 1:1 (3 mL) was added Conc. HCl 
(1.5 mL) and reaction mixture was refluxed for 2 h. The solvent was removed in vacuo to 
leave a white solid as a hydrochloride salt (97%).  
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Rf  (SiO2, CH2Cl2/MeOH/NH3 10:1:0.2) = 0.13; m.p. = 180-182 °C; 1H NMR (300 MHz, 
DMSO): δ = 2.97 (t, J = 7.25 Hz, 2 H, CH2CH2N), 3.13 (tq, J = 7.25, 6.03 Hz, 2 H, CH2NH3), 
3.93 (d, J = 7.68 Hz, CH2CO), 4.68 (t, J = 7.68 Hz, 2 H, CHCH2CO), 5.1-6.5 (s, very broad, 
Imi-NH), 7.12-7.41 (m, 10 H, aromatic), 7.54 (s, 1 H, Imi-5-H), 8.24 (s, broad 3 H, CH2NH3); 
13C NMR (75.5 MHz, DMSO) δ: 23.5 (-, CH2CH2), 37.6 (-, CHCH2), 43.51 (-, CHCH2), 
45.31 (+, CHCH2), 121.5 (+, CH, Imi-C5, broad), 126.3 (+, CH, aromatic), 127.6 (+, CH, 
aromatic), 128.4 (+, CH, aromatic), 135.1 (+, Cquat, Imi-C4, broad), 141.4 (+, Cquat, Imi-C2, 
broad), 144.1 (+, Cquat, aromatic), 186.33(+, Cquat, CO); IR (KBr): ~ν  = 3448, 3029, 1699, 
1495, 1213, 1034, 749, 702 , 567, cm-1; HRMS: Calcd for C20H21N3O: 319.1685. Found: 
319.1685. 
 
1,3-bis(2-(1-((2methoxyethoxy)methyl)-2-(3,3-diphenylpropanoyl)-1H-imidazol-4-
yl)ethyl)urea (203):  
 
N
N
H
N
Ph
Ph
O
H
N
O N
N
Ph
Ph
O
MEM MEM
 
 
To a suspensation of acid 198 (300 mg, 687 mmol) in CH2Cl2 (4 mL) at 0 °C was slowly 
added Oxalyl chloride (175 mg, 1.37 mmol) and reaction mixture was stirred at room 
temperature for 3 h. N2 was bubbled to remove the excess of Oxalyl chloride. CH2Cl2 (4 mL) 
was added and evaporated by bobbling N2 and dried under high vacuum (30 min.) to remove 
any traces of Oxalyl chloride. Again CH2Cl2 (4 mL) was added followed by TMS-azide (159 
mg, 1.375 mmol) and the reaction mixture was stirred at room temperature for 4 h. N2 was 
bubbled and dried under high vacuum (30 min.) to leave the corresponding azide as a pale 
yellow oil. To a solution of azide in toluene (5 mL) was added  to a flask pre heated to 80 °C 
and heated to 100 °C for 3 h. H2O (3 mL) was added and the reaction mixture was refluxed 
for 16 h. The solvent was removed in vacuo. The residue was purified by chromatography on 
silica (CH2Cl2/MeOH 95:5)  
Rf (SiO2, CH2Cl2/MeOH 95:5) = 0.16; thick oil; 1H NMR (300 MHz CDCl3): δ = 2.75 (t, J = 
6.59 Hz, 4 H, CH2CH2), 3.29 (s, 6 H, OCH3), 3.32-3.39 (m, 8 H, OCH2CH2O), 3.42-3.52 (m, 
4 H, CH2NH), 3,85 (d, J = 7.96 Hz, 4 H, CHCH2), 4.76 (t, J = 7.96 Hz, 2 H, CHCH2), 5.00 
(bs, 2 H, NH), 5.65 (s, 2 H, NCH2O), 7.04 (s, 2 H, Imi-5H), 7.09-7.15 (m, 4 H, aromatic), 
7.19-7.28 (m, 20 H, aromatic); 13C NMR (75.5 MHz, CDCl3): δ = 28.6 (-, CH2CH2), 40.1 (-, 
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CH2CON), 45.0 (-, CHCH2), 46.5 (+, CHCH2), 59.1 (+, OCH3), 68.3 (-, OCH2), 71.5 (-, 
OCH2), 77.2 (-, NCH2O), 122.6 (+, CH, Imi-C5), 126.4 (+, CH, aromatic), 128.0 (+, CH, 
aromatic), 128.6 (+, CH, aromatic), 141.0 (+, Cquat, Imi-C4), 142.3 (+, Cquat, Imi-C2), 144.0 
(+, Cquat, aromatic), 158.3 (+, Cquat, CONH), 191.0 (+, Cquat, CO); IR (film): ~ν  = 3365, 3129, 
3061, 2926, 1676, 1556, 1491, 1454, 1364, 1249, 1099, 1029, 982, 850, 796, 757, 702, 665, 
607 cm-1; MS (ESI,CH2Cl2/MeOH/NH4Ac): m/z (%) = 841.6 [M + H+]. 
 
1,3-bis(2-(2-(3,3-diphenylpropanoyl)-1H-imidazol-4-yl)ethyl)urea (204):  
 
N
HN
H
N
Ph
Ph
O
H
N
O NH
N
Ph
Ph
O
 
 
To a solution of 203 (170 mg, 0.42 mmol) in EtOH:H20 1:1 (8 mL) was added conc. HCl (4 
mL) and reaction mixture was refluxed for 1.5 h. After most of the EtOH was evaporated in 
vacuo, aqueous phase was made strongly basic by the addition of solid K2CO3 and extracted 
in CH2Cl2:MeOH 9:1 (4×20 mL) dried (MgSO4) filtration and evaporation gave the free base 
as a white solid (92%). 
Rf (SiO2, CH2Cl2/MeOH 9:1) = 0.33; m.p. = 109-110 °C; 1H NMR (300 MHz CD3OD): δ = 
2.76 (t, J = 6.82 Hz, 4 H, CH2CH2), 3.36 (t, J = 6.82 Hz, 4 H, CH2NH), 3.76 (d, J = 7.72 Hz, 4 
H, CHCH2), 4.74 (t, J = 7.72 Hz, 2 H, CHCH2), 7.02 (s, 2 H, Imi-5H), 7.08-7.13 (m, 4 H, 
aromatic), 7.18-7.29 (m, 16 H, aromatic); 13C NMR (75.5 MHz, CD3OD): δ = 28.3 (-, 
CH2CH2, broad), 40.5 (-, CH2CON), 47.4 (+, CHCH2), 124.8 (+, CH, Imi-C5, broad), 127.3 
(+, CH, aromatic), 128.9 (+, CH, aromatic), 129.5 (+, CH, aromatic), 145.5 (+, Cquat, Imi-
C4), 145.5 (+, Cquat, aromatic), 146.0 (+, Cquat, Imi-C2), 160.9 (+, Cquat, CONH), 189.8 (+, 
Cquat, CO); IR (neat): ~ν  = 3026, 1676, 1650, 1456, 1562, 1492, 1428, 1400, 1267, 1069, 1032, 
966, 753, 734, 699, 666 cm-1; MS (ESI,CH2Cl2/MeOH/NH4Ac): m/z = 665.5 [M + H+], 
1330.9 [2M + H+]; Elemental analysis calcd (%) for C41H40N6O3 (664.32) C 74.07, H 6.706, 
N 12.64; found C 73.26, H 5.64, N 12.40. 
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tert-butyl 2-(1-((2-methoxyethoxy)methyl)-2-(3,3-diphenylpropanoyl)-1H-imidazol-4-
yl)ethylcarbamate (212):  
 
N
N
NHBoc
Ph
Ph O MEM
 
 
To a solution of the 199 (1.1 g, 2.031 mmol) and (Boc)2O (532 mg 2.43 mmol) in MeOH (20 
mL) was treated with 10 % Pd/C (110 mg) and purged with hydrogen followed by vigorous 
stirring in an atmosphere of hydrogen (via balloon) for 1 h. The reaction mixture was filtered 
through a pad of Celite, washed with MeOH (30 mL). The solvent was removed in vacuo. The 
residue was purified by chromatography on silica (EtOAc/hexanes1:1) to obtain 212 (94 %). 
Rf  (SiO2, hexanes/EtOAc 6:4) = 0.33; thick oil; 1H NMR (300 MHz CDCl3): δ = 1.44 (s, 9 
H, CMe3), 2.77 (t, J = 6.59 Hz, 2 H, CH2CCH2), 3.30 (s, 3 H, OCH3), 3.33-3.39 (m, 4 H, 
OCH2CH2O), 3.42-3.48 (m, 2 H, CH2NH), 3,89 (d, J = 7.86 Hz, 2 H, CHCH2), 4.77 (t, J = 
7.86 Hz, 1 H, CHCH2), 5.30 (bs, 1 H, NH), 5.67 (s, 2 H, NCH2O), 7.06 (s, 1 H, Imi-5H), 
7.10-7.15 (m, 2 H, aromatic), 7.20-7.32 (m, 8 H, aromatic); 13C NMR (75.5 MHz, CDCl3): δ 
= 28.1 (-, CH2CH2), 28.5 (+, CMe3), 40.0 (-, CH2NH), 44.8 (-, CHCH2), 46.5 (+, CHCH2), 
58.9 (+, OCH3), 68.2 (-, OCH2), 71.3 (-, OCH2), 77.0 (-, NCH2O), 79.1 (+, Cquat, CMe3), 
122.4 (+, CH, Imi-C5), 126.3 (+, CH, aromatic), 127.9 (+, CH, aromatic), 128.5 (+, CH, 
aromatic), 140.9 (+, Cquat, Imi-C4), 142.2 (+, Cquat, Imi-C2), 143.9 (+, Cquat, aromatic), 156.4 
(+, Cquat, CO2Bn), 191.1 (+, Cquat, CO); IR (KBr): ~ν  = 3362, 3061, 3026, 2977, 2928, 1730, 
1679, 1512, 1455, 1392, 1366, 1250, 1169, 1105, 1050, 982, 853, 791, 751, 702 cm-1; MS 
(CI, NH3) m/z (%) = 508.3 (100) [MH+], 509.4 (21.2). 
 
tert-butyl 2-(1-((2-methoxyethoxy)methyl)-2-(1-hydroxy-3,3-diphenylpropyl)-1H-
imidazol-4-yl)ethylcarbamate (217):  
 
N
N
NHBoc
Ph
Ph OH MEM
 
 
To a solution of 212 (65 mg 0.128 mmol) in isopropanol (2 mL) was added NaBH4 (12.2 mg 
0.32 mmol). The reaction mixture was stirred for 6-8 h at room temperature. The reaction 
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mixture was cooled to 0 °C, aqueous sat. ammonium chloride (4 mL) was added and the 
reaction mixture was extracted in CH2Cl2 (3×10 mL), washed with brine (8 mL), dried over 
MgSO4 and concentrated in vacuo to leave an oil which was purified by column 
chromatography (EtOAc/hexanes 8:2) and the alcohol 217 was obtained (92 %). 
Rf (SiO2, EtOAc) = 0.30; thick oil; 1H NMR (300 MHz CDCl3): δ = 1.42 (s, 9 H, CMe3), 
2.59-2.76 (m, 4 H, CH2CH2 + CH2CH), 3.28 (s, 3 H, OCH3), 3.31-3.44 (m, 6 H, OCH2CH2O 
+ CH2NH), 4.15 (bs, 1 H, OH), 4.23 (dd, J = 9.14, 6.81 Hz, 1 H, CHCH2), 4.55 (dd, J = 8.26, 
5.59 Hz, 1 H, CHOH), 4.99 (d, J = 10.81 Hz NCHHO), 5.05 (d, J = 10.81 Hz NCHHO), 5.22 
(bs, 1 H, NH), 6.67 (s, 1 H, Imi-5H), 7.12-7.29 (m, 10 H, aromatic); 13C NMR (75.5 MHz, 
CDCl3): δ = 28.0 (-, CH2CH2), 28.5 (+, CMe3), 40.2 (-, CH2NH), 41.5 (-, CHCH2), 47.1 (+, 
CHCH2), 59.0 (+, OCH3), 63.9 (+, CHOH), 67.5 (-, OCH2), 71.4 (-, OCH2), 75.4 (-, NCH2O), 
79.1 (+, Cquat, CMe3), 117.2 (+, CH, Imi-C5), 126.3 (+, CH, aromatic), 126.4 (+, CH, 
aromatic), 127.9 (+, CH, aromatic), 128.2 (+, CH, aromatic), 128.5 (+, CH, aromatic), 128.6 
(+, CH, aromatic), 138.0 (+, Cquat, Imi-C4), 144.0 (+, Cquat, aromatic), 144.6 (+, Cquat, 
aromatic), 149.7 (+, Cquat, Imi-C2), 156.1 (+, Cquat, CO); IR (Film): ~ν  = 3353 (broad), 3060, 
2976, 2930, 1703, 1496, 1452, 1392, 1364, 1252, 1169, 1095, 1028, 736, 702 cm-1; MS 
(ESI,CH2Cl2/MeOH/NH4Ac): m/z = 510.4 [M + H+]. 
 
1-(1-((2-methoxyethoxy)methyl)-4-(2-aminoethyl)-1H-imidazol-2-yl)-3,3-
diphenylpropan-1-ol hydrochloride (218)  
 
N
N
NH2
Ph
Ph OH
.HCl
MEM
 
 
To a solution of 217 (40 mg, 0.0785 mmol) in MeOH:H20 1:1 (2 mL) was added Conc. HCl 
(1 mL) and reaction mixture was refluxed for 2 h. The solvent was removed in vacuo to leave 
a residue as a hydrochloride salt (quantitative).  
Rf (SiO2, CH2Cl2/MeOH 8:2) = 0.28; thick oil; 1H NMR (300 MHz CD3OD): δ = 2.51-2.60 
(m, 1 H, CHHCHOH), 2.75-2.85 (m, 1 H, CHHCHOH), 3.04 (t, J = 7.48 Hz, 2 H, CH2CH2), 
3.22-3.25 (m, 2 H, CH2NH2), 3.29 (s, 3 H, OCH3), 3.46-3.57 (m, 2 H, OCH2CH2O), 3.69 (J = 
4.32 Hz, 2 H, OCH2CH2O), 4.93 (dd, J = 10.41, 5.20 Hz, 1 H, CHCH2), 4.97 (dd, J = 9.07, 
3.58 Hz, 1 H, CHOH), 5.42 (d, J = 10.94 Hz NCHHO), 5.47 (d, J = 10.94 Hz NCHHO), 7.12-
7.41 (m, 10 H, aromatic), 7.51 (s, 1 H, Imi-5H); 13C NMR (75.5 MHz, CDCl3): δ = 23.5 (-, 
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CH2CH2), 39.0 (-, CH2NH2), 42.2 (-, CHCH2), 47.8 (+, CHCH2), 59.2 (+, OCH3), 64.2 (+, 
CHOH), 70.4 (-, OCH2), 72.6 (-, OCH2), 78.7 (-, NCH2O), 121.7 (+, CH, Imi-C5), 127.4 (+, 
CH, aromatic), 127.7 (+, CH, aromatic), 128.6 (+, CH, aromatic), 129.2 (+, Cquat, Imi-C4), 
129.3 (+, CH, aromatic), 129.6 (+, CH, aromatic), 129.8 (+, CH, aromatic), 144.5 (+, Cquat, 
aromatic), 144.6 (+, Cquat, aromatic), 152.2 (+, Cquat, Imi-C2); IR (KBr): ~ν  = 3304 (broad), 
2932, 2836, 2628, 1627, 1520, 1494, 1449, 1411, 1329, 1137, 1095, 1025, 847, 739, 699, cm-
1; MS (CI, NH3) m/z (%) = 410.3 (100) [M + H+], 392.2 (3.0), 380.2 (3.5), 200.1 (1.1). 
tert-butyl 2-(1-((2-methoxyethoxy)methyl)-2-(4,4-diphenylbut-1-en-2-yl)-1H-imidazol-4-
yl)ethylcarbamate (213):  
 
N
N
NHBoc
Ph
Ph CH2 MEM
 
 
To a suspension of Ph3PCH3I (210.3 mg 0.394 mmol) in THF (4 mL) at 0 °C was added t-
BuOK (44.2 mg 0.394 mmol) and pail yellow reaction mixture was stirred for 10 min. and 
warmed to RT and stirred further for 1 h. The reaction mixture was cooled to 0 °C again and 
ketone 212 (100 mg 0.197 mmol) in THF (4 mL) was added. The reaction mixture was 
allowed to come to RT and stirred further for 2-3 h. Water (x mL) was added and the reaction 
mixture was extracted in ether (3×10 mL). Organic layers were combined and washed with 
brine (10 mL), dried over MgSO4 and concentrated in vacuo to leave an oil which was 
purified by column chromatography (EtOAc/hexanes 4:6) to obtain 213 (95 %) 
Rf (SiO2, hexanes/EtOAc 6:4) = 0.30; thick oil; 1H NMR (300 MHz CDCl3): δ = 1.42 (s, 9 H, 
CMe3), 2.75 (t, J = 6.48 Hz, 2 H, CH2CH2), 3.33 (s, 3 H, OCH3), 3.37 (d, J = 8.37 Hz, 2 H, 
CH2CH), 3.42-3.48 (m, 6 H, OCH2CH2O + CH2NH), 4.17 (t, J = 8.37 Hz, 1 H, CHCH2), 4.66 
(s, 2 H, NCH2O), 5.35 (bs, 3 H, =CH2 + NH), 6.71 (s, 1 H, Imi-5H), 7.08-7.23 (m, 10 H, 
aromatic); 13C NMR (75.5 MHz, CDCl3): δ = 28.0 (-, CH2CH2), 28.5 (+, CMe3), 40.4 (-, 
CH2NH), 42.0 (-, CHCH2), 50.1 (+, CHCH2), 59.1 (+, OCH3), 67.7 (-, OCH2), 71.6 (-, OCH2), 
75.5 (-, NCH2O), 79.0 (+, Cquat, CMe3), 117.7 (+, CH, Imi-C5), 120.4 (-, =CH2), 126.2 (+, 
CH, aromatic), 128.1 (+, CH, aromatic), 128.3 (+, CH, aromatic), 136.4 (+, Cquat, Imi-C4), 
138.7 (+, Cquat, Imi-C2), 143.9 (+, Cquat, aromatic), 148.0 (+, Cquat, C=CH2), 156.1 (+, Cquat, 
CO); IR (KBr): ~ν  = 3352 (broad), 3059, 2972, 2828, 1710, 1454, 1389, 1366, 1251, 1170, 
1088, 740, 703 cm-1; MS (CI, NH3) m/z (%) = 506.3 (100) [M + H+], 340.2 (4.9), 167.0 (1.0). 
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tert-butyl 2-(1-((2-methoxyethoxy)methyl)-2-(4,4-diphenylbutan-2-yl)-1H-imidazol-4-
yl)ethylcarbamate (214):  
 
N
N
NHBoc
Ph
Ph CH3 MEM
 
 
A solution of Comp. 213 (40 mg 0.079 mmol) in MeOH (2 mL) was treated with 10 wt % 
Pd/C (5 mg) and purged with a atmosphere of hydrogen followed by vigorous stirring in an 
atmosphere of hydrogen (via balloon) for 16 h. The reaction mixture was filtered through a 
pad of Celite, washed with MeOH (10 mL). The solvent was removed in vacuo to obtain 
quantitative yield of the product. 
Rf  (SiO2, hexanes/EtOAc 1:1) = 0.25; thick oil; 1H NMR (300 MHz CDCl3): δ = 1.30 (d, J = 
6.86 Hz, CH3CH), 1.41 (s, 9 H, CMe3), 2.31-2.41 (m, 1 H, CHHCH), 2.61-2.69 (m, 1 H, 
CHHCH), 2.71-2.83 (m, 3 H, CH2CH2 + CHCH3), 3.28-3.31 (m, 5 H, CH2NH + OCH3), 3.34-
3.48 (m, 4 H, OCH2CH2O), 3.82 (dd, J = 9.05, 7.13 Hz, 1 H, CHCH2), 4.59 (d, J = 10.98 Hz, 
1 H, NCHHO), 4.76 (d, J = 10.98 Hz, 1 H, NCHHO), 5.27 (bs, 1 H, NH), 6.60 (s, 1 H, Imi-
5H), 7.10-7.27 (m, 10 H, aromatic); 13C NMR (75.5 MHz, CDCl3): δ = 20.9 (+, CH3CH), 
28.0 (-, CH2CH2), 28.5 (+, CMe3), 29.2 (+ CHCH3), 40.4 (-, CH2NH2), 41.8 (-, CHCH2), 49.0 
(+, CHCH2), 58.1 (+, OCH3), 67.4 (-, OCH2), 71.5 (-, OCH2), 74.9 (-, NCH2O), 78.9 (+, Cquat, 
CMe3), 115.8 (+, CH, Imi-C5), 126.2 (+, CH, aromatic), 126.5 (+, CH, aromatic), 127.8 (+, 
CH, aromatic), 128.1 (+, CH, aromatic), 128.4 (+, CH, aromatic), 128.6 (+, CH, aromatic), 
137.9 (+, Cquat, Imi-C4), 152.3 (+, Cquat, Imi-C2), 143.9 (+, Cquat, aromatic), 144.6 (+, Cquat, 
aromatic), 156.1 (+, Cquat, CO); IR (KBr): ~ν  = 3346 (broad), 2974, 2930, 1690, 1495, 1454, 
1366, 1251, 1169, 1090, 853, 739, 702 cm-1; MS (CI, NH3) m/z (%) = 508.4 (100) [M + H+], 
524.2 (1.3) [M + NH3+]. 
 
2-((4-(2-aminoethyl)-2-(4,4-diphenylbut-1-en-2-yl)-1H-imidazol-1-yl)methoxy)ethanol 
hydrochloride (215)) 
 
N
N
NH2
Ph
Ph CH2
HCl
O
OH
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Rf (SiO2, MeOH/EtOAc 6:4) = 0.27; thick oil; 1H NMR (300 MHz CD3OD): δ = 3.09 (t, J = 
7.44 Hz, 2 H, CH2CH2), 3.28-3.40 (m, 2 H, NH2), 3.49 (d, J = 8.13 Hz, 2 H, CH2CH), 3.65 (s, 
4 H, OCH2CH2O), 4.13 (t, J = 8.13 Hz, 1 H, CHCH2), 5.12 (s, 2 H, NCH2O), 5.91-5.99 (m, 2 
H, =CH2), 7.13-7.19 (m, 2 H, aromatic), 7.23-7.31 (m, 8 H, aromatic) 7.59 (s, 1 H, Imi-5H); 
13C NMR (75.5 MHz, CD3OD): δ = 23.6 (-, CH2CH2), 39.0 (-, CH2NH), 41.7 (-, CHCH2), 
52.0 (+, CHCH2), 61.8 (-, CH2OH), 72.8 (-, OCH2), 78.9 (-, NCH2O), 122.1 (+, CH, Imi-C5), 
127.8 (+, CH, aromatic), 128.9 (+, CH, aromatic), 129.7 (+, CH, aromatic), 130.3 (-, =CH2), 
132.2 (+, Cquat, Imi-C4),144.5 (+, Cquat, aromatic), 144.7 (+, Cquat, Imi-C2), 147.5 (+, Cquat, 
C=CH2); IR (KBr): ~ν  = 3382 (broad), 2918, 1628, 1491, 1453, 1366, 1238, 1163, 1125, 1078, 
1032, 955, 746, 704 cm-1; MS (CI, NH3) m/z (%) = 392.3 (53.1) [M + H+], 318.2 (11.1), 226.2 
(100). 
 
methyl 3-(1-((2-methoxyethoxy)methyl)-2-(4,4-diphenylbut-1-en-2-yl)-1H-imidazol-4-
yl)propanoate (211):  
 
N
N
CO2Me
Ph
Ph CH2 MEM
 
 
To a suspension of Ph3PCH3I (558 mg 1.043 mmol) in THF (5 mL) at 0 °C was added t-
BuOK (117.1 mg 1.043 mmol) and pail yellow reaction mixture was stirred for 10 min. and 
warmed to RT and stirred further for 1 h. The reaction mixture was cooled to 0 °C again and 
ketone 197 (235 mg 0.522 mmol) in THF (5 mL) was added. The reaction mixture was 
allowed to come to RT and stirred further for 1 h. Water (x mL) was added and the reaction 
mixture was extracted in ether (3×10 mL), washed with brine (10 mL), dried over MgSO4 and 
concentrated in vacuo to leave an oil which was purified by column chromatography 
(EtOAc/hexanes 4:6) to obtain 211 (92 %) 
Rf (SiO2, hexanes/EtOAc 7:3) = 0.15; thick oil; 1H NMR (300 MHz CDCl3): δ = 2.73 (t, J = 
7.38 Hz, 2 H, CH2CO), 2.92 (t, J = 7.38 Hz, 2 H, CH2CH2), 3.31 (s, 3 H, OCH3), 3,35 (d, J = 
8.30 Hz, 2 H, CHCH2), 3.40-3.47 (m, 4 H, OCH2CH2O), 3.65 (s, 3 H, CO2CH3), 4.10 (t, J = 
8.30 Hz, 1 H, CHCH2), 4.61 (s, 2 H, NCH2O), 5.29-5.31 (m, 2 H, =CH2), 6.69 (s, 1 H, Imi-
5H), 7.08-7.22 (m, 10 H, aromatic); 13C NMR (75.5 MHz, CDCl3): δ = 23.5 (-, CH2CO), 33.8 
(-, CH2CH2), 42.0 (-, CHCH2), 49.6 (+, CHCH2), 51.5 (+, CO2CH3), 59.0 (+, OCH3), 67.6 (-, 
OCH2), 71.5 (-, OCH2), 75.4 (-, NCH2O), 117.1 (+, CH, Imi-C5), 120.0 (-, =CH2), 126.1 (+, 
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CH, aromatic), 128.0 (+, CH, aromatic), 128.2 (+, CH, aromatic), 136.5 (+, Cquat, Imi-C4), 
139.7 (+, Cquat, C=CH2), 144.0, (+, Cquat, aromatic), 147.8 (+, Cquat, Imi-C2), 173.7 (+, Cquat, 
CO2CH3). 
 
methyl 3-(1-((2-methoxyethoxy)methyl)-2-(3,3-diphenylpropanoyl)-1H-imidazol-5-
yl)propanoate (205):  
 
N
N
Ph
Ph O MEM
O
O
 
 
A solution of compound 176 (2.4 g 5.35 mmol) in MeOH (60 mL) was treated with 10 wt % 
Pd/C (250 mg) and purged with hydrogen followed by vigorous stirring in an atmosphere of 
hydrogen (via balloon) for 10 h. The reaction mixture was filtered through a pad of Celite, 
washed with MeOH (40 mL). The solvent was removed in vacuo to obtain quantitative yield 
of the product which was used for the next step without any purification. 
Rf (SiO2, hexanes/EtOAc 7:3) = 0.14; thick oil; 1H NMR (300 MHz CDCl3): δ = 2.71 (t, J = 
7.38 Hz, 2 H, CH2CO), 2.98 (t, J = 7.38 Hz, 2 H, CH2CH2), 3.24-3.32 (m, 7 H, OCH2CH2O + 
OCH3), 3.68 (s, 3 H, CO2CH3), 3,90 (d, J = 7.92 Hz, 2 H, CHCH2), 4.78 (t, J = 7.92 Hz, 1 H, 
CHCH2), 5.82 (s, 2 H, NCH2O), 6.98 (s, 1 H, Imi-5H), 7.10-7.31 (m, 10 H, aromatic); 13C 
NMR (75.5 MHz, CDCl3): δ = 19.5 (-, CH2CO), 32.4 (-, CH2CH2), 44.9 (-, CHCH2), 46.5 (+, 
CHCH2), 51.9 (+, CO2CH3), 58.9 (+, OCH3), 67.3 (-, OCH2), 71.2 (-, OCH2), 73.6 (-, 
NCH2O), 126.3 (+, CH, aromatic), 127.9 (+, CH, aromatic), 128.0 (+, CH, Imi-C4), 128.5 (+, 
CH, aromatic), 138.0 (+, Cquat, Imi-C5), 143.4 (+, Cquat, Imi-C2), 144.0 (+, Cquat, aromatic), 
172.5 (+, Cquat, CO2CH3), 191.2 (+, Cquat, CO); with calibration IR (neat): ~ν  = 2927, 2884, 
1737, 1672, 1429, 1261, 1199, 1169, 1089, 1030, 995, 924, 846, 733, 699 cm-1; MS (CI, 
NH3): m/z (%) = 451.2 (100) [M + H+], 243.1 (2.65), 94.2 (1.63);  
 
3-(1-((2-methoxyethoxy)methyl)-2-(3,3-diphenylpropanoyl)-1H-imidazol-5-yl)propanoic 
acid (206):  
 
N
N
Ph
Ph O MEM
OH
O
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Prepared following the similar procedure for 170 (96 % yield); Rf  (SiO2, EtOAc) = 0.17; 
white solid m.p. = 132-133 °C; 1H NMR (300 MHz CDCl3): δ = 2.75 (t, J = 7.31 Hz, 2 H, 
CH2CO), 2.98 (t, J = 7.31 Hz, 2 H, CH2CH2), 3.26-3.32 (m, 7 H, OCH2CH2O + OCH3), 3,91 
(d, J = 7.79 Hz, 2 H, CHCH2), 4.77 (t, J = 7.79 Hz, 1 H, CHCH2), 5.82 (s, 2 H, NCH2O), 7.07 
(s, 1 H, Imi-5H), 7.11-7.15 (m, 2 H, aromatic), 7.21-7.32 (m, 8 H, aromatic); 13C NMR (75.5 
MHz, CDCl3): δ = 19.4 (-, CH2CO), 32.4 (-, CH2CH2), 45.0 (-, CHCH2), 46.4 (+, CHCH2), 
58.9 (+, OCH3), 67.4 (-, OCH2), 71.2 (-, OCH2), 73.6 (-, NCH2O), 126.4 (+, CH, aromatic), 
127.7 (+, CH, Imi-C4), 127.9 (+, CH, aromatic), 128.5 (+, CH, aromatic), 138.0 (+, Cquat, 
Imi-C5), 142.9 (+, Cquat, Imi-C2), 143.9 (+, Cquat, aromatic), 176.2 (+, Cquat, CO2H), 190.9 (+, 
Cquat, CO); IR (neat): ~ν  = 2921, 1722, 1674, 1457, 1394, 1362, 1249, 1207, 1181, 1125, 1075, 
1052, 1033, 976, 954, 862, 842, 794, 775, 750, 733, 701 cm-1; MS (ESI, 
CH2Cl2/MeOH/NH4Ac): m/z = 437.3 [M + H+], 459.3 [M + Na+], 391.4 [M - EtOH]. 
 
benzyl 2-(1-((2-methoxyethoxy)methyl)-2-(3,3-diphenylpropanoyl)-1H-imidazol-5-
yl)ethylcarbamate (207):  
 
N
N
Ph
Ph O MEM
NHCbz
 
 
prepared following the similr procedure for 199 (78 % yield) 
Rf  (SiO2, hexanes/EtOAc 1:1) = 0.26; thick oil; 1H NMR (300 MHz CDCl3): δ = 2.85 (t, J = 
6.69 Hz, 2 H, CH2CH2), 3.19 (s, 3 H, OCH3), 3.25-3.27 (m, 4 H, OCH2CH2O), 3.42-3.49 (m, 
2 H CH2NH), 3,90 (d, J = 7.92 Hz, 2 H, CHCH2), 4.78 (t, J = 7.92 Hz, 1 H, CHCH2), 4.07 (s, 
2 H, CH2OCO), 5.44 (t, J = 7.92 Hz, 1 H, NH), 5.75 (s, 2 H, NCH2O), 6.99 (s, 1 H, Imi-5H), 
7.08-7.13 (m, 2 H, aromatic), 7.18-7.31 (m, 8 H, aromatic); 13C NMR (75.5 MHz, CDCl3): δ 
= 24.5 (-, CH2CH2), 39.5 (-, CH2NH), 44.8 (-, CHCH2), 46.4 (+, CHCH2), 58.6 (+, OCH3), 
66.6 (-, CH2OCO), 67.1 (-, OCH2), 71.1 (-, OCH2), 73.2 (-, NCH2O), 127.9 (+, CH, 
aromatic), 128.0 (+, CH, aromatic), 128.1 (+, CH, aromatic),128.4 (+, CH, aromatic), 128.5 
1(+, CH, aromatic), 29.2 (+, CH, Imi-C5), 136.4 (+, Cquat, aromatic), 136.5 (+, Cquat, Imi-C4), 
143.4 (+, Cquat, Imi-C2), 143.9 (+, Cquat, aromatic), 156.4 (+, Cquat, NHCO), 191.1 (+, Cquat, 
CO); IR (neat): ~ν  = 3356 (broad), 2927, 1717, 1672, 1529, 1494, 1450, 1426, 1242, 1133, 
1085, 995, 845, 776, 735, 698 cm-1; MS (CI, NH3): m/z (%) = 542.3 (100) [M + H+], 434.2 
(6.5), 408.3 (9.6), 334.2 (6.9), 167.0 (2.4), 108.1 (3.6);  
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tert-butyl 2-(1-((2-methoxyethoxy)methyl)-2-(3,3-diphenylpropanoyl)-1H-imidazol-5-
yl)ethylcarbamate (208)  
 
N
N
Ph
Ph O MEM
NHBoc
 
 
Prepared following the similar procedure for 212 (95 % yield); Rf  (SiO2, hexanes/EtOAc 1:1) 
= 0.27; thick oil; 1H NMR (300 MHz, CDCl3): δ = 1.43 (s, 9 H, CMe3), 2.86 (t, J = 6.76 Hz, 2 
H, CH2CH2), 3.25 (s, 3 H, OCH3), 3.26-3.31 (m, 4 H, OCH2CH2O), 3.37-3.44 (m, 2 H, 
CH2NH), 3,91 (d, J = 7.96 Hz, 2 H, CHCH2), 4.79 (t, J = 7.96 Hz, 1 H, CHCH2), 4.99 (bs, 1 
H, NH), 5.79 (s, 2 H, NCH2O), 7.02 (s, 1 H, Imi-5H), 7.09-7.15 (m, 2 H, aromatic), 7.20-7.31 
(m, 8 H, aromatic); 13C NMR (75.5 MHz, CDCl3): δ = 24.6 (-, CH2CH2), 28.4 (+, CMe3), 
39.1 (-, CH2NH), 44.8 (-, CHCH2), 46.5 (+, CHCH2), 58.7 (+, OCH3), 67.2 (-, OCH2), 71.2 (-, 
OCH2), 73.4 (-, NCH2O), 79.4 (+, Cquat, CMe3), 126.3 (+, CH, aromatic), 127.9 (+, CH, 
aromatic), 128.5 (+, CH, aromatic), 129.2 (+, CH, Imi-C5), 136.7 (+, Cquat, Imi-C4), 143.4 (+, 
Cquat, Imi-C2), 143.9 (+, Cquat, aromatic), 155.9 (+, Cquat, NHCO), 191.1 (+, Cquat, CO); IR 
(neat): ~ν  = 3348 (broad), 3027, 2976, 2930, 1708, 1676, 1600, 1515, 1494, 1427, 1392, 1366, 
1265, 1170, 1136, 1087, 1031, 847, 736, 702 cm-1; MS (CI, NH3): m/z (%) = 508.3 (100) [M 
+ H+], 300.2 (7.2), 228.1 (1.1), 94.1 (1.1);  
 
tert-butyl 2-(1-((2-methoxyethoxy)methyl)-2-(1-hydroxy-3,3-diphenylpropyl)-1H-
imidazol-5-yl)ethylcarbamate (209):  
 
N
N
Ph
Ph OH MEM
NHBoc
 
 
Prepared following the similar procedure for 217 (94 % yield); Rf (SiO2, EtOAc) = 0.30; 
thick oil; 1H NMR (300 MHz CDCl3): δ = 1.43 (s, 9 H, CMe3), 2.61-2.70 (m, 4 H, CH2CH2 + 
CH2CH), 3.26 (s, 3 H, OCH3), 3.24-3.35 (m, 6 H, OCH2CH2O + CH2NH), 4.25 (t, J = 7.96 
Hz, 1 H, CHCH2), 4.48 (t, J = 6.99 Hz, 1 H, CHOH), 4.92 (t, J = 5.76 Hz, 1 H, NH) 4.95 (d, J 
= 10.98 Hz NCHHO), 5.10 (d, J = 10.98 Hz NCHHO), 6.67 (s, 1 H, Imi-5H), 7.12-7.26 (m, 
10 H, aromatic); 13C NMR (75.5 MHz, CDCl3): δ = 23.7 (-, CH2CH2), 27.5 (+, CMe3), 38.5 (-
, CH2NH), 40.3 (-, CHCH2), 46.1 (+, CHCH2), 57.9 (+, OCH3), 62.9 (+, CHOH), 66.1 (-, 
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OCH2), 70.4 (-, OCH2), 71.5 (-, NCH2O), 78.4 (+, Cquat, CMe3), 124.4 (+, CH, Imi-C5), 125.2 
(+, CH, aromatic), 125.3 (+, CH, aromatic), 126.9 (+, CH, aromatic), 127.2 (+, CH, 
aromatic), 127.5 (+, CH, aromatic), 127.6 (+, CH, aromatic), 129.0 (+, Cquat, Imi-C4), 143.3 
(+, Cquat, aromatic), 143.6 (+, Cquat, aromatic), 149.4 (+, Cquat, Imi-C2), 155.0 (+, Cquat, CO); 
IR (neat): ~ν  = 3340 (broad), 3027, 2978, 2929, 1702, 1494, 1451, 1391, 1365, 1266, 1250, 
1168, 1081, 1031, 892, 734, 629 cm-1; MS (CI, NH3) m/z (%) = 510.2 (100) [M + H+], 405.2 
(3.9), 300.1 (4.8), 228 (3.7). 
 
tert-butyl 2-(1-((2-methoxyethoxy)methyl)-2-(2-methyl-3,3-diphenylpropanoyl)-1H-
imidazol-5-yl)ethylmethylcarbamate (223):  
 
N
N
Ph
Ph O
N Boc
CH3
CH3MEM
 
 
To a solution of 208 (105 mg 0.207 mmol) in DMF (2 mL) at 0 °C was added NaH (60 % 
dispersion in oil)( 15.56 mg 414 mmol) and the reaction mixture was warmed up to RT and 
stirred further for 2 h. Diethyl ether (5 mL) was added followed by water (4 mL). The reaction 
mixture was extracted in 2:1 mixture of ether and CH2Cl2 (3×10 mL), washed with brine (10 
mL), dried over MgSO4 and concentrated in vacuo to leave an oil which was purified by 
column chromatography (EtOAc/hexanes 1:1) to obtain 223 (83 %). 
Rf (SiO2, hexanes/EtOAc 1:1) = 0.28; thick oil; 1H NMR (300 MHz CDCl3): δ = 1.13 (d, J = 
6.83 Hz, 3 H, CH3CH), 1.43 (bs, 9 H, CMe3), 2.78-2-89 (m, 6 H, NCH3 + CH2O + CHHCH2), 
3.02-3.09 (m,1 H, CHHCH2), 3.14-3.24 (m, 2 H, CH2O), 3.27 (s, 3 H, OCH3), 3.48 (bs, 2 H, 
CH2NH), 4.28 (d, J = 11.87 Hz, 1 H, CHCHCH3), 4.93-5.04 (m, 1 H, CHCH3), 5.59 (d, J = 
10.94 Hz, NCHHO), 6.02 (d, J = 10.94 Hz, NCHHO), 6.96-7.18 (m, 5 H, aromatic), 7.24-
7.40 (m, 6 H, aromatic + Imi-4H); 13C NMR (75.5 MHz, CDCl3): δ = 17.9 (+, CH3CH), 22.5-
22.9 (-, CH2CH2, rotamer), 28.4 (+, CMe3), 34.4-34.7 (+, NCH3, rotamer), 45.2 (+, CHCH2), 
47.3-47.9 (-, CH2NH, rotamer), 54.8 (+, CHCHCH3), 58.9 (+, OCH3), 66.9 (-, OCH2), 71.1 (-, 
OCH2), 73.4 (-, NCH2O), 79.8 (+, CMe3), 126.0 (+, CH, aromatic), 126.5 (+, CH, aromatic), 
128.0 (+, CH, aromatic), 128.3 (+, CH, aromatic), 128.4 (+, CH, aromatic), 128.6 (+, CH, 
aromatic), 128.9-129.0 (+, CH, Imi-C4, rotamer), 136.9 (+, Cquat, Imi-C5), 143.0 (+, Cquat, 
Imi-C2), 143.1 (+, Cquat, aromatic), 143.8 (+, Cquat, aromatic), 155.4-155.6 (+,Cquat, NHCO, 
roramer), 196.4 (+, Cquat, CO); IR (KBr): ~ν  = 2974, 2930, 1694, 1678, 1453, 1422, 1393, 
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1366, 1146, 1104, 993, 847, 744, 702 cm-1; MS (ESI,CH2Cl2/MeOH/NH4Ac): m/z = 536.5 [M 
+ H+]. 
 
2-methyl-1-(4-(2-(methylamino)ethyl)-1H-imidazol-2-yl)-3,3-diphenylpropan-1-one 
dihydrochloride (224):  
 
N
N
H
H
N
Ph
Ph O
CH3 CH3
2HCl
 
 
To a solution of 223 (60 mg, 0.112 mmol) in MeOH:H20 1:1 (3 mL) was added Conc. HCl 
(1.5 mL) and reaction mixture was refluxed for 2 h. The solvent was removed in vacuo to 
leave a white solid as a hydrochloride salt.  
Rf  (SiO2, = 0.33; white solid m.p.  = 238-240 °C; 1H NMR (300 MHz CD3OD): δ = 1.22 (d, 
J = 6.72 Hz, 3 H, CH3CH), 2.77 (s, 3 H, NCH3), 3.20 (t, J = 6.80 Hz, 2 H, CH2CH2), 3.36-
3.41 (m, 2 H, CH2NH), 4.25 (d, J = 11.42 Hz, 1 H, CHCHCH3), 4.63-4.73 (m, 1 H, CHCH3), 
7.10-7.15 (m, 2 H, aromatic), 7.00-7.20 (m, 4 H, aromatic); 7.33-7.38 (m, 4 H, aromatic), 
750-752 (m, 2 H, aromatic), 7.62 (s, 1 H, Imi-5H); 13C NMR (75.5 MHz, CD3OD): δ = 17.1 
(+, CH3CH), 22.9 (-, CH2CH2), 33.7 (+, NCH3), 47.6 (+, CHCH2), 56.8 (+, CHCHCH3), 122.0 
(+, CH, Imi-C5), 127.8 (+, CH, aromatic), 128.0 (+, CH, aromatic), 129.1 (+, CH, aromatic), 
129.4 (+, CH, aromatic), 129.7 (+, CH, aromatic), 129.9 (+, CH, aromatic), 134.1 (+, Cquat, 
Imi-C4), 141.2 (+, Cquat, Imi-C2), 143.1 (+, Cquat, aromatic), 144.0 (+, Cquat, aromatic), 190.7 
(+, Cquat, CO); IR (KBr): ~ν  = 3434 (broad), 2932, 2770, 2730, 1697, 1494, 1452, 1426, 1376, 
1339, 1221, 1082, 1047, 947, 749, 704, 635, 592 cm-1; MS (EI, 70 eV) m/z (%) = 347.3 (1) 
[M+•], 304.2 (37.8) [M – C2H5N], 167.0 (38.9) [CHPh2+], 91.1 (8.9), 44.1 (100), 32.1 (12.5). 
HRMS: Calcd for C22H25N3O: 347.1998. Found: 347.1994. 
 
tert-butyl 2-(2-(3,3-diphenylpropanoyl)-1H-imidazol-4-yl)ethylcarbamate(219):  
 
N
N
H
NHBoc
Ph
Ph O
 
 
Experimental part H1-Receptor 85 
  
To a solution of dihydrochloride salt 201 (230 mg 0.586 mmol) and (Boc)2O (166 mg 0.762 
mmol) in water (4 mL) was added dropwise a solution of NaOH (70 mg 1.759 mmol) in water 
(2 mL). The reaction mixture was stirred at RT for 30 min. and extracted in extracted in 6:4 
mixture of ether and CH2Cl2 (3×10 mL). Organic phases were combined and washed with 
brine (10 mL), dried over MgSO4 and concentrated in vacuo to leave an oil which was 
purified by column chromatography (EtOAc/hexanes 1:1) to obtain 219 (91 %) 
Rf (SiO2, hexanes/EtOAc 4:6) = 0.27; white solid; m.p. =78-80 °C; 1H NMR (300 MHz 
CDCl3): δ = 1.42 (s, 9 H, CMe3), 2.77 (t, J = 6.89 Hz, 2 H, CH2CH2), 3.39 (bs, 2 H, CH2NH), 
3,89 (d, J = 7.68 Hz, 2 H, CHCH2), 4.79 (t, J = 7.68 Hz, 1 H, CHCH2), 525 (bs, 1 H, NH, very 
broad), 6.93 (bs, 1 H, Imi-5H), 7.11-7.16 (m, 2 H, aromatic), 7.20-7.30 (m, 8 H, 
aromatic),11.15 (bs, 1 H Imi-NH); 13C NMR (75.5 MHz, CDCl3): δ = 26.8 (-, CH2CH2 very 
broad), 28.5 (+, CMe3), 39.9 (-, CH2NH, broad), 43.5 (-, CHCH2), 46.0 (+, CHCH2), 79.6 
(+,Cquat, CMe3), 118.2 (+, CH, Imi-C5 broad), 126.4 (+, CH, aromatic), 127.8 (+, CH, 
aromatic), 128.5 (+, CH, aromatic), 142.0 (+, Cquat, Imi-C4, broad), 144.0 (+, Cquat, 
aromatic),144.6 (+, Cquat, Imi-C2), 156.2 (+, Cquat, NHCO), 189.9 (+, Cquat, CO); IR (Film): ~ν  
= 3270 (broad), 3022, 2976, 1690. 1674, 1393, 1366, 1250, 1169, 1069, 959, 849, 753, 701 
cm-1; MS (CI, NH3) m/z (%) = 420.2 (100) [M + H+], 254.1 (5.0). 
 
tert-butyl 2-(2-(1-hydroxy-3,3-diphenylpropyl)-1H-imidazol-4-yl)ethylcarbamate (220): 
 
N
N
H
NHBoc
Ph
Ph OH
 
 
To a solution of 219 (46 mg 0.11 mmol) in isopropanol (2 mL) was added NaBH4 (12 mg 
0.33 mmol). The reaction mixture was stirred for 6-8 h at room temperature. The reaction 
mixture was cooled to 0 °C, aqueous sat. ammonium chloride (4 mL) was added and the 
reaction mixture was extracted in CH2Cl2 (3×10 mL), washed with brine (8 mL), dried over 
MgSO4 and concentrated in vacuo to leave an oil which was purified by column 
chromatography (EtOAc/hexanes 8:2). 
Rf  (SiO2, EtOAc) = 0.23; white solid; m.p. =135-137 °C; 1H NMR (300 MHz CDCl3): δ = 
1.41 (s, 9 H, CMe3), 2.35-2.45 (m, 1 H, CHHCH), 2.54 (t, 2 H, CH2CH2), 2.61 (dd, J = 9.71, 
4.22 Hz, 1 H, CHHCH), 3.19 (dd, J = 12.73, 6.55 Hz, 2 H, CH2NH), 4.21 (dd, J = 9.71, 5.69 
Hz, 1 H, CHCH2), 4.47 (dd, J = 8.78, 4.22 Hz, 1 H, CHOH), 5.09 (t, J = 6.55 Hz,1 H, NH), 
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6.44 (s, 1 H, Imi-5H), 7.09-7.23 (m, 10 H, aromatic); 13C NMR (75.5 MHz, CDCl3): δ = 27.4 
(-, CH2CH2), 28.5 (+, CMe3), 40.2 (-, CH2NH), 42.2 (-, CHCH2), 46.9 (+, CHCH2), 65.8 (+, 
CHOH), 79.5 (+,Cquat, CMe3), 116.7 (+, CH, Imi-C5, broad), 126.2 (+, CH, aromatic), 126.4 
(+, CH, aromatic), 127.9 (+, CH, aromatic), 128.3 (+, CH, aromatic), 128.5 (+, CH, 
aromatic), 128.6 (+, CH, aromatic), 134.3 (+, Cquat, Imi-C4, broad), 143.7 (+, Cquat, aromatic), 
144.9 (+, Cquat, aromatic), 150.7 (+, Cquat, Imi-C2), 156.2 (+, Cquat, CO); IR (KBr): ~ν  = 3356 
(broad), 3027, 2977, 2931, 1690, 1451, 1392, 1366, 1275, 1253, 1169, 1056, 753, 702 cm-1; 
MS (CI, NH3) m/z (%) = 422.2 (100) [M + H+], 348.1 (2.0), 254 (3.0), 228.9 (10.2), 212.1 
(3.4). 
 
1-(4-(2-aminoethyl)-1H-imidazol-2-yl)-3,3-diphenylpropan-1-ol dihydrochloride (221): 
 
N
N
H
NH2
Ph
Ph OH
2HCl
 
 
To a solution of 00 (40 mg, 0.095 mmol) in ether (2 mL) was added a solution of saturated 
HCl in ether (2 mL) and reaction mixture was stirred for 16 h. The solvent was removed in 
vacuo to leave a white solid as a hydrochloride salt (quantitative).  
Rf  (SiO2, CH2Cl2/MeOH/NH3 10:3:0.2) = 0.17; white solid; m.p. = 195-197 °C; 1H NMR 
(300 MHz DMSO): δ = 2.36 (ddd, J = 14.11, 9.82, 4.56 Hz, CHHCH), 2.89-2.97 (m, 3 H, 
CHHCH + CH2CH2), 3.05-3.16 (m, 2 H, CH2NH), 3.58 (bs, 1 H, OH), 4.31 (dd, J = 10.70, 
4.56 Hz, 1 H, CHCH2), 4.62 (dd J = 9.81, 2.85 Hz, 1 H, CHOH), 6.58 (bs, 1 H, Imi-5H), 7.12-
7.36 (m, 8 H, aromatic), 7.44-7.47 (m, 2 H, aromatic), 8.32 (bs, 3 H, NH3), 14.22 (bs, I H, 
Imi-NH), 14.58 (bs, 1 H, Imi-N+H). 13C NMR (75.5 MHz, DMSO): δ = 22.3 (-, CH2CH2), 
37.1 (-, CH2NH), 40.3 (-, CH2CH), 46.0 (+, CHCH2), 62.9 (+, CHOH), 116.2 (+, CH, Imi-
C5), 126.1 (+, CH, aromatic), 126.3 (+, CH, aromatic), 127.4 (+, CH, aromatic), 128.1 (+, 
CH, aromatic), 128.4 (+, CH, aromatic), 128.4 (+, Cquat, Imi-C4),128.5 (+, CH, aromatic), 
142.9 (+, Cquat, aromatic), 144.9 (+, Cquat, aromatic), 149.6 (+, Cquat, Imi-C2); IR (KBr): ~ν  = 
3375 (broad), 2924, 1638, 1600, 1494, 1448, 1227, 1082, 1031, 947, 846, 753, 702 cm-1; MS 
(EI, 70 eV) m/z (%) = 321.1 (3.6) [M+•], 292.2 (71.8) [M – CH2NH3], 217.2 (70.7), 167.0 
(100) [CHPh2], 141.1 (47.8), 107.1 (80.8), 81.1 (11.6). HRMS: Calcd for C20H23N3O: 
321.1841. Found: 321.1842.  
Experimental part H1-Receptor 87 
  
Compounds (226) and (227):  
 
N
N
CO2H
MEM
N
N
MEM
CO2H
226 227
 
 
A 92:8 mixture of 171 and 172 (3.2 g, 13.32 mmol) was dissolved in THF-MeOH-H2O (3:1:1, 
65 mL) and cooled to 0 °C and treated with LiOH (19.98 mmol) dissolved in water (15 mL). 
The reaction mixture was allowed to come to RT and stirred for 8 h. After most of the THF 
and MeOH were evaporated, the aqueous phase was acidified (pH = 4) with the addition of 2 
N HCl and extracted with CH2Cl2 (6×40 mL). Combined organic layers were washed with 
brine (20 mL), dried (MgSO4) filtration and evaporation gave a nonseparable mixture (93:7) 
of acids 226 and 227 (84%). 
 
Compounds (228) and (229): 
 
N
N
CO2H
MEM
N
N
MEM
CO2H
228 229
 
 
A solution of mixture of 226 and 227 (2.7 g 11.935 mmol) in MeOH (80 mL) was treated 
with 10 wt % Pd/C (270 mg) and purged with an atmosphere of hydrogen followed by 
vigorous stirring in an atmosphere of hydrogen (via balloon) for 12 h. The reaction mixture 
was filtered through a pad of Celite, washed with MeOH (60 mL). The solvent was removed 
in vacuo to obtain a mixture of 228 and 229 (93 %) which was used for the next step without 
any purification. 
 
Compounds (230) and (231): 
 
N
N
NHCbz
MEM
N
N
MEM
NHCbz
230 231
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To a suspensation of mixture of acids 228 and 229 (1.8 g, 7.89 mmol) in CH2Cl2 (25 mL) at 0 
°C was slowly added Oxalyl chloride (2.0 g, 1.35 mL, 15.78 mmol) and reaction mixture was 
stirred at room temperature for 3 h. N2 was bubbled to remove the excess of Oxalyl chloride. 
CH2Cl2 (10 mL) was added and evaporated by bobbling N2 and dried under high vacuum (30 
min.) to remove any traces of Oxalyl chloride. Again CH2Cl2 (25 mL) was added followed by 
TMS-azide (1.82 g, 2.06 mL, 15.78 mmol) and the reaction mixture was stirred at room 
temperature for 4 h. N2 was bubbled and dried under high vacuum (30 min.) to leave the 
corresponding azide as a pale yellow oil which was used for the rearrangement without any 
further purification.  
Rearrangement: To a solution of azide in toluene (30 mL) was added benzyl alcohol (5.5 
mL) and the reaction mixture was refluxed for 18 h. The solvent was removed in vacuo. The 
residue was purified by chromatography on silica (hexanes/EtOAc 1:1) to obtain a 
nonseparable mixture of 230 and 231 (72 %). 
 
tert-butyl 2-(1-((2-methoxyethoxy)methyl)-1H-imidazol-4-yl)ethylcarbamate (232):  
 
N
N
NHBoc
MEM
 
 
To a solution of the mixture of 230 and 231 (358 mg, 1.075 mmol) and (Boc)2O (281 mg 2.43 
mmol) in MeOH (10 mL) was treated with 10 % Pd/C (40 mg) and purged with hydrogen 
followed by vigorous stirring in an atmosphere of hydrogen (via balloon) for 1 h. The reaction 
mixture was filtered through a pad of Celite, washed with MeOH (20 mL). The solvent was 
removed in vacuo. The residue was purified by chromatography on silica (EtOAc/hexanes1:1) 
to obtain a mixture of 232 and 233. However at this stage regioisomers could be separated by 
column chromatography and 232 was obtained (83 %). 
Rf (SiO2, EtOAc ) = 0.22; thick oil; 1H NMR (300 MHz CDCl3): δ = 1.39 (s, 9 H, CMe3), 
2.71 (t, J = 6.62 Hz, 2 H, CH2CH2), 3.32 (s, 3 H OCH3), 3.34-3.40 (m, 2 H, CH2NH), 3.45-
3.52 (m, 4 H, OCH2CH2O), 3,89 (d, J = 7.86 Hz, 2 H, CHCH2), 4.77 (t, J = 7.86 Hz, 1 H, 
CHCH2), 5.15 (bs, 1 H, NH), 5.26 (s, 2 H, NCH2O), 6.81 (s, 1 H, Imi-5H), 7.53 (s, 1 H, Imi-
2H); 13C NMR (75.5 MHz, CDCl3): δ = 28.4 (-, CH2CH2), 28.5 (+, CMe3), 40.2 (-, CH2NH), 
59.1 (+, OCH3), 67.7 (-, OCH2), 71.6 (-, OCH2), 76.6 (-, NCH2O), 79.0 (+,Cquat, CMe3), 115.6 
(+, CH, Imi-C5), 137.1 (+, CH, Imi-C2), 140.9 (+, Cquat, Imi-C4), 156.1 (+, Cquat, NHCO); IR 
Experimental part H1-Receptor 89 
  
(KBr): ~ν  = 3541, 3356, 2974, 2928, 2881, 1711, 1452, 1392, 1364, 1177, 1089, 1035, 984, 
956, 922, 853, 758, 623 cm-1; MS (CI, NH3) m/z (%) = 300.1 (100) [M + H+]. 
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3. Synthesis of conformationaly restricted analogs of FUB-372 and 
proxyfan: Interaction with histamine H3-Receptor 
 
3.1 Introduction 
Drugs targeting G-protein coupled receptors (GPCRs) represent one of the most 
successful classes of pharmaceutical remedies known. It was estimated that at present more 
than 50% of all available drugs act directly via stimulating or blocking GPCRs.73 Histamine 
has proven to exert tremendous influence over a variety of physiological processes including 
inflammatory triple response and gastric acid secretion. The importance of histamine H1 and 
H2 receptor agonists and specially antagonists is unquestioned to the human health. 
Antagonists that target histamine H1 or H2 receptors and are used in the treatment of allergic 
conditions such as rhinitis and gastric acid release disorders have been ‘blockbuster’ drugs for 
many years74 and proved to be financially profitable for the pharmaceutical industry. 
Recently, following the completion of Human Genome Project, the family of histamine 
receptors has been extended to include four different GPCRs, H1, H2, H3 and H4 receptors.75 
In the view of blockbuster status of the histamine H1 and H2 receptor antagonists, current 
expectations for the therapeutic potential of drugs that target the H3 and H4 receptors are high. 
 
3.1.1 Discovery of histamine H3Rs 
Histamine is known to act on target cells in the mammalian brain via stimulation of 
two classes of receptor H1 and H2 previously characterized in peripheral organs.7,8 It is well 
established that several neurotransmitters affect neuronal activity in the central nervous 
system (CNS) through the stimulation of not only post, but also presynaptically located 
receptors, often displaying distinct pharmacological specificity by which they may control 
their own release. Such autoreceptors have been found in the case of noradrenaline, 
dopamine, serotonin, acetylcholine and γ-aminobutyric acid (GABA) neutrons76,77 but not in 
case of histamine. In 1983 Arrang et al. found that histamine inhibits its own release from 
depolarized slices of rat cerebral cortex by an action apparently mediated by another receptor 
subtype which is pharmacologically distinct from H1 and H2 receptors. This novel 
presynaptically located autoreceptor was named as histamine H3R, and subsequently 
definitively characterized11 in 1987. 
The H3R, primarily located on nerve terminals and in the central nervous system 
(CNS), modulates the production and release of histamine.15,32 The pharmacological blockade 
of H3R enhances the release of histamine and other neurotransmitters74,78-80 and has been 
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shown to enhance the vigilance or alertness.81,82 Consequently, H3R antagonists are thought to 
have a potential as drug therapies for attention-deficit hyperactivity disorder (ADHD), 
Alzheimer’s disease, Parkinson’s disease, Epilepsy, and sleep related disorders.83-85 Recently, 
the role of histamine neurotransmission in the CNS was extensively reviewed by Panula and 
Haas.86 Histaminergic neurons are localized in the tuberomammillary nucleus of the 
hypothalamus, projects to all major areas of the brain and are involved in many functions, 
including the regulation of sleep/wakefulness, feeding and memory processes. Although the 
H3R can also be found in the periphery (mainly, but not exclusively, on neurons), the CNS 
contains the great majority.12,87,88 
 
3.1.2 Molecular Architecture of H3R gene and its isoforms 
Although H3R was identified more than a couple of decades, its molecular architecture 
was unknown until 1999. For the past few years, the histamine H3R has been the target of 
cloning and purification attempts, yet its molecular identity was remained an enigma. 
Lovenberg et al. using molecular cloning technique showed that like H1 and H2 receptors,18,89 
the H3R also belongs to the large super-family of GPCRs.12 The human H3R shows very low 
sequence similarity with other GPCRs. Overall similarity between the H3R and other biogenic 
amine receptors is 20 - 27%. Its also show very low homology with H1 (22%) and H2 (20%) 
receptors. Because of this remarkable divergence H3R gene was not cloned by similarity 
screening with H1 or H2 receptor-specific probes. On the other hand it shows the greatest 
degree of homology at 37% with human histamine H4R. Moreover their homology in the 
transmembrane domain is 58% and both H3 and H4 receptors have a long third intracellular 
loop 
Unlike other histamine receptors the analysis of H3R gene revealed the presence of 
several splice variants. The histamine H4R has a similar genomic structure to the H3R in that it 
contains two introns and three exons but so far no splice variants of H4R have been reported. 
The human H3R gene has been suggested to consist of either three exons and two introns,90,91 
or four exons and three introns.92,93 The various H3R isoforms that are derived from 
alternative splicing of H3R gene differ in four different parts of the receptor protein. In the 
region between N-terminus and TM-I alternative splicing results H3R with a shortened amino-
terminal domain. Alternative splicing might also occur in region of TM-II which results in the 
partial deletion of second TM domain and first extracellular loop. In the long intracellular 
loop between TM-V and TM-VI which has 132 amino acids, alternative splicing occurs most 
extensively and yields H3R isoforms with a third intracellular loop of variable length or 
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putative H3R proteins. Finally, alternative splicing at the C-terminus results H3R protein with 
additional eight amino acids. At present a full characterization is available for only a limited 
number of isoforms. The H3R445 isoform12 described by Lovenberg et al. is currently the best 
characterized H3R isoform. Isoforms of the H3R are not limited to human but are also found in 
other species including guinea pig, and mice.94 Interestingly, rat H3R isoforms with deletion 
in the third intracellular loop differ in their effectiveness to activate cAMP-response element 
(CRE)-dependent transcription or MAPK activation. The role of the activation of 
PKB/GSK3β by the H3R in the brain is currently less clear, but the disregulation of GSK3 is 
linked to several prevalent pathological conditions, like diabetes and/or insulin resistance, and 
Alzheimer’s disease.95  
 
3.1.3 Potential binding sites for the H3R ligands 
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Fig 3.1.1 The snake plot of human histamine H3R protein  
 
The human histamine H3R protein consists of 445 amino acids and is predicted to have 
seven transmembrane (TM) domains along with a helix VIII (Fig. 2.1.1). Helix VIII is 
referred as only helix and not as transmembrane and is supposed to be perpendicular to the 
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TM domains. Amino acids represented in gray circles belong to the intra and extracellular 
loop of the receptor protein. Amino acids shown in black bold circles point to the head groups 
of the lipids and belong to the TM domain. Blue circles represent the amino acids point to the 
lipid and belong to the TM domain. Amino acids pointing inside the binding crevice are 
shown with red circles and also belong to the TM domain. Amino acids with gray background 
represent the most conserved amino acids. Amino acids designated with red letters are 
supposed to be the important binding sites. 
Overall homology between histamine H3R of human and rat is more than 90% and 
differ by only five amino acids in TM domain region. The strong binding of endogenous 
ligand histamine at both species makes it more evident. In contrast discrepancy in binding has 
been found for some antagonists suggesting the different possible binding sites in the 
receptor. Structural identification of bovine rhodopsin,96 resolved by X-ray crystallographic 
analysis, has given a major breakthrough in the  understanding of GPCRs. Stark et al. used 
molecular modeling studies to generate a computational model97 of human and rat histamine 
H3Rs which shows close resemblance to the crystal structure of rhodopsin. Like rhodopsin the 
H3R is also stabilized by an intramolecular disulfide bridge between Cys 107 and 188 (Fig. 
2.1.1). This bridge is also supposed to be responsible for the deep folding of the extracellular 
loop into the binding pocket. Recently, Schlegel et al98. has performed molecular modeling 
studies very extensively and some of the features from Stark (mainly on imidazole containing 
H3R antagonists) and Schlegel (mainly on non-imidazole containing H3R antagonists) are 
summarized below. 
From the molecular modeling experiments which have been studied using different 
ligands to form ligand-receptor complexes it can be seen that there are several different 
binding sites found for variety of agonistic and antagonistic ligands, glutamate 206 is one of 
the most important amino acids involved in the binding. 
Ligand to receptor interactions can be briefly divided into two main types 
1. Polar interactions like hydrogen binding or ionic interaction. 
2. Non-polar interactions like aromatic or lipophilic interaction. 
 
3.1.4 Polar Interactions: 
In a receptor-ligand complex model involving ciproxifan 246 with the human H3R the 
possible interaction of amino acids involved in the binding can be explained. The imidazole 
ring of ligand was located in a polar pocket formed by many residues like Tyr 115, Glu 191, 
Glu 206, Ser 203 and Thr 375 capable of forming hydrogen bonds. Especially Glu 206 which 
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is one of the most important amino acids located on TM-V and Glu 191 located on second 
extracellular loop which fold deeply in the binding pocket can make hydrogen bond 
interactions with the imidazole ring. Moreover, the tautomerism of the imidazole ring allows 
the molecule to interact with both glutamate 191 and 206 residues. Schlegel et al98 in their 
recent studies showed that protonated heterocyclic moieties like piperidine, piperazine, 
pyrrolidine as well as imidazoles are able to interact with Asp 114. The side chain of Asp 114 
is flexible allowing the carboxylate group to interact with different linker of H3R antagonists 
residues. Thr 119 and Ala 122 (human H3R) and Ala 119 and Val 122 (rat H3R) are located in 
close proximity to Glu206 and Tyr 115 and influences the geometry of the binding pocket. 
Both residues have been shown to be important for the species selectivity of the investigated 
compounds.99  
 
3.1.5 Non-polar Interactions: 
The hydrophobic part of the binding pocket is constituted by several aromatic and 
aliphatic amino acid residues like Tyr 91, Trp 110, Leu 111, Cys 188, Phe 398 and Tyr 402. 
These amino acids interact with aliphatic chains of the lipophilic part of antagonists. In 
receptor complex studies involving compound SCH79687 (252) it is observed that aromatic 
ring systems in the linker moieties are expected to be oriented orthogonal to the membrane 
plane. It is also thought that the aromatic system lies parallel displaced to Tyr 189 from 
second extracellular loop and at the same time a T-shaped interaction could be formed with 
Tyr 267. De Esch et al.100 suggested two lipophilic binding pockets for inverse agonist 
binding located between TM-III, IV and TM-V and TM-V and VI. 
 
3.1.6 The signal transduction pathways of H3R protein 
The signal transduction pathways for H3R are very well explained by Leurs et al. as 
shown in the figure 3.1.2. H3R can activate the members of the Gi/o protein family and the 
activated Gi/o proteins inhibits adenylyl cyclase (AC), the enzyme responsible for the 
induction of cyclic AMP, which in turn results in the activation of protein kinase A (PKA) 
and consequently cAMP responsive element binding protein (CREB) to modulate gene 
transcription. Other effective pathways of H3R-mediated activation of Gi/o proteins include 
mitogen-activated protein kinase (MAPK) and phosphatidyl-inositol 3-kinase (PI3K). H3R 
mediated activation of Gi/o proteins might also lead to the activation of phospholipase 
A2(PLA2) which includes the release of arachidonic acid as well as the inhibition of Na+/H+ 
exchange and the lowering of intracellular Ca2+ levels. The subsequent activation of the 
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AMPK and PI3K pathways results in the phosphorylation of extracellular signal-regulated 
kinases (ERKs) and protein kinase B (PKB) respectively. Activated PKB will subsequently 
phosphorylate and thereby inhibit the action of glycogen synthase kinase 3β (GS3Kb). 
 
 
Figure 3.1.2 Diverse signaling pathways of H3R activation. Reproduced with permission from 
Nature Reviews Drug Discovery79 copyright (2005) Macmillan Magazines Ltd. 
 
3.1.7 The structure activity relationships (SARs) of histamine H3R agonists 
Structurally diverse H3R agonists having different chain length, rigidity and different 
polar groups are shown in Fig. 3.1.3. All known H3R agonists contain the imidazole 
heterocycle. The initial attempts for the development of H3R ligands were mainly focused on 
the endogenous ligand histamine, probably because of its high affinity to the human H3R (pKi, 
7.8). So far all H3R agonists closely resemble histamine and contain 4(5)-substituted 
imidazole moieties. 
The stepwise chemical modification of histamine lead to the variety of different 
molecules but the efforts to replace imidazole heterocyclic moieties have so far been 
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unsuccessful,101,102 prompting speculations that the capacity of imidazole to tautomerise might 
be of importance in the receptor activation. There is also evidence that histamine could bind 
to the human H3R in its di-protonated state. Additional substituents on the imidazole ring 
eliminate H3R activity,101 but surprisingly, small structural modifications of side chains 
resulted in very potent and selective H3R agonists. The methylation of histamine at different 
position is known to produce the selective analogues for different subtypes among histamine 
receptors. Methylation of side chain at α and β position is allowed. Moreover 
monomethylation of the primary amine enhances the activity but dimethylation results in 
significant loss of agonistic activity. Introducing relatively bigger groups like ethyl or propyl 
eliminates the activity significantly, probably indicating that the space in the agonistic binding 
site is very limited.102 
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Figure 3.1.3 Imidazole containing H3R agonists, pKi values are given for human (h), rat (r) 
and guinea-pig (gp) receptors 
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Stereoisomers also play an important role in the binding, suggesting specific 
conformational aspects of the receptor. (R)-α-methylhistamine (RAMH; Fig. 3.1.3) shows 
very high activity at human H3R (pKi, 8.4)11 and has been used in many pharmacological 
studies together with its less active (S)-isomer. Its high basicity, hydrophilicity, extensive 
metabolism and low bioavailability limit its in vitro use. By applying a Prodrug concept 
Schunack et al. prepared its hydrophobic derivative BP 2-94 (235 Fig 2.1.3).103 This prodrug 
has significantly improved oral bioavailability and pharmacokinetic properties.104 In humans 
the administration of BP 2-94 results in a 100-fold increase in the plasma RAMH. 
 
3.1.8 The potential therapeutic applications of H3R agonists 
Unlike histamine receptor antagonists/inverse agonists, the therapeutic applications for 
agonists are limited as can be seen for both H1 and H2 receptors. Nevertheless, H3R agonists 
might be of therapeutic use for the treatment of insomnia, myocardial ischaemic arrhythmias 
or could also be antinociceptive. Since the CNS contains the great majority of H3Rs which are 
also found in the periphery (mainly, but not exclusively, on neurons), H3R agonists might be 
of therapeutic use in both CNS as well as peripheral nervous system. Histaminergic neurons 
mainly located in the hypothalamus are thought to have an important role in the regulation of 
sleep and wakefulness.105 The H3R activation in CNS results in the lower hypothalamic 
histamine release, suggesting the potential use of H3R agonists against insomnia.105 Moreover 
studies in various preclinical model with the prodrug BP 2-94 and SCH50971 ,106 (Fig. 2.1.3), 
also confirmed that sleep is induced by H3R agonists. The H3R activation also modulates 
ischaemic noradrenaline release in animal as well as human models of protected myocardial 
ischaemia. The excessive nonadrenaline is regarded as an important cause for cardiac 
arrhythmias in human. The H3R agonists could provide an attractive new approach for 
preventing and treating myocardial ischaemic arrhythmias.107 Finally H3R agonists such as BP 
2-94 and SCH50791 are reported to inhibit neurogenic inflammatory processes in various 
tissues, including the lungs and dura matter.104,106,108,109 These observations indicate a 
potential use of H3R agonists in inflammation, asthma and migraine.  
 
3.1.9 Histamine H3R antagonists 
The H3R is known to modulate various neurotransmitter systems in the brain. In 
rodent and/or in human brains, the H3R activation inhibits presynaptically the release of many 
important neurotransmitters. Despite this interesting feature the drugs that target H3R have 
until 1999 been mainly developed by academic research groups. Since the identification of 
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H3R at molecular level,5 many pharmaceutical companies have put considerable recourses 
into the development of H3R antagonists because of its potential therapeutic applications, as 
can be judged from the recent literature. Currently, many pharmaceutical companies are 
active in this field which includes Abbott Laboratories, Boehringer Ingelheim, De Novo 
Pharmaceutical, Eli Lilly, GlaxoSmithKline, Johnson & Johnson PRD/Ortho-McNeil, Merck, 
NovoNordisk, Pfizer, Sanofi-Synthelabo, Schering-Plough and UCB Pharma. The 
development of H3R antagonists has recently been extensively reviewed.110-112 
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Figure 3.1.4 Imidazole containing H3R antagonists, pKi values are given for human (h), rat (r) 
and guinea pig (gp) receptors 
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3.1.10 Classification of H3R antagonists 
Histamine H3R antagonists can be briefly classified into two types  
1. Imidazole containing H3R antagonists 
2. Non-imidazole H3R antagonists  
 
3.1.11 Imidazole containing H3R antagonists 
Thioperamide 244 (Fig. 3.1.4) was the first potent H3R antagonist described in the 
literature that lacked H1 and H2 receptor activity.11,113 More recently, this and many other 
compounds that were initially classified as H3R antagonist have had to be reclassified as 
inverse H3R agonists. Thioperamide 244 has been used as a reference H3R antagonist for 
almost twenty years, and many preclinical studies have been carried out with this compound. 
244 shows high affinity for rat H3R (pKi, 7.2).114 At the same time 244 shows high activity at 
human H4R (pKi, 7.3), the rat 5-HT3 receptor (pKi 5.6) and α 2A receptor (pKi 6.9), and the 
human α
 2C receptor (pKi = 6.5).115 
 
3.1.12 SARs of imidazole containing H3R antagonists 
Clobenpropit 245 (Fig. 3.1.4),116 is one of the early imidazole containing H3R 
antagonists that has been extensively used to characterize H3R. 245 (pKi, 9.2, human H3R) can 
be considered as a imetit analogue (Fig. 3.1.4) and illustrates a trend in the SARs for the H3R 
antagonists. One of the strategies in the design of imidazole containing inverse agonist is 
increasing the distance between the basic moieties observed in the agonists. For example, by 
increasing the distance between histamine and/or the attachment of larger lipophilic moieties 
in the side chain, potent H3R antagonists can be obtained. Attachment of lipophilic groups to 
the linker moiety can increase the inverse agonistic activity and large aromatic as well as 
aliphatic groups are shown to be well tolerated. The basic moieties in the imidazole side chain 
can however be omitted, as shown by compounds of the proxyfan class. Proxyfan (Fig. 3.1.4) 
has recently been identified as a neutral H3R antagonist (pKi, 8.0, rat H3R).117 However the 
proxyfan is a particular H3R ligand, because it shows both H3R agonistic (partial), neutral 
H3R antagonistic and inverse H3R agonistic properties, depending on the signaling assay 
used.118,119  
The linker moiety can have a great structural diversity and thus can play an important 
role. There are many compounds known with different linker groups; some of the potent, 
structurally diverse H3R antagonists are shown in figure 3.1.4. Many compounds contain 
linkers like, ethers (e.g. proxyfan 247 and ciproxifan 246), thioethers, ketones, carbamates, 
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esters, urea, thiourea (e.g. thioperamide 244), isothiourea (e.g. clobenpropit 245), sulfoxides, 
sulphonamides, sulphamide, amine, amide, amidine and guanidine. Linkers are not limited to 
polar groups, some nonpolar linkers are also known like methylene units, phenyl rings (e.g. 
SCH79687 252), unsaturated hydrocarbons and heterocyclic ring systems. In the proxyfan 
class of compounds the replacement of ether functionality by other functional groups like 
carbamates, esters and amides120 and even simple methylene units was achieved without 
loosing its H3R activity.121,122 246 (Fig. 3.1.4) has also been extensively used in various in 
vitro studies but show only moderate affinity for human H3R (pKi, 7.2). Inspired by the results 
from proxyfan 247 Stark et al. examined the SARs of a series of proxyfan and found that the 
para-substituted 4-(3-(phenoxy)propyl)-1H-imidazoles show nanomolar activities which led 
to the compound FUB-372 249.123 Later Sasse et al. synthesized its oxime derivative 
imoproxyfan 251 (Fig. 3.1.4) which displays even more potency in vitro as well as in vivo 
H3R assays.124 
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Figure 3.1.5 Influence of small structural changes on the activity 
 
However in the FUB series it is observed that small structural changes can greatly 
influence the pharmacological profile (Fig. 3.1.5). Compounds FUB373 and FUB407 show 
partial agonism while, similar compounds like FUB335 and FUB397 were found to be inverse 
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agonist. A similar kind of relationship was also observed for the class of VUF series (Fig. 
3.1.5), where small structural changes in the side chain can shift the activity from full 
agonism to the inverse agonism. 
 
3.1.13 Non-imidazole H3R antagonist 
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268
Cmp19
pKi (gp) 9.0
276
VUF5391
pKi (r) 8.2
 
 
Figure 3.1.6 Structurally diverse non-imidazole H3R antagonist 
 
One potential liability of imidazole based drug candidates like 244, clobenpropit 245 
and ciproxifan 246 is their possibility for mechanism based inhibition of hepatic CYPs 
(cytochrome P450).125,126 This inhibition is known to be caused by the imidazole nitrogen 
complexation to heme iron in the active site of enzyme.127 Since these enzymes are a major 
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route of clearance for most medicines, drugs that are cytochrome P450 inhibitors perpetrate 
drug-drug interaction by reducing or preventing the clearance of co-administered medicines. 
Additionally, the inhibition of CYPs by imidazole based H3R antagonists can interfere with 
adrenal steroids126 synthesis via inhibition of heme containing enzymes. As such interactions 
are unwanted in drug development, many research groups have also been developing non-
imidazole H3R antagonists. In the last 5-6 years many new classes of compounds have 
appeared good show good activity; some of them are depicted in Fig. 3.1.6. Compared to the 
imidazole containing H3R antagonists the structural diversity among non imidazole H3R 
antagonists is higher. But on the other hand such type of interaction needs higher dowses of 
compounds, and at nanomolar level these interaction can be minimized. 
 
3.1.14 Radiolabeled H3R ligands 
Radioligands are useful tools to localize and characterize the functions of receptors. 
The available H3R radioligands were either tritiated agonists like [3H]-Nα-
methylhistamine128,129 and its more selective analogue [3H]-(R)-α-methylhistamine11,130 (Fig. 
3.1.7) or the [125I]-iodinated antagonist iodophenpropit131,132 (Fig. 3.1.7). The agonists have 
been useful for demonstrating the G-protein coupling of H3R and their distribution in brain. 
Despite these facts, agonistic tritiated ligands have problems as their binding is more complex 
than that of antagonists, and they are not allowing a sensitive receptor detection. Moreover 
low sensitivity of the tritium limits their use because the density of the H3Rs in the brain is 
lower than that of the many other aminergic receptors. On the other hand [125I]-
iodophenpropit, being a antagonist overcomes these problems but unfortunately has some 
other limitations.133  
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Figure 3.1.7 Radiolabeled H3R ligands 
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To overcome these problems Stark et al. in 1996 developed a H3R antagonist 
radioligand [125I]-iodoproxyfan 280 (Fig. 3.1.7) which displays extremely high affinity and 
selectivity for H3R. The developed ligand has been successfully used for binding assay as well 
as for autoradiographic studies.133 Introduction of rigidity by incorporating the cyclopropane 
ring in iodoproxyfan 248 could lead to more potent analogues and can be further converted to 
their corresponding radioligand which will be helpful to understand the functions of H3R in 
more details.  
 
3.1.15 Why rigid H3R antagonists? 
Many research groups have been trying to make more rigid H3 R antagonists to 
increase their druglikeness. Ali S. M. et al. incorporated cyclopropane rings and acetylene 
moieties. The resulting compound GT2331 250 (Fig. 3.1.4) showed very high affinity (pKi, 
9.9, rat H3R) and contains a imidazole heterocycle along with a very rigid and lipophilic side 
chain.134 Recently, some controversy over its absolute configuration has emerged. The 
absolute configuration (1R, 2R) which was assigned by the developers was reassigned to 
(1S,2S) by Abbott scientist after re-synthesis and X-ray crystallographic analysis.135 This 
compound shows somewhat lower affinity at human H3R (pKi, 8.4), demonstrating the species 
differences like other imidazole containing compounds. Schering-Plough also developed 
relatively more rigid and lipophilic H3R antagonist by incorporation of phenyl rings into the 
side chain that resulted in the lead compound SCH79687 252136 (Fig. 3.1.4, pKi, 8.7, rat H3R). 
Looking at the extensive history of SARs of H3R antagonists rigid antagonists like 250 and 
252 fulfils many criteria, display very high potency and have apparently reached clinical 
studies. Therefore rigid analogues of other lead structures (Fig. 3.1.4) consequently could also 
result in more potent compounds, lead to interesting activity and will also help to understand 
the SARs of imidazole containing rigid H3R antagonists. 
 
3.1.16 The therapeutic utility of H3R antagonist 
Unlike H3R agonists, antagonists or inverse agonists provides a broader spectrum of 
potential therapeutic applications due to their implication in the regulation of body weight, 
arousal and sleep or wakefulness. But on the other hand due to the potential liability of 
imidazole containing H3R antagonists to interact with cytochrome P450, many research groups 
are trying to develop non-imidazole H3R antagonists, and in last 5-7 years and many different 
classes of H3R antagonists have appeared.111 Despite the large number of non-imidazole 
antagonists only a few reports of their preclinical use have so far been made. To review most 
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promising applications for H3R antagonists, one still has to rely to a large extent on the 
observed effects of the early imidazole-containing H3R antagonists. 
 
3.1.17 H3R antagonists a potential drug target for obesity: 
The need for the development of anti-obesity drugs is rapidly growing with the 
increasing incidence of obesity, diabetes and associated health risks specially in the modern 
western society.137 The role of neuronal histamine in food intake has been established for 
many years,110,138 and the blockade of its action at hypothalamic H1R has been indicated as 
mechanistic action of weight gain after therapy with various antipsychotics.139 In brain, the 
H3R is implicated in the regulation of histamine release in the hypothalamus. Moreover, 
recent in situ hybridization studies revealed H3R mRNA expression in rat brown adipose 
tissue,140 indicating H3R ligands might (peripherally) regulate thermogenesis. These 
observations reveals that H3R antagonists elevate hypothalamic histamine level in the 
CNS.141,142 That is the reason why H3R antagonists have gained considerable attention for 
anti-obesity. A study with compounds like 244 or 246 (imidazole containing H3R antagonists) 
also provides evidence for the modulatory role of H3R in feeding behaviour. Moreover H3R 
antagonists have been reported to be effective in various models of acute food intake.110 
On the basis of data obtained from the preclinical models, it is clear that H3R blockers 
reduce weight gain, lower plasma ghrelin and leptin levels, and seem to be well tolerated. The 
blockade of H3R by selective antagonists or inverse H3R agonists might be an attractive 
mechanism of action for anti-obesity compounds. Clinical data on human obesity from H3R 
antagonists is eagerly awaited, but, unfortunately at present no clinical trials in this area have 
been announced. 
 
3.1.18 Therapeutic use of H3R antagonists in sleep and cognitive disorders 
It is often considered that indirect modulation of brain functions by H3R antagonists 
might be a means to modulate attention and memory processes. On the other hand the H3R 
agonists are shown to induce sleep in preclinical animal models. 244 increases wakefulness in 
wild type mice, but has no effect on sleep/wakefulness in H3R-/- mice.143 These data indicate 
that the H3R antagonists promote wakefulness. Therefore, the H3R antagonists might be 
useful in sleep-related disorders like narcolepsy. Recently, modafinyl (novel wakefulness-
promoting drug for the treatment of narcolepsy) has shown to increase hypothalamic 
histamine release,144 and studies using the classic Doberman model of narcolepsy with 
GT2331 250 showed that H3R antagonists reduce the number of narcoleptic attacks and its 
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duration. In many neuropsychiatric conditions like ADHD, schizophrenia and Alzheimer’s 
disease, cognitive deficits are an integral part of the disease. It is therefore of a great interest 
that a variety of the H3R antagonists can improve cognitive performance in various animal 
models.145 In addition imidazole-containing H3R antagonists like 246 and 250 improve 
acquisition in an inhibitory avoidance model with rat pups.81 On the basis of these 
observations compound 250 has reached clinical trials.146 However, the development of this 
drug for the treatment of ADHD has been halted in Phase II for unknown reasons. 
Many potent and relatively selective H3R antagonists and inverse agonists have been 
developed by many academic and industrial scientists. For both H3R agonists and H3R 
antagonists/inverse agonists, many interesting activities in several preclinical models of 
important human diseases have been reported. Results from the clinical trials are eagerly 
awaited and will be the next step in the process of moving from knowledge of the gene 
encoding H3R to the development of drugs for a range of indications. The preclinical finding 
indicates that the H3R antagonists might become future ‘wonder drugs’. 
Aim of the work H3-Receptor 106 
  
3.2. Aim of the work 
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Figure 3.2.1 General structural pattern of imidazole containing H3R antagonists 
 
Recent developments in the medicinal chemistry field of H3R antagonists have 
generated numerous compounds that are highly active in vitro and also in vivo. Although 
these compounds possess different functionalities, they all have more or less in common, the 
4(5)-substituted imidazole heterocycle connected by a spacer (commonly aliphatic carbon 
chain) with a linker (polar groups), being optionally connected to a lipophilic moiety 
(aromatic or aliphatic) (Fig. 3.2.1). The aim of the present study was to develop compounds, 
structurally related to FUB-372, proxyfan and iodoproxyfan (Fig. 3.1.14) with more rigidity 
to achieve druglikeness. The required rigidity could either be obtained by introducing 
different spacer groups such as, cis and/or trans double bonds, triple bonds or cyclopropane 
rings. Moreover, the use the basic pharmacophores present in the lead compounds (Fig. 
3.1.14), can be used to develop novel histamine H3R antagonists with nanomolar affinities. By 
keeping this goal in mind the novel compounds shown in figure 3.1.2 were targeted for the 
synthesis. 
 
N
HN
O
O
N
HN
O
I N
HN
O
N OH
N
HN
O
X
H
H
X = H,CH3, I, Br, CN, CF3.....
N
N
H
O
O
N
HN
N
HH
H
N
HN O
O
 
 
Figure 3.2.2.Target structures for imidazole containing H3R antagonists 
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In formulating a general synthetic approach for the synthesis of variety of 
conformationally restricted analogues (Fig. 3.1.2), allyl alcohol 284 was recognized as a key 
intermediate which is readily accessible from commercially available trans urocanic acid 
(162) by known procedures.61,147 Ether formation for FUB-372 and proxyfan analogues were 
sought to accomplish by Mitsunobu type reactions and/or by nucleophilic substitution. For the 
Cyclopropane analogues the Simon-Smith reaction of 284 was envisioned, in which the ether 
formations can be performed either before or after the cyclopropanation.  
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Figure 3.2.3 General retrosynthetic strategy for the imidazole containing H3R antagonists: 
EWG (electron withdrawing groups), EDG (electron donating groups) 
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3.3 Synthesis of conformationally restricted histamine H3R antagonists 
 
3.3.1 Synthesis of the key intermediate 
The campaign was began with trans urocanic acid (162), esterification was achieved 
by known procedure,61 followed by trityl protection.148 The ester functionality was then 
reduced to the corresponding allyl alcohol using DIBAL-H with slight modification of the 
literature procedure,147 and the key intermediate (E)-3-(1-trityl-1H-imidazol-4-yl)prop-2-en-1-
ol (284) was obtained in high yield (Scheme 3.3.1). 
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Scheme 3.3.1 Reagents and conditions: (a) MeOH, H2SO4 (cat.), reflux, 36 h, 95%; (b) Tr-Cl, 
TEA, DMF, RT, 1 h, 92%; (c) DIBAL-H, CH2Cl2, 0 °C → RT, 12 h, 82%. 
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Scheme 3.3.2 Reagents and conditions: (a) PPh3, DEAD, 4-hydroxy acetophenone, THF, 0 °C 
→ RT, 4 h, 42% of 285 and 12-15% of 286; (b) 2N HCl, acetone, reflux 1.5 h 75%. 
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Ether formation was achieved by a Mitsunobu type reaction149 with 4-
hydroxyacetophenone as a nucleophile. During the course of the reaction, along with the 
desired isomer 285, being obtained as a major product formation of the minor isomer 286 was 
always observed (Fig. 3.3.2). All attempts to completely suppress the formation of 286 were 
unsuccessful. Finally deprotection123 of the trityl group under acidic condition furnished 287, 
a trans olefinic analogue of FUB-372. 
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Figure 3.3.1 Transition state for the ether formation 
 
3.3.2 Synthesis of alkyne analogue of FUB-372 
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Fig. 3.3.2 Retrosynthetic strategy for olefinic/alkyne analogue of FUB-372 
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From the retrosynthetic analysis the target compounds can be assembled as shown in 
Figure 3.3.2. The Sonogashira coupling was envisioned as a key step in which the coupling 
products can also be utilized further for the formation of cis olefinic analogue 295 of FUB 
372. Synthons, such as N-protected 4-iodoimidazole can be obtained from imidazole, and 
alkyne 290, could be easily obtained from propargyl alcohol via Mitsunobu type reactions. 
 
3.3.3 Sonogashira coupling 
The synthesis of the precursor 289 for the Sonogashira coupling was achieved by 
sequential iodination and deiodination of imidazole followed by trityl protection following 
known procedures.150,151 The alkyne precursor 290 was obtained via Mitsunobu type reaction 
using 4-hydroxyacetophenone and propargyl alcohol in quantitative yield (Scheme 3.3.4). 
 
O
O
OH
HO
O
a)+
N
N
H
N
N
I
Tr
288 289
290
3 steps
propargyl
alcohol
4-hydroxy
acetophenone
 
 
Scheme 3.3.4 Reagents and conditions: (a) PPh3, DEAD, THF, 0 °C → RT, 3 h, 98%. 
 
Palladium catalyzed Sonogashira coupling, the reaction of a terminal alkyne with a 
variety of organic halides, has been one of the most powerful tools for the C-C bond 
formation.152,153 The coupling of trityl protected 4-iodoimidazole 289 with alkyne 290 was 
carried out using 1 mol % of PdCl2(Ph3P)2 catalyst in conjunction with 10 mol % of CuI 
(Table 3.3.1). Initially, with DMF as a solvent bases such as, K2CO3 or TEA the reaction 
yields were low and also led to the dimerization product of alkyne 290 in small amounts. 
Moreover, it has been reported that Sonogashira reactions proceed more efficiently when 
carried out with an excess amine.154 However, the use of an excess diisopropylamine (DIPA) 
led to very bad solubility of the starting materials and hence could not be used. Nevertheless, 
a THF:DIPA mixture proved to be the method of choice, furnishing moderate yields of the 
desired product. Other attempts to improve the yield of the reaction failed. 
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Scheme 3.3.5 Reagents and conditions: (a) 2N HCl, acetone, reflux 1.5 h, 82%. 
 
Table 3.3.1 Sonogashira coupling 
 
Entry Base Solvent Time Temp. Yield 
1 K2CO3 DMF 3 h 70 °C 28 % 
2 TEA DMF 6 h RT 10 % 
3 TEA THF 16 h RT 15 % 
4 Excess TEA THF 6 h RT 25 % 
5 Excess DIPA THF 6 h RT 52 % 
 
3.3.4 Synthesis of oximes 
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Scheme 3.3.6 Reagents and conditions: (a) Na2CO3, NH2OH.HCl, EtOH, reflux, 2 h, 82%; (b) 
Na2CO3, NH2OH.HCl, EtOH, reflux, 1 h, 94% 
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Oximes are known to be more potent H3R antagonist than their parent ketones.124 
Both, trans olefinic and alkyne ketones 287 and 292 were converted to their corresponding 
oximes 293 and 294 respectively by refluxing with hydroxylamine hydrochloride and sodium 
carbonate as a base in ethanol (Scheme 3.3.6). 
 
3.3.5 Structure elucidation of oxime 294 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.3 NOE spectrum of oxime 294 
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For the structure elucidation of 294, the main concern was the geometry of the oxime. 
X-ray analysis would be one of the best choices to confirm the geometry, and moreover, Stark 
and co-workers have confirmed the geometry of its saturated analogue imoproxyfan 251 (Fig. 
3.1.4) by X-ray analysis.124 Unfortunately, our attempts to grow suitable crystals were not 
successful to carry out a X-ray. However, the geometry of the oxime was confirmed by NOE 
experiments in which the cis stereochemistry between hydroxyl proton at 11.01 ppm and the 
methyl protons at 2.12 ppm (a cross peak highlighted in yellow eclipse, Fig. 3.3.3). On the 
other hand the methyl protons also show a cross peak to ortho protons of the aromatic group 
(highlighted in green eclipse), where as there was no signal corresponding to a cross peak of 
the aromatic protons with the oxime proton. 
 
3.3.6 Synthesis of the cis olefinic analogue 295 of FUB-372 
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Scheme 3.3.8 Reagents and conditions: (a) Pd-BaSO4, H2, RT, 16 h, 92% 
 
To get the more information regarding the binding of the novel ligand and in order to 
compare the effects of conformationaly restricted analogues with respect to the known ligand 
such as FUB-372, it was necessary to synthesize the cis olefinic analogue 295. The synthesis 
of 65 was achieved via controlled hydrogenation of 292 using BaSO4 poisoned Pd (Lindlar’s 
catalyst). On the other hand, the analogous transformation with the trityl protected substrate 
291 was not successful. 
 
3.3.7 Synthesis of cyclopropyl building block 
The importance of the cyclopropyl moiety for the H3R antagonist activity is evident 
from the highly active cyclopropyl derivative GT 2331 (250, Fig 3.1.4). To incorporate the 
cyclopropane ring into FUB 372 or into the proxyfan class of compounds was one of the main 
aims of the present study to enhance the activity. The ester 296 was obtained by refluxing 152 
with 2-butanol and catalytic H2SO4 in a Dean-stark apparatus. The yield of 296 was improved 
by changing the work-up procedures reported by Liu et al.135 The cyclopropyl ester 297 was 
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obtained by trityl protection of 296 followed by cyclopropanation using sulphur ylides 
following known procedures.135 Finally LAH reduction of 297 afforded the corresponding 
alcohol 298, a key intermediate for many novel H3R antagonists in high yield. 
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Scheme 3.3.9 Reagents and conditions: (a), (b) Lit135 (c) LAH, ether, 0 °C → RT, 30 min, 
96%. 
 
3.3.8 Attempted synthesis of cyclopropanated analogue of FUB-372 
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Scheme 3.3.10 Reagents and conditions: (a) PPh3, DEAD, THF, 0 °C → RT, 4 h, 65%; (b) 2 
N HCl, acetone, reflux 1.5 h, 82%. 
 
Initially, the synthesis of the cyclopropanated analogue 300 of FUB-372 was 
envisioned using a Simon-Smith reaction. However, treatment of 285 with excess of 
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diiodomethane and diethyl zinc at room temperature did not led to the product formation. On 
the other hand, refluxing the mixture in toluene led to the decomposition of starting material 
285. Moreover, the reaction of detrytilated compound 287 under similar conditions, only 
starting materials were recovered. 
A second strategy was envisioned using a Mitsunobu type reaction as a key step. 
Unfortunately, the Mitsunobu type reaction of alcohol 298 using 4-hydroxy acetophenone 
failed to give desired product 299 and surprisingly led to the formation of ring opened product 
71, even though the alcohol 298 is known to undergo Mitsunobu type reaction using 
pthalamide as a nucleophile.155 The possible mechanism for the formation of the unexpected 
product is given in Figure 3.3.4. Later the trityl group of 301 was removed under acidic 
condition to achieve the compound 302 which could be screened for the H3R antagonist 
activity. 
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Figure 3.3.4 Probable mechanism for ring opened product 301 
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3.3.9 Synthesis of iodoproxyfan and its trans olefinic analogue 
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Scheme 3.3.10 Reagents and conditions: (a) Ref.120; (b) NaH, 4-iodobenzylbromide, DMF, 
overnight 70%; (c) 2N HCl, MeOH, reflux, 1.5 h, 68%; (d) NaH, 4-iodobenzylbromide, DMF, 
overnight 75%; (e) 2N HCl, MeOH, reflux, 1.5 h, 87%.  
 
The key intermediate 303 for the synthesis of iodoproxyfan 248 was obtained 
following known procedures.120 Starting from urocanic methyl ester 152, hydrogenation with 
Pd-C/H2 and protection of the imidazole ring by trityl chloride afforded a compound with 
increased lipophilicity and in turn facilitated the easy isolation of 303 after reduction with 
complex hydrides. The intermediate alcohol 303 was then successfully used to form the 
benzyl ether 304 on treatment with sodium hydride and 4-iodobenzyl bromide in DMF. The 
deprotection could be easily performed by refluxing 304 in 2N HCl and methanol for 1.5 
hours to form 248 in good yield (Scheme 3.1.11). Similarly allyl the alcohol 284 was 
converted to 306, a trans olefinic analogue of iodoproxyfan. 
 
3.3.10 Synthesis of cyclopropanated analogues of proxyfan with oxygen linker 
Cyclopropane derivatives 314-320 were synthesized from the 298 by reacting it with 
different 4-substituted benzylbromides and sodium hydride in DMF, followed by the 
deprotection of trityl group. Yields of benzyl ethers were good with the exception of 
compound 313, in this case the maximum isolated yield was 34 %. Deprotection of the trityl 
group was achieved by refluxing the corresponding ethers in 2N HCl and methanol. For cyano 
compound 320 mild conditions could be used: the deprotection was carried out at ambient 
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temperature using 2N HCl and ethanol as a solvent. All compounds were isolated as free base 
while the exception of the only cyano compound 320 that was isolated as a hydrochloride salt. 
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Scheme 3.3.14 Reagents and conditions: (a) NaH, 4-substituted benzylbromides, DMF, 
overnight 34-94 %; (b) 2 N HCl, MeOH, reflux, 1.5 h, 66-91 %.  
 
In an attempt to achieve more lipophilicity, which will help the ligands to cross the 
blood brain barrier (BBB), analogues 322 was envisioned to synthesize. Starting from 298 the 
benzyl ether 321 was obtained in a straightforward way (Scheme 3.3.15), nevertheless in 
moderate yield, which is probably because of steric effects of the methyl substituents on the 
aromatic ring. On usual treatment with 2N HCl, all the starting material was consumed but the 
desired product 322 was not isolated and 1H NMR revealed the presence of 323 in the 
reaction mixture. Moreover, by changing the reaction conditions from 2N HCl to 
trifluoroacetic acid (TFA) at room temperature or even at 0 °C did not improve the outcome 
of the reaction. 
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Scheme 3.3.15 Reagents and conditions: (a) NaH, 4-iodobenzylbromide, DMF, overnight 
38%; (b) i) 2 N HCl, MeOH, reflux, 1.5 h; or ii) TFA, CH2Cl2, 0 °C or RT. 
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3.3.11 Synthesis of cyclopropyl analogues of proxyfan with nitrogen linker 
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Scheme 3.3.16 Reagents and conditions: (a), (b) Lit.155, (c) PhCHO, MgSO4, CH2Cl2, NaBH4, 
MeOH, 0 °C → RT 24 h 36%; (d) 2 N HCl, MeOH, reflux, 1.5 h, 96%. 
 
To evaluate the effect of a polar linker the cyclopropyl derivative 327 with a nitrogen 
bridge was envisioned. Cyclopropyl alcohol 298 was succefully converted to cyclopropyl 
amine 325 by known procedures155 via Mitsunobu reaction using pthalamide as a nucleophile, 
followed by refluxing 324 with hydrazine hydrate. Reductive amination of 325 was 
successfully carried out even though in bad yields using in situ imine formation with freshly 
distilled benzaldehyde followed by the reduction with NaBH4 in methanol. Finally the trityl 
group was removed with 2N HCl in methanol to obtain 327 as a dihydrochloride salt.  
In conclusion, many diverse, conformationally restricted compounds have been 
developed. Moreover, the synthesis of a series of cyclopropanated analogues with different 
linker has been described in an efficient way. All novel compounds are currently screened for 
histamine H3R antagonistic activity on guinea-pig. Moreover, these compounds will also be 
screened for H1R as well as Muscarinic receptor (M3R) activity to study the selectivity.  
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3.4 Pharmacology 
 
All novel, conformationally restricted imidazole containing compounds were screened 
in vitro for functional interactions with histamine H3Rs of guinea-pig ileum according to 
standard procedures. Moreover, compounds were also screened in vitro for functional 
interactions with muscarinic M3-Receptors (M3R) to identify suitable concentration that could 
be tested in the H3R assay. Some compounds were also studied at histamine H1R of guinea-
pig ileum with regard to subtype selectivity (Table 3.4.1). Cyclopropanated analogues will 
also be studied at histamine H1Rs of guinea-pig ileum in near future. 
The H3R antagonistic activity of the new compounds structurally related to FUB-372 
was not found to be as good as it was anticipated. Nevertheless, most of the compounds 
showed moderate to good H3R antagonistic activity. The compound 287 a trans olefinic 
analogue of FUB-372 showed 2 orders of magnitude lower activity (pA2 = 5.92 ± 0.08) than 
its parent one (pA2 = 7.8 ± 0.1, Table 3.4.1). To view the difference in binding, the cis olefinic 
compound 295 was also synthesized and screened for the H3R activity. The compound 295 
did not show any significant deviation (pA2 = 6.06 ± 0.06) in the activity and also behaved 
similarly like the trans analogue (287). On the other hand alkyne analogue 292 which is more 
rigid, did not show any significant antagonism (pA2 < 5.5) when screened against R-alpha-
methyl histamine (RAMH). 
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Figure 3.4.1: Concentration response curve for 293 
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Table 3.4.1 H1 and H3R activity of FUB-372 analoguesa 
 
Comp. 
Nu. 
Structure 
H3R antagonism 
(pA2 ± SEM; Nb) 
H1R activity 
249 N
HN
O
O
 
7.8 ± 0.1 
pEC50 = 4.7 ± 0.1 
pKP = 4.2 ± 0.1 
287 N
HN
O
O
 
5.92 ± 0.08  (12) pD‘2 = 4.3 ± 0.2 
295 
N NH
O
O
 
6.06 ± 0.06  (6) pD‘2 < 4.5 ± 0.2 
292 O
O
N
HN
 
< 5.5  (5)  pD‘2 = 4.2 ± 0.2 
302 N
HN
O
O
 
< 6  (2) ndc 
293 
N
HN
O
N
OH
 
7.06 ± 0.06  (14)  pD‘2 < 4.2 ± 0.2 
294 O
N
N
HN OH
 
< 5.7  (4) pD‘2 < 4.5 ± 0.2 
 
a
 Experimental protocol and definition of parameters see (3.5, pharmacological methods)  
b
 Number of experiments for affinity determination. 
c
 pD‘2 value not determined 
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Table 3.4.2 H3R activity of cyclopropanated analoguesa 
 
Comp. Structure 
H3R antagonism 
(pA2 ± SEM; Nb) 
Relaxant effect (%) 
(± SEM) 
314 
N
N
H
O
H
 
7.29 ± 0.03  (5) 0 
315 
N
N
H
O
CH3
 
7.21 ± 0.06  (6) 24 ± 4 
316 
N
N
H
O
CF3
 
7.36 ± 0.09  (4) 39 ± 5 
317 
N
N
H
O
OCF3
 
7.34 ± 0.14  (4) 38 ± 4 
318 
N
N
H
O
I
 
7.44 ± 0.08  (8) 62 ± 6 
319 
N
N
H
O
Br
 
7.40 ± 0.07  (4) 56 ± 8 
320 
N
N
H
O
CNHCl
 
6.82 ± 0.05  (6) 0 
327 
N
N
H
N
H
H2HCl
 
6.58 ± 0.11  (4) 0 
 
a
 Experimental protocol and definition of parameters see (3.5, pharmacological methods)  
b
 Number of experiments for agonism or determination. 
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It is well known in the literature that the oximes are more potent H3R antagonists than 
their parent ketones.124 In order to achieve more potency, the oximes were synthesized from 
corresponding ketones (Scheme 3.3.6). The oxime 294 of alkyne analogue 292 did not show 
any significant antagonism (pA2 = < 5.7) On the other hand oxime derivative 293 was found 
to be more potent (pA2 = 7.06 ± 0.06) than the parent ketone (287) which is well in agreement 
with the current concept of SARs of histamine H3R antagonists. A concentration response 
curve for most active compound (293) is shown in Fig. 3.4.1. Apart from this a new class of 
structural isomer 302 of FUB-372 was also screed, but showed no detectable antagonism 
verses RAMH (pA2 < 6).  
In cyclopropanated series, mostly independent of the nature of substituents at the para 
position of the phenyl ring, the H3R antagonism was found in the range of 0.03-0.1 µmol/L. 
The compounds 314-319 showed good antagonistic activity (pA2 = 7.2-7.4). Compound 318 
was found to be the most active among the cyclopropanated analogues (Fig. 3.4.2). On the 
other hand amino analogue 327 of ether 314 was found to be less potent. Several compounds, 
after addition to the organ bath produced a relaxant response which was not related to the 
M3R antagonism because the applied concentration of the antagonist was too low. 
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Figure 3.4.2: Concentration response curve for 318 
 
Interestingly, in preliminary experiments for 318 it was shown that this pseudo-H3R 
agonism was not sensitive to the presence of H3R antagonist such as FUB-372 of ciproxifan 
(data not shown), and therefore, this effect has to be related to a different mechanism, may be 
an interaction with ion channels. 
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Table 3.4.2 H3R activity of iodoproxyfan and its trans olefinic analoguea 
 
Comp. 
Nu. 
Structure 
H3R antagonism 
(pA2 ± SEM; Nb) 
Relaxant effect (%) 
(± SEM) 
248 
N
N
H
O
I
 
9.0c - 
307 
N
N
H
O
I
 
6.64 ± (6) 46 ± 3 
 
a
 Experimental protocol and definition of parameters see (3.5, pharmacological methods)  
b
 Number of experiments for agonism or affinity determination. 
c
 pA2values was calculated from pKB value given in Lit.133. 
 
Finally compound 307 a trans configurated olefinic analogue of iodoproxyfan (248) 
display only 1% relative affinity compared with the potent lead 248. 
 
As a conclusion, it has been shown that all attempts to rigidize flexible H3R 
antagonists, such as FUB-372 and/or iodoproxyfan, have ultimately led to more or less severe 
attenuation of H3R affinity. 
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3.5 Pharmacological methods 
For pharmacology, data handling and pharmacological parameters and histamine H1R 
assay on the isolated guinea-pig ileum, see (2.5 and 2.5.1, chapter 2) and references cited 
therein  
 
3.5.1 Histamine H3-Receptor assay on electrically stimulated guinea-pig ileum 
longitudinal muscle with adhering myenteric plexus.  
Strips of guinea-pig ileal longitudinal muscle, with adhering myenteric plexus of 
approximately 2 cm length and proximal to the ileocaecal junction, were prepared as 
previously described.156,157 The strips were mounted isometrically under an initial tension of 
approximately 7.5 mN in a jacketed 20-mL organ bath of filled with modified Krebs-
Henseleit solution of the following composition [mM]: NaCl 117.9, KCl 5.6, CaCl2 2.5, 
MgSO4 1.2, NaH2PO4 1.3, NaHCO3 25.0, glucose 5.5, and choline chloride 0.001. The 
solution was aerated with 95% O2-5% CO2 and warmed to a constant temperature of 37 °C. 
After an equilibration period of 1 h with washings every 15 min, the preparations were 
stimulated for 30 min with rectangular pulses of 15 V and 0.5 ms at a frequency of 0.1 Hz. 
Viability of the muscle strips was monitored by addition of the histamine H3-Receptor agonist 
(R)-α-methylhistamine (100 nM). The agonist caused a relaxation of the twitch response of 
more than 50% up to 100%. After washout, reequilibration and 30 min field-stimulation, a 
cumulative concentration-response curve to (R)-α-methylhistamine (1-1000 nM) was 
constructed. Subsequently, the preparations were washed intensively and reequilibrated for 
20-30 min. During the incubation period of the antagonist under study, the strips were 
stimulated continuously for 30 min. Finally, a second concentration-response curve to (R)- -
methylhistamine was obtained. The rightward displacement of the curve to the histamine H3-
Receptor agonist evoked by the antagonist under study was corrected with the mean shift 
monitored by daily control preparations in the absence of antagonist. New antagonists were 
tested at concentrations that did not block ileal cholinergic M3Rs. Mepyramine (1 µM) and 
cimetidine (30 µM) were present throughout the experiments to block H1 and H2 receptors, 
respectively. 
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3.5.2 Acetylcholine M3-Receptor assay on the isolated guinea-pig ileum.  
Guinea-pigs of either sex were stunned by a blow on the head and exsanguinated. The 
ileum was removed, and whole segments (1.5-2 cm) were mounted isotonically (preload 0.5 
g) at 37 °C in Tyrode's solution,158 aerated with 95% O2-5% CO2, in the continuous presence 
of 1–3 µM mepyramine, a concentration not affecting M3Rs. During an equilibration period 
of ca. 80 min, the organs were stimulated three times with carbachol (1 and 10 µM) followed 
by washout. Each preparation was used to establish a cumulative concentration-effect curve 
for carbachol (0.003-10 µM) followed by up to three curves for carbachol in the presence of 
increasing concentrations of antagonist (incubation time 10-15 min). The pEC50 difference 
was not corrected since four successive curves for carbachol were superimposable (n > 10). In 
most cases, it was sufficient to determine a range of concentrations for the new compounds 
where there was no apparent interaction with the carbachol response. Such concentrations 
were then chosen to be used during the H3R experiments. For most of the new compounds, a 
precise M3-Receptor affinity was not determined to avoid the loss of compound. 
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3.6 Experimental part 
 
For general remarks see (2.6.1 experimental part chapter 2) 
 
3.6.1 Experimental procedures and analysis of data 
 
(E)-methyl3-(1-trityl-1H-imidazol-4-yl)acrylate (283): 
 
N
N
CO2CH3
Ph3C
 
 
To a solution of methyl urocanate(152) (6 g, 39.43 mmol) and triethylamine (13.7 mL, 98.57 
mmol) in dry DMF (40 mL) was added dropwise a solution of triphenylmethyl chloride (12.1 
g, 43.38 mmol) in dry DMF (12 mL) at RT. After stirring at RT for 4 h the reaction mixture 
was poured into ice water (300 g). The precipitates were collected and dried to give 283 (15.5 
g, quantitative), which was essentially pure for the next step. 
Rf (SiO2, MeOH/CH2Cl2 2:98) = 0.25; 1H NMR (300 MHz, CDCl3): δ = 3.74 (s, 3 H, 
CO2CH3), 6.55 (d, J = 15.6 Hz, 1 H, =CHCO), 7.03 (d, J = 1.2, Hz, 1 H, Imi-5H), 7.09-7.17 
(m, 6 H, aromatic), 7.32-7.36 (m, 9 H, aromatic), 7.45 (d, J = 1.2, Hz, 1 H, Imi-2H), 7.51 (d, 
J = 15.6 Hz, 1 H =CH); 13C NMR (75.5 MHz CDCl3): δ = 51.5 (+, CO2CH3), 75.8 (+, Cquat, 
CPh3), 115.8 (+, CH, Imi-C5), 124.2 (+, =CHCO), 128.3 (+, CH, aromatic) 128.4 (+, CH, 
aromatic) 129.7 (+, CH, aromatic) 136.5 (+, =CH), 137.1 (+, Cquat, Imi-C4) 140.4 (+, CH, 
Imi-C2) 141.9 (+, Cquat, aromatic), 168.0 (+, Cquat, CO). All other data was in good agreement 
with the literature.159  
 
(E)-3-(1-trityl-1H-imidazol-4-yl)prop-2-en-1-ol (284):  
 
N
N
Ph3C
OH
 
 
Methyl ester 283 (3.94 g, 10 mmol) was dissolved in CH2Cl2 (100 mL) under N2 and cooled 
to 0 °C. DIBAL-H (1 M in CH2Cl2, 30 mL, 30 mmol) was added dropwise. The mixture was 
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allowed to warm up to RT slowly and stirred for 6-8 h and cooled to 0 °C again. Water (10 
mL) was added slowly, followed by NaOH (2N, 10 mL) and H2O (10 mL). The mixture was 
filtered through Celite and washed several times with CH2Cl2. The organic layer of the filtrate 
was separated. Aqueous phase was extracted with CH2Cl2 (4×50 mL). The combined organic 
phase was dried over MgSO4 and filtered. The filtrate was concentrated under reduced 
pressure and the residue was subjected to column chromatography (95/5, EtOAc/MeOH) to 
afford allyl alcohol 284 (2.72 g, 75 %) as a white solid.  
Rf (SiO2, MeOH/EtOAc 5:95) = 0.28; 1H NMR (300 MHz CD3OD): δ 4.15 (d, J = 5.0 Hz, 2 
H CH2OH), 6.31 (dt, J = 15.9, 5.0 Hz, 1 H, =CHCH2), 6.41 (d, J = 15.9 Hz, 1H =CH), 6.87 
(d, J = 1.2 Hz, 1 H, Imi-5H), 7.11-7.17 (m, 6 H, aromatic CH), 7.34-7.38 (m, 9 H, aromatic 
CH), 7.41 (d, J = 1.2 Hz, 1 H, Imi-2H); 13C NMR (75.5 MHz CD3OD): δ = 63.5 (-, CH2OH), 
76.9 (+, Cquat, CPh3), 120.8 (+, =CH), 122.7 (+, CH Imi-C5) 129.2 (+, =CHCH2) 129.3 (+, 
CH, aromatic) 129.4 (+, CH, aromatic) 130.8 (+, CH, aromatic) 139.9 (+, Cquat, Imi-C4) 
140.1 (+, CH, Imi-C2) 143.5 (+, Cquat, aromatic). All other data was in good agreement with 
the literature.160  
 
1-(4-((E)-3-(1-trityl-1H-imidazol-4-yl)allyloxy)phenyl)ethanone (285):  
 
N
N
Ph3C
O
O
 
 
Triphenylphospine (1.57 g, 6 mmol) was dissolved in THF (30 mL) together with allyl 
alcohol 284 (1.83 g, 5mmol) and 4-hydroxyacetophenone (817 mg, 6 mmol) and cooled to an 
ice bath. Diethyl azodicarboxylate (DEAD) (0.95 mL, 6 mmol) was added slowly followed by 
additional stirring for 4 h at ambient temperature. THF was removed and diethyl ether (40 
mL) was added washed with H2O (20 mL) and brine (20 mL). Filtration and evaporation of 
the solvent gave a residue which was purified by column chromatography (EtOAc/hexanes 
1:1) and the 285 was obtained as white solid (42%) along with the minor isomer 286 (≈ 15 %) 
Rf (SiO2, hexanes/EtOAc 1:1) = 0.21; m.p. = 187-189 °C; 1H NMR (spectra is not first 
order). (300 MHz CDCl3): δ = 2.54 (s, 3 H, COCH3), 4.72 (d, J = 4.94 Hz, 2 H, OCH2), 6.51 
(dt, J = 4.94, 15.92 Hz, 1 H, =CHCH2), 6.58 (d, J = 15.92 Hz, =CH), 6.79 (d, J = 1.23 Hz, 
Imi-5H), 6.93-6.97 (m, 2 H, aromatic), 7.10-7.16 (m, 6 H, aromatic), 7.30-7.35 (m, 9 H, 
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aromatic), 7.42 (d, J = 1.23 Hz, Imi-2H), 7.89-7.93 (m, 2 H, aromatic); 13C NMR (75.5 MHz 
CDCl3): δ = 26.5 (+, COCH3), 68.7 (-, CH2O), 75.5 (+, Cquat, CPh3), 114.5 (+, CH, aromatic), 
120.1 (+, =CH), 121.9 (+, CH, Imi-C5), 125.3 (+, CH, aromatic), 128.2 (+, CH, aromatic), 
128.2 (+, CH, aromatic), 129.8 (+, =CHCH2), 130.3 (+, Cquat, Imi-C4), 130.7 (+, CH, 
aromatic), 138.2 (+, Cquat, aromatic), 139.4 (+, CH, Imi-C2) , 142.3 (+, Cquat, aromatic), 162.7 
(+, Cquat, aromatic), 196.9 (+, Cquat, CO); IR (KBr): ~ν  = 3059, 2928, 1732, 1672, 1597, 1491, 
1445, 1358, 1272, 1242, 1171, 1127, 981, 928, 834, 748, 702 cm-1; MS (ESI, 
CH2Cl2/MeOH/NH4Ac): m/z = 485.2 [M + H+], 969.6 [2 M + H+]. 
 
1-(4-((E)-3-(1H-imidazol-4-yl)allyloxy)phenyl)ethanone (287):  
 
N
HN
O
O
 
 
To a solution of 285 (150 mg, 0.31 mmol) in acetone (3 mL) was added 2M solution of HCl 
(3 mL) and reaction mixture was refluxed for 1.5 h. most of the acetone was evaporated in 
vacuo and aqueous phase was made strongly basic by adding solid K2CO3 and extracted in 
CH2Cl2:MeOH 9:1 (4×10 mL) dried (MgSO4). The solvent was removed in vacuo. The 
residue was purified by chromatography on silica (CH2Cl2/MeOH/NH3 50:1:0.5) to get the 
product as a cream white solid (56 mg, 74.6 %). 
Rf (SiO2, MeOH/CH2Cl2 5:95) = 0.20; m.p. = 160-161 °C; 1H NMR (300 MHz DMSO): δ = 
2.51 (s, 3 H, COCH3), 4.77 (dd, J = 1.20, 6.11, Hz, 2 H, CH2O), 6.28 (dt, J = 15.81, 6.11, Hz, 
1 H, =CHCH2), 6.63 (d, J = 15.81, Hz, 1 H, =CH), 7.04-7.09 (m, 2 H, aromatic), 7.11 (bs, 
Imi-5H), 7.62 (bs, Imi-2H), 7.89-7.94 (m, 2 H, aromatic), 12.15 (bs, Imi-NH); 13C NMR 
(75.5 MHz DMSO): δ = 26.4 (+, COCH3), 68.4 (-, CH2OH), 114.6 (+, CH, aromatic), 120.4, 
(+, =CHCH2), 120.4 (+, CH, aromatic), 124.8 (+, CH, Imi-C5, broad), 129.8 (+, Cquat, Imi-
C4), 130.5 (+, CH, aromatic), 136.3 (+, CH, Imi-C2 and vinyl, broad), 162.2 (+, Cquat, 
aromatic), 196.3 (+, Cquat, CO); IR (KBr): ~ν  = 3101, 3070, 2970, 2922, 2806, 2602, 1662, 
1598, 1571, 1506, 1461, 1420, 1381, 1353, 1306, 1251, 1176, 1112, 996, 854, 832, 631, 590 
cm-1;MS (EI, 70 eV): m/z (%) = 242.1 (3) [M+], 136 (4.8) [phenoxy acetyl], 121 (13.6), 107 
(100), 80 (41.6), 53 (15.7); HRMS calcd for C14H14N2O2, 242.1055. Found 242.1053.  
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1-(4-((E)-3-(1H-imidazol-4-yl)allyloxy)phenyl)ethanone oxime (293)  
 
N
HN
O
N
OH
 
 
To a solution of ketone 287 (110 mg, 0.45 mmol) and hydroxylamine hydrochloride (69.49 
mg, 0.91 mmol) in dry EtOH (5 mL) was added Na2CO3 (106 mg, 0.91 mmol). The reaction 
mixture was heated to reflux for 2 h. After the filtration of inorganic salts, the solvent was 
evaporated under reduced pressure. The product was purified by column chromatography 
(CH2Cl2/MeOH 90/10) to obtain a cream white solid (96 mg 82 %). 
Rf  (SiO2, MeOH/ CH2Cl2 10:90) = 0.4; m.p. = 178-180 °C and start to become brown from 
172 °C; 1H NMR (300 MHz CD3OD): δ = 2.19 (s, 3 H, COCH3), 4.68 (dd, J = 1.42, 5.78, Hz, 
2 H, CH2O), 6.36 (dt, J = 15.96, 5.78, Hz, 1 H, =CHCH2), 6.65 (d, J = 15.96, Hz, 1 H, =CH), 
6.93-6.98 (m, 2H, aromatic), 7.06 (bs, Imi-5H), 7.55-7.60 (m, 2H, aromatic), 7.63 (bs, Imi-
2H); 13C NMR (75.5 MHz CD3OD): δ = 12.1 (+, COCH3), 69.5 (-, CH2OH), 115.6 (+, CH, 
aromatic), 115.6 (+, CH, aromatic), 116.7 (+, CH, Imi-C5), 123.6, (+, =CHCH2), 128.4 (+, 
CH, aromatic), 129.6 (+, Cquat, Imi-C4), 131.1 (+, Cquat, aromatic), 137.2 (+, CH, Imi-C2 and 
vinyl, broad), 155.8, (+, Cquat, CNOH), 160.8 (+, Cquat, aromatic); IR (neat): ~ν  = 3350-3200 
(broad), 2850, 1602, 1511, 1303, 1243, 1177, 1002, 921, 831 cm-1; MS (EI-MS,70 eV): m/z 
(%) = 257.1 (7 %) [M + ۠۟], 107 (100 %); HRMS calcd for C14H14N2O2, 257.1164. Found 
257.1166. 
 
1-(4-(prop-2-ynyloxy)phenyl)ethanone (290):  
 
O
O
 
 
Triphenylphospine (13.17 g, 48 mmol) was dissolved in THF (70 mL) together with 
propargyl alcohol (2.5 mL, 43.64 mmol) and 4-hydroxyacetophenone (6.54 g, 48 mmol) and 
cooled to an ice bath. DEAD (8.74 mL, 48 mmol) was added slowly followed by additional 
stirring for 6 h at ambient temperature. THF was removed and diethyl ether (200 mL) was 
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added washed with H2O (2×75 mL). Filtration and evaporation of the solvent gave a residue 
which was purified by column chromatography (EtOAc/hexanes 2:8) to get the product as 
white solid. (7.56, 99%)  
Rf  (SiO2, hexanes/EtOAc 8:2) = 0.3; m.p. = 72-73 °C; 1H NMR (300 MHz CDCl3): δ = 2.54 
(s, 3 H, COCH3), 2.55 (t, J = 2.5 Hz, 1 H, CH, acetylynic), 4.73 (d, J = 2.5 Hz, 2 H, CH2O), 
7.02-7.26 (m, 2 H, aromatic), 7.90-7.95 (m, 2 H, aromatic); 13C NMR (75.5 MHz CDCl3): δ 
= 26.5 (+, COCH3), 55.9 (-, CH2O), 76.3 (+, CH, acetylynic), 77.8, (+, Cquat, acetylynic), 
114.6 (+, CH aromatic), 130.6 (+, CH aromatic), 131.1 (+, Cquat, aromatic), 161.3 (+, Cquat, 
aromatic), 196.8 (+, Cquat, CO); IR (KBr): ~ν  = 3225, 2923, 2871, 2117, 1611, 1603, 1573, 
1421, 1377, 1355, 1277, 1244, 1182, 1018, 959, 827, 756, 696 cm-1; MS (EI +VE): m/z (%) = 
174.1 (40.84) [M+], 159.1, (100) [M+ - CH3], 131.1 (44.8) [M+ - COCH3]; Elemental analysis 
calcd (%) for C11H10O2 (174.07) C 75.84, H 5.79; found C 75.76, H 5.66. 
 
1-(4-(3-(1-trityl-1H-imidazol-4-yl)prop-2-ynyloxy)phenyl)ethanone (291):  
 
O
O
N
N
Ph3C
 
 
To a (1:1) mixture of Diisopropyl amine and THF (12 ml), degased with N2 for 10 min., was 
added 4-iodo-1-trityl-imidazole (437 mg, 1 mmol), CuI (19mg, 0.1 mmol), PdCl2(Ph3P)2 (7 
mg, 0.01 mmol) and acetyline 290 (174 mg, 1 mmol) and stirred at ambient temprature for 6 
h. Diethyl ehter (20 mL) was added and reaction mixture was filtered through a small pad of 
celite, washed with H2O (10 mL) and dryed over MgSO4. Filtration and evaporation of the 
solvent gave a residue which was purified by column chromatography (EtOAc/hexanes 1:1) 
to get the product as pale yellow solid (252 mg, 52 %). 
Rf  (SiO2, hexanes/EtOAc 1:1) = 0.28; m.p. = 194-196 °C; 1H NMR (300 MHz CDCl3): δ 
2.53 (s, 3 H, COCH3), 4.93 (bs, 2 H, CH2O), 7.00-7.13 (m, 9 H, aromatic), 7.30-7.35 (m, 9 H, 
aromatic and Imi-5H), 7.39 (bs 1 H, Imi-2H), 7.90-7.95 (m, 2 H, aromatic); 13C NMR (75.5 
MHz CDCl3): δ = 26.4 (+, COCH3), 56.8 (-, CH2O), 75.9 (+, Cquat, CPh3), 81.8 (+, Cquat, 
acetylinic), 83.4 (+, Cquat, acetylynic), 114.6 (+, CH, aromatic), 122.3 (+, Cquat, Imi-C4, 
broad), 126.5 (+, CH, Imi-C5, broad), 128.3 (+, CH, aromatic), 128.4 (+, CH, aromatic), 
129.7 (+, CH, aromatic), 130.6 (+, CH, aromatic), 130.8 (+, Cquat, aromatic), 139.2 (+, CH, 
Imi-C2, broad), 141.9 (+, Cquat, aromatic), 161.6 (+, Cquat, aromatic), 196.8 (+, Cquat, CO); IR 
(neat): ~ν  = 3130, 2238, 1680, 1596, 1443, 1356, 1249, 1168, 1139, 1044, 956, 825, 749, 703 
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cm-1; MS (70 eV, EI): m/z (%) = 482.3 [M+•], 243.2 (100) [CPh3+], 165.1 (52.8) [CPh2+], 
121.0 (9.8), 105.0 (8.2). 
 
1-(4-(3-(1H-imidazol-4-yl)prop-2-ynyloxy)phenyl)ethanone (292):  
 
O
O
N
HN
 
 
To a solution of 291 (240 mg, 0.49 mmol) in acetone (5 mL) was added 2M solution of HCl 
(5 mL) and reaction mixture was refluxed for 1 h. most of the acetone was evaporated in 
vacuo and aqueous phase was made strongly basic by adding solid K2CO3 and extracted in 
CH2Cl2:MeOH 9:1 (4×10 mL) dried (MgSO4).The solvent was removed in vacuo. The residue 
was purified by chromatography on silica (CH2Cl2/MeOH/NH3 50:1:0.5) to get the product as 
a cream white solid. (98 mg, 82%) 
Rf  (SiO2, MeOH/CH2Cl2 5:95) = 0.28; m.p. = 165-166 °C; 1H NMR (300 MHz DMSO): δ = 
2.55 (s, 3 H, COCH3), 5.04 (s, 2 H, CH2O), 7.08-7.13 (m, 2 H, aromatic), 7.30 (bs, Imi-5H), 
7.65 (bs, Imi-2H), 7.96-8.01 (m, 2 H, aromatic); 13C NMR (75.5 MHz DMSO): δ = 26.4 (+, 
COCH3), 57.4 (-, CH2O), 81.7 (+, Cquat, acetylinic, broad), 85.5 (+, Cquat, acetylinic, broad), 
115.8 (+, CH, aromatic), 124.8 (+,CH, Imi-C5, broad), 131.7 (+, CH, aromatic), 131.8 (+, 
Cquat, Imi-C4), 137.2 (+, CH, Imi-C2), 163.4 (+, Cquat, aromatic), 196.4 (+, Cquat, CO); IR 
(KBr): ~ν  = 3122, 2918, 2852, 2245, 1680, 1601, 1511, 1454, 1420, 1377, 1307, 1252, 1043, 
1009, 956, 827, 766 cm-1; MS (EI-MS, 70 eV): m/z (%) = 240.0 (3.5) [M+ ۠۟], 197 (3) [M+ - 
COCH3 ۠۟],105 (100 %) [M+ - phenoxy acetyl], 51.1 (11); HRMS calcd for C14H12N2O2, 
240.0899. Found 240.0900; Elemental analysis calcd (%) for C14H12N2O2 (240.09): calc. C 
69.99, H 5.03, N 11.66; found C 68.51, H 5.00, N 11.49. 
 
1-(4-(3-(1H-imidazol-4-yl)prop-2-ynyloxy)phenyl)ethanone (294)  
 
O
N
N
HN
OH
 
 
To a solution of ketone 291 (20 mg, 0.083 mmol) and hydroxylamine hydrochloride (23.11 
mg, 0.33 mmol) in dry EtOH (4 mL) was added Na2CO3 (35.25 mg, 0.33 mmol). The reaction 
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mixture was heated to reflux for 1 h. After the filtration of inorganic salts, the solvent was 
evaporated under reduced pressure to obtain a cream white solid. H2O was added and the 
precipitate was filtered and washed with H2O and dried (20 mg 94 %).Structure was 
determined by NOE experiments. 
Rf  (SiO2, MeOH/CH2Cl2 5:95) = 0.23; m.p. = 180-182 °C 1H NMR (300 MHz DMSO): δ = 
2.12 (s, 3 H, COCH3), 5.04 (s, 2 H, CH2O), 7.00-7.05 (m, 2 H, aromatic), 7.44 (bs, Imi-5H), 
7.58-7.63 (m, 2 H, aromatic), 7.67 (bs, Imi-2H), 11.01 (s, NOH), 12.34 (bs, 1 H, Imi-NH); 
13C NMR (150.9 MHz DMSO): δ = 11.4 (+, CNCH3), 56.1 (-, CH2O), 82.1 (+, Cquat, 
acetylinic), 83.3 (+, Cquat, acetylinic), 114.6 (+, CH, aromatic), 121.4 (+, Cquat, Imi-C4), 121.6 
(+, CH, Imi-C5), 126.8 (+, CH, aromatic), 130.0 (+, CH, aromatic), 136.1 (+, CH, Imi-C2), 
152.3 (+, Cquat, C=NOH, 157.7 (+, Cquat, aromatic); IR (neat): ~ν  = 3250-3100 (broad), 2320, 
2242, 1604, 1512, 1449, 1373,1306, 1221, 1037, 1002, 831, 754, 656 cm-1; MS (EI-MS, 70 
eV): m/z (%) = 255.1 (9 %) [M + ۠۟], 238.1 (12 %) [M+ - OH], 105.0 (100 %) [M+ - phenoxy 
oxime]; HRMS calcd for C14H14N2O2, 255.1008. Found 255.1009; Elemental analysis calcd 
(%) for C14H14N2O2 (255.10): C 65.87, H 5.13, N 16.46; found C 65.21, H 5.32, N 16.59. 
 
1-(4-((Z)-3-(1H-imidazol-4-yl)allyloxy)phenyl)ethanone (295):  
 
N NH
O
O
 
 
ketone 292 (30 mg 0.125 mmol) was dissolved in MeOH (3 mL) and was treated with 10 wt 
%Pd-BaSO4 (5 mg) and purged with a atmosphere of hydrogen followed by vigorous stirring 
in an atmosphere of hydrogen (via balloon) for 16 h. The reaction mixture was filtered 
through a pad of Celite, washed with MeOH (10 mL). The solvent was removed in vacuo to 
leave the oil which was precipitated by ether. Finally ether was decanted to leave the pail 
brown (92 %). 
Rf (SiO2, MeOH/ CH2Cl2 5:95) = 0.19; m.p. = 170-173 °C; 1H NMR (300 MHz CD3OD): δ = 
2.55 (s, 3 H, COCH3), 4.94 (dd, J = 1.27, 5.56 Hz, 2 H, CH2O), 6.26 (dt, J = 11.97, 5.55 Hz, 1 
H, =CHCH2), 6.57 (dt, J = 11.96, 1.26 Hz, 1 H, =CH), 7.03-7.06 (m, 2 H, aromatic), 7.63 (bs, 
Imi-5H), 7.96-7.99 (m, 2 H, aromatic), 8.83 (bs, Imi-2H); with calibration 13C NMR (75.5 
MHz CD3OD): δ = 26.4 (+, COCH3), 66.3 (-, CH2O), 115.6 (+, CH, aromatic), 117.5 (+, 
CH=CHCH2), 119 1 (+, CH, Imi-C5), 131.8 (+, Cquat, Imi-C4), 131.9 (+, CH, aromatic), 
132.8 (+, =CHCH2), 135.5 (+, CH, Imi-C2), 163.8 (+, Cquat, aromatic), 199.3 (+, Cquat, CO); 
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IR (KBr): ~ν  = 3101, 3070, 2970, 2922, 2806, 2602, 1662, 1598, 1571, 1506, 1461, 1420, 
1381, 1353, 1306, 1251, 1176, 1112, 996, 854, 832, 631, 590 cm-1; MS (EI, 70 eV): m/z (%) 
= 242.1 (3) [M+], 136 (4.8) [M+ - ] 121 (13.6), 107 (100) 80 (41.6), 53 (15.7); HRMS calcd 
for C14H14N2O2, 242.1055. Found 242.1053. 
 
1-(4-(1-(1-trityl-1H-imidazol-4-yl)but-3-enyloxy)phenyl)ethanone (301):   
 
N
N
O
O
Ph3C
 
 
Triphenylphospine (288 mg, 1.1 mmol) was dissolved in THF (10 mL) together with 
cyclopropyl alcohol 298 (381 mg, 1 mmol) and 4-hydroxyacetophenone (150 mg, 1.1 mmol) 
and cooled to an ice bath. DEAD (0.19 mL, 1.2 mmol) was added and stirred for 1 h, slowly 
followed by additional stirring for 2 h at ambient temperature. THF was removed and diethyl 
ether (20 mL) was added washed with H2O (10 mL) and brine (20 mL). Filtration and 
evaporation of the solvent gave a residue which was purified by column chromatography 
(EtOAc/hexanes 1:1) to get the product as a white solid (324 mg 65%). 
Rf  (SiO2, hexanes/EtOAc 1:1) = 0.21; m.p. = 125-126 °C; 1H NMR (300 MHz CDCl3): δ = 
2.54 (s, 3 H, COCH3), 2.81 (t, J = 6.35 Hz, 2 H, CH2CO), 5.04-5.13 (m, 2 H, =CH2), 5.35 (t, J 
= 6.35 Hz, CH2OCH), 5.85 (ddt, J = 17.33, 10.19, 6.93 Hz, 1 H, CH=CH2), 6.66 (d, J = 1.23 
Hz, Imi-5H), 6.90-6.95 (m, 2 H, aromatic), 7.02-7.06 (m, 6 H, aromatic), 7.22-7.32 (m, 9 H, 
aromatic), 7.41 (d, J = 1.37 Hz, Imi-2H), 7.82-7.87 (m, 2 H, aromatic); 13C NMR (75.5 MHz 
CDCl3): δ = 26.4 (+, COCH3), 40.2 (-, CH2CO), 75.3 (+, CH, OCHCH2), 75.4 (+, Cquat, 
CPh3), 115.8 (+, CH, aromatic), 117.8 (-, =CH2), 119.9 (+, CH, Imi-C5), 128.0 (+, CH, 
aromatic), 128.1 (+, CH, aromatic), 129.7 (+, CH, aromatic), 130.2 (+, Cquat, Imi-C4), 130.3 
(+, CH, aromatic), 133.7 (+, CH, aromatic), 138.5 (+, CH, Imi-C2), 140.3 (+, Cquat, 
aromatic), 142.1 (+, Cquat, aromatic), 162.1 (+, Cquat, aromatic), 196.8 (+, Cquat, CO); IR 
(KBr): ~ν  = 3332, 3146, 3061, 2921, 1729, 1674, 1597, 1493, 1445, 1420, 1358, 1306, 1249, 
1171, 1130, 1037, 1001, 956, 914, 835, 754, 702 cm-1; MS (ESI, CH2Cl2/MeOH/NH4Ac): m/z 
= 499.3 [M+ + H+], 997.7 [2M+ + H+], 243.1 [Ph3C+]. 
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1-(4-(1-(1H-imidazol-4-yl)but-3-enyloxy)phenyl)ethanone (302):  
 
N
N
H
O
O
 
 
To a solution of 301 (150 mg, 0.30 mmol) in acetone (3 mL) was added 2M solution of HCl 
(3 mL) and reaction mixture was refluxed for 1 h. most of the acetone was evaporated in 
vacuo and aqueous phase was made strongly basic by adding solid K2CO3 and extracted in 
CH2Cl2 (4×6 mL), dried (MgSO4) and solvent was removed in vacuo. The residue was 
purified by chromatography on silica (CH2Cl2/MeOH/NH3 50:1:0.5) to get the product as a 
cream white solid (68 mg, 88 %). 
Rf  (SiO2, MeOH/CH2Cl2 1:9) = 0.42; m.p. = 116-117 °C; 1H NMR (300 MHz CDCl3): δ = 
2.48 (s, 3 H, COCH3), 2.78 (ddd, J = 6.94, 14.42, 28.24 Hz, 2 H, CH2CH=CH2), 5.04-5.13 (m, 
2 H, =CH2 terminal), 5.39 (t, J = 6.69 Hz, CH2OCH), 5.81 (ddt, J = 17.10, 10.20, 6.90 Hz, 1 
H, CH=CH2), 6.89-6.92 (m, 2 H, aromatic), 6.99 (bs, 1 H, Imi-5H), 7.63 (bs, 1 H, Imi-2H), 
7.78-7.82 (m, 2 H, aromatic), 9.88 (bs, 1 H, Imi-NH); 13C NMR (75.5 MHz CDCl3): δ = 26.4 
(+, COCH3), 40.4 (-, CH2CO), 74.5 (+, CH, OCHCH2), 115.5 (+, CH, aromatic), 114.6 (+, 
CH, Imi-C5), 118.1 (-, =CH2), 130.3, (+, Cquat, aromatic), 130.5 (+, CH, aromatic), 133.5 (+, 
CH, aromatic), 135.3 (+, CH, Imi-C2), 138.6 (+, Cquat, Imi-C4), 162.2 (+, Cquat, aromatic), 
197.3 (+, Cquat, CO); IR (KBr): ~ν  = 3306, 3085, 2986, 2858, 2738, 2670, 2631, 1662, 1598, 
1573, 1504, 1468, 1422, 1386, 1308, 1281, 1251, 1178, 1111, 996, 974, 914, 836, 631, 589 
cm-1; MS (EI, 70 eV): m/z (%) = 256.3 (<1) [M+•], 218.2 (2.7), 136.2 (9.3) [phenoxy acetyl], 
122.2 (7.8), 121.2 (100), 94.2 (14.9), 81.2 (6.0), 65.2 (10.3) 44.2 (18.4); HRMS calcd for 
C15H16N2O2, 256.1219. Found 256.1212. 
 
4-(3-(4-iodobenzyloxy)propyl)-1-trityl-1H-imidazole (304):  
 
N
N
O
Ph3C
I
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A solution of alcohol 303 (709 mg 1.923 mmol) and 4-iodobenzylbromide (600 mg 2.02 
mmol) in DMF (5 mL) was cooled to 0 °C and treated with NaH (60% in oil) (84.5 mg 2.11 
mmol). The reaction mixture was allowed to come to room temperature and stirred overnight. 
Water (10 mL) was added and the reaction mixture was extracted with ether (3×15 mL). The 
combined organic phase was dried over MgSO4 and filtered. The filtrate was concentrated 
under reduced pressure and the residue was subjected to column chromatography (95/5, 
EtOAc/MeOH) to afford 304 (787 mg, 70 %) as a white solid. 
Rf (SiO2, hexanes/EtOAc 1:1) = 0.29; thick oil; 1H NMR (300 MHz CDCl3): δ = 1.88-1.98 
(m, 2 H CH2CH2CH2), 2.63 (t, J = 7.67, Hz 1 H, CH2CH2), 3.46 (t, J = 6.41, Hz 2 H, 
CH2CH2O), 4.38 (s, 2 H, CH2O), 6.51 (bs,1 H, Imi-C5), 7.01-7.05 (m, 2 H, aromatic), 7.09-
7.16 (m, 6 H, aromatic), 7.27-7.34 (m, 9 H, aromatic), 7.35 (d, J = 1.40, 1 H, Imi-C2), 7.59-
7.64 (m, 2 H, aromatic); 13C NMR (75.5 MHz CDCl3): δ = 25.1 (-, CH2CH2CH2), 29.4 (-, 
CH2CH2,), 69.9 (-, CH2CH2O), 72.2 (-, CH2O), 75.2 (+, Cquat, CPh3), 92.9 (+, Cquat, C-I), 
118.1 (+, CH, Imi-C5), 128.0 (+, CH, aromatic), 128.1 (+, CH, aromatic), 129.5 (+, CH, 
aromatic), 129.9 (+, CH, aromatic), 137.5 (+, CH, aromatic), 138.4 (+, CH, Imi-C2), 138.5 
(+, Cquat, Imi-C4), 141.2 (+, Cquat, aromatic), 142.6 (+, Cquat, aromatic); IR (Film): ~ν  = 3058, 
2926, 2856, 1713, 1586, 1485, 1446, 1393, 1266, 1236, 1156, 1126, 1099, 1036, 1005, 746, 
701, 658 cm-1; MS (ESI,CH2Cl2/MeOH/NH4Ac): m/z = 585 [M + H+], 243.1 [CPh3+]. 
 
4-(3-(4-iodobenzyloxy)propyl)-1H-imidazole (248):  
 
N
N
H
O
I
 
 
To a solution of 304 (600 mg, 1.03 mmol) in MeOH (10 mL) was added 2M solution of HCl 
(10 mL) and reaction mixture was refluxed for 1.5 h. Most of the MeOH was evaporated in 
vacuo and aqueous phase was made strongly basic by adding solid K2CO3 and extracted in 
CH2Cl2 (4×15 mL), dried (MgSO4) and solvent was removed in vacuo. The residue was 
purified by chromatography on silica (CH2Cl2/MeOH 9:1) to get the product as a cream white 
solid (243 mg, 69 %). 
Rf  (SiO2, MeOH/CH2Cl2 1:9) = 0.18; m.p. = 65-66 °C, free base, (Lit.120 123-124 °C as a 
hydrogen maleate); 1H NMR (300 MHz CDCl3): δ = 1.89-1.98 (m, 2 H CH2CH2CH2), 2.71 (t, 
J = 7.58, Hz 1 H, CH2CH2), 3.49 (t, J = 6.23 Hz, 2 H, CH2CH2O), 4.41 (s, 2 H, CH2O), 6.76 
(bs, 1 H, Imi-C5), 7.03-7.07 (m, 2 H, aromatic), 7.55 (bs, 1 H, Imi-2H), 7.61-7.65 (m, 2 H, 
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aromatic), 11.56 (bs,1 H, Imi-NH); 13C NMR (75.5 MHz CDCl3): δ = 23.4 (-, CH2CH2CH2), 
29.4 (-, CH2CH2,), 69.9 (-, CH2O), 72.3 (-, CH2O), 93.1 (+, Cquat, C-I), 117.9 (+, CH, Imi-C5), 
129.6 (+, CH, aromatic), 134.4 (+, CH, Imi-C2), 136.1 (+, Cquat, Imi-C4), 137.5 (+, CH, 
aromatic), 138.2 (+, Cquat, aromatic); IR (KBr): ~ν  = 3436, 3113, 3074, 2943, 2851, 2731, 
2619, 1585, 1470, 1386, 1356, 1262, 1234, 1199, 1170, 1097, 1058, 1026, 1005, 943, 878, 
842, 788, 666, 627 cm-1; MS (EI +VE): m/z (%) = 342.2 (2.5) [M•+], 217.1 (19.4), 125.2 
(49.2), 110.2 (51.1), 95.2 (37.2), 82.2 (100), 68.3 (4.2); HRMS calcd for C13H15IN2O, 
342.0229. Found 342.0226. 
 
4-((E)-3-(4-iodobenzyloxy)prop-1-enyl)-1-trityl-1H-imidazole (305):  
 
N
N
O
Ph3C
I
 
 
A solution of alcohol 284 (71 mg 0.194 mmol) and 4-iodobenzylbromide (63.3 mg 0.213 
mmol) in DMF (2 mL) was cooled to 0 °C and treated with NaH (60% in oil) (8.5 mg 0.213 
mmol). The reaction mixture was allowed to come to room temperature and stirred overnight. 
Water (5 mL) was added and the reaction mixture was extracted with ether (3×8 mL). The 
combined organic phase was dried over MgSO4 and filtered. The filtrate was concentrated 
under reduced pressure and the residue was subjected to column chromatography 
(EtOAc/hexanes 1/1) to afford 305 (85 mg, 75 %) as a white solid. 
Rf  (SiO2, hexanes /EtOAc1:1) = 0.28; m.p. = 170-171 °C; 1H NMR (300 MHz CDCl3): δ = 
4.15 (d, J = 4.67, Hz 2 H, CHCH2O), 4.48 (s, 2 H, CH2O), 6.42 (dt, J = 15.91, 4.67, Hz 1 H, 
=CHCH2), 6.49 (d, J = 15.91, Hz 1 H, =CH), 6.78 (d, J = 1.13 Hz, 1 H, Imi-5 H), 7.08-7.10 
(m, 2 H, aromatic), 7.13-7.17 (m, 6 H, aromatic), 7.31-7.35 (m, 9 H, aromatic), 7.43 (d, J = 
1.13 Hz, 1 H, Imi-2 H), 7.62-7.66 (m, 2 H, aromatic), 13C NMR (75.5 MHz CDCl3): δ = 70.8 
(-, CHCH2O), 71.2 (-, CH2O), 75.5 (+, Cquat, CPh3), 92.9 (+, Cquat, C-I), 119.6 (+, CH, Imi-
C5), 124.4 (+, CH, =CHCH2 and =CH), 128.2 (+, CH, aromatic), 128.2 (+, CH, aromatic), 
129.6 (+, CH, aromatic), 129.8 (+, CH, aromatic), 137.5 (+, CH, aromatic), 138.3 (+, Cquat, 
aromatic), 138.5 (+, Cquat, Imi-C4), 139.2 (+, CH, Imi-C2), 142.2 (+, Cquat, aromatic), IR 
(KBr): ~ν  = 3057, 3028, 2917, 2848, 1591, 1484, 1444, 1394, 1355, 1292, 1216,  1185, 1156, 
1110, 1038, 1004, 949, 829, 791, 747, 701, 656 cm-1; MS (ESI): m/z (%) = 495.2 [M + H+], 
243.0 [CPh3+], 1165.6 [2M + H+]. 
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4-((E)-3-(4-iodobenzyloxy)prop-1-enyl)-1H-imidazole (306):  
 
N
NH
O
I
 
 
Prepared by following the same procedure used for 304, (87% yield); Rf  (SiO2, 
MeOH/CH2Cl2 1:9) = 0.19; thick oil; 1H NMR (300 MHz CDCl3): δ = 4.08 (dd, 2 H, J = 
6.00, 1.26 Hz =CHCH2), 4.50 (s, 2 H, OCH2), 6.22 (dd, 1 H, J = 15.91, 6.00 Hz, =CHCH2), 
6.50 (dt, 1 H, J = 15.91, 1.26 Hz, =CH), 6.99 (bs, Imi-5H), 7.05-7.08 (m, 2 H, aromatic), 7.61 
(bs, Imi-2H), 7.62-7.66 (m, 2 H, aromatic) 9.91 (bs, 1 H, Imi-NH); 13C NMR (75.5 MHz 
CDCl3): δ = 69.7 (-, =CHCH2), 70.4 (-, OCH2), 92.2 (+, Cquat, C-I), 117.9 (+, CH, Imi-C5), 
121.6 (+, =CHCH2), 123.5 (+, =CH), 128.7 (+, CH, aromatic), 134.1 (+, Cquat,. Imi-C4), 134.7 
(+, CH, Imi-C2), 136.6 (+, CH aromatic), 137.0 (+, Cquat,. aromatic); IR (Film): ~ν  =  3063, 
2852, 16641, 1481, 1357, 1303, 1247, 1106, 1007, 965, 908, 829, 798, 731, cm-1; MS (EI 
+VE): m/z (%) = 341.0/340.0 (3.5/16.0) [M•+], 311.0 (9.8) 297.0, (13.6) 218.0/217.0 
(3.2/42.8) 124/123.0 (3.5/58.8), 95.0 (100), 68.0 (12.2); HRMS calcd for C13H13IN2O, 
340.0073. Found 340.0068. 
 
(E)-1-(1H-imidazol-4-yl)-4-methylhex-1-en-3-one (296):  
 
N
N
H
O
O
 
 
Trans urocanic acid 162 (4 g, 28.95 mmol) and 2-butanol (30 mL) were added to benzene (15 
mL). H2SO4 (2 mL) was added and the reaction refluxed (96 °C) using a Dean-Stark trap for 
24 hours. The reaction mixture was cooled to room temperature and concentrated in vacuo. 
The aqueous layer was slowly neutralized with 10% NaOH and extracted with EtOAc (3 × 30 
mL), combined organic layers were washed with H2O (2 × 20 mL) dried over MgSO4. 
Filtration and evaporation of the solvent afforded the ester as thick pail yellow oil (5.07 g, 
98%). All data were in good agreement with the literature.135 
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(2-(1-trityl-1H-imidazol-4-yl)cyclopropyl)methanol (298):  
 
N
N
OH
Ph3C
 
 
To a suspension of LiAlH4 (291.5 mg, 7.68 mmol) in ether (10 mL) at 0 °C was added 
dropwise a solution of ester 297 (1.73 g, 3,84 mmol) in ether (15mL). The reaction mixture 
was allowed to come to RT and stirred for 30 min. 0.1 M NaOH (35 mL) was added slowly 
and mixture was extracted with CHCl3 (4 × 25 mL). Combined organic layers were washed 
with saturated aq NaHCO3 (25 mL) and brine (25 mL) dried over MgSO4. Filtration and 
evaporation of the solvent afforded the corresponding alcohol as a white solid (1.41 g, 96%). 
All data were in agreement with the literature.135 
 
General procedure for preparation of cyclopropanated benzyl ethers: To a suspension of 
NaH (1.2 eq.) in DMF at 0 °C was added the solution of alcohol 298 (1 equv.) and the 
corresponding benzyl bromide (1.2 equv.). The reaction mixture was stirred at ambient 
temperature for 3-12 h. A (2:1) mixture of ether and CH2Cl2 (15 mL) was added, washed with 
H2O twice and dried over MgSO4. Filtration and evaporation of the solvent afforded the 
benzyl ethers which were purified by column chromatography (EtOAc/hexanes 1:1).
 
 
4-(2-((benzyloxy)methyl)cyclopropyl)-1-trityl-1H-imidazole (307):  
 
N
N
O
Ph3C
 
 
Stirred for 12 h, (87% yield); Rf (EtOAc/hexanes 1:1) = 0.30; m.p. = 141-143 °C; 1H NMR 
(300 MHz CDCl3): δ = 0.75-0.82 (m, 1 H, CHH, cyclopropane), 0.99-1.05 (m, 1 H, CHH, 
cyclopropane), 1.47-1.57 (m, 1 H, CHCH2O), 1.68-1.74 (m, 1 H, CHCHCH2), 3.38 (dd, J = 
10.42, 6.96 Hz, 1 H, CHCH2O), 3.53 (dd, J = 10.42, 6.38 Hz, 1 H, CHCH2O), 4.53 (s, 2 H, 
CH2O), 6.54 (d, J = 1.37 Hz, Imi-5 H), 7.09-7.16 (m, 6 H, aromatic), 7.28-7.32 (m, 16 H, 
aromatic); 13C NMR (75.5 MHz CDCl3): δ = 12.5 (-, CH2, cyclopropane), 15.2 (+, CH, 
cyclopropane), 20.5 (+, CH, cyclopropane), 72.4 (-, CH2O), 73.5 (-, CH2O), 75.2 (+, Cquat, 
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CPh3), 116.9 (+, CH, Imi-C5), 127.5 (+, CH, aromatic), 127.8 (+, CH, aromatic), 128.0 (+, 
CH, aromatic), 128.4 (+, CH, aromatic), 129.9 (+, CH, aromatic), 138.3 (+, CH, Imi-C2), 
138.6 (+, Cquat, Imi-C4), 142.2 (+, Cquat, aromatic), 142.6 (+, Cquat, aromatic); IR (neat): ~ν  = 
3050, 3223, 1492, 1445, 1359, 1229, 1130, 1102, 1001, 821, 749, 701, 656 cm-1; MS (EI 
+VE): m/z (%) = 470.4 [M•+], 243.2, (100) [CPh3+], 241.2 (14.6) , 228.2 (10.2), 165.1 (65.2), 
91.1 (22.2); HRMS calcd for C33H30N2O, 470.2358. Found 470.2359. 
 
4-(2-((4-(methyl)benzyloxy)methyl)cyclopropyl)-1-trityl-1H-imidazole (308):  
 
N
N
O
Ph3C
CH3
 
 
Stirred for 12 h, (80% yield); Rf  (EtOAc/hexanes 1:1) = 0.33; m.p. = 141-142 °C; 1H NMR 
(300 MHz CDCl3): δ = 0.78 (ddd, 1 H, J = 8.77, 5.32, 4.50 Hz CHH, cyclopropane), 0.98-
1.04 (m, 1 H, CHH, cyclopropane), 1.46-1.56 (m, 1 H, CHCH2O), 1.68-1.74(m, 1 H, 
CHCHCH2), 2.32(s, 3 H, CH3), 3.35 (dd, J = 10.36, 6.89, Hz, 1 H, CHCH2O), 3.50 (dd, J = 
10.36, 6.39, Hz, 1 H, CHCH2O), 4.49 (s, 2 H, CH2O), 6.54 (d, J = 1.37 Hz, Imi-5 H), 7.09-
7.15 (m, 8 H, aromatic), 7.19-7.22 (m, 2 H, aromatic), 7.28-7.33 (m, 10 H, aromatic); 13C 
NMR (75.5 MHz CDCl3): δ = 12.5 (-, CH2, cyclopropane), 15.1 (+, CH, cyclopropane), 20.6 
(+, CH, cyclopropane), 21.2 (+, CH3), 72.3 (-, CHCH2O), 73.2 (-, CH2O), 75.2 (+, Cquat, 
CPh3), 116.9 (+, CH, Imi-C5), 127.9 (+, CH, aromatic), 128.1 (+, CH, aromatic), 129.1 (+, 
CH, aromatic), 129.9 (+, CH, aromatic), 135.5 (+, Cquat, aromatic), 137.2 (+, CH, Imi-C2), 
138.2 (+, Cquat, Imi-C4), 142.1 (+, Cquat, aromatic), 142.5 (+, Cquat, aromatic); IR (neat): ~ν  = 
3010, 2820, 1491, 1445, 1360, 1224, 1085, 1005, 805, 746, 700, 656 cm-1; MS (EI +VE): m/z 
(%) = 484.3 [M•+], 244.2 (16.5), 243.1, (100) [CPh3+], 241.0 (7.7) , 228.1 (4.5), 165.0 (33.7), 
105.0 (13.2); HRMS calcd for C34H32N2O, 484.2515. Found 484.2514. 
 
4-(2-((4-(trifluoromethyl)benzyloxy)methyl)cyclopropyl)-1-trityl-1H-imidazole (309):  
 
N
N
O
Ph3C
CF3
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Stirred for 16 h, (79% yield); Rf  (EtOAc/hexanes 1:1) = 0.32; m.p. = 127-129 °C; 1H NMR 
(300 MHz CDCl3): δ = 0.77-0.83 (m, 1 H, CHH, cyclopropane), 1.00-1.07 (m, 1 H, CHH, 
cyclopropane), 1.47-1.58 (m, 1 H, CHCH2O), 1.70-1.76 (m, 1 H, CHCHCH2), 3.42 (dd, J = 
10.42, 6.89, Hz, 1 H, CHCH2O), 3.54 (dd, J = 10.42, 6.48, Hz, 1 H, CHCH2O), 4.59 (s, 2 H, 
CH2O), 6.55 (d, J = 1.37 Hz, Imi-5 H), 7.10-7.16 (m, 6 H, aromatic), 7.29-7.34 (m, 10 H, 
aromatic), 7.42-7.45 (m, 2 H, aromatic), 7.56-7.58 (m, 2 H, aromatic); 13C NMR (75.5 MHz 
CDCl3): δ = 12.4 (-, CH2, cyclopropane), 15.3 (+, CH, cyclopropane), 20.5 (+, CH, 
cyclopropane), 71.6 (-, CHCH2O), 73.9 (-, CH2O), 75.2 (+, Cquat, CPh3), 117.0 (+, CH, Imi-
C5), 124.3 (+, q, j = 271.97 CF3,), 125.4 (+, q, j = 3.81 CHC-CF3), 127.6 (+, CH, aromatic), 
128.0 (+, CH, aromatic + Cquat, CCF3), 129.9 (+, CH, aromatic), 138.3 (+, Cquat, Imi-C4), 
138.4 (+, CH, Imi-C2), 142.0 (+, Cquat, aromatic), 142.6 (+, Cquat aromatic), 142.9 (+, Cquat, 
aromatic); IR (neat): ~ν  = 2825, 1490, 1443, 1325, 1223,1165, 1121, 1089, 1065, 823, 749, 
699, 657 cm-1; MS (EI +VE): m/z (%) = 538.4 [M•+], 244.2 (36.5), 243.2, (100) [CPh3+], 
242.2 (10.0) , 241.1 (12.8), 165.0 (61.3), 159.1 (10.4), 122.1 (5.3); HRMS calcd for 
C34H29F3N2O, 538.2232. Found 538.2227. 
 
4-(2-((4-(trifluoromethoxy)benzyloxy)methyl)cyclopropyl)-1-trityl-1H-imidazole (310):  
 
N
N
O
Ph3C
O CF3
 
 
Stirred for 16 h, (79% yield); Rf  (EtOAc/hexanes 1:1) = 0.29; m.p. = 85-87 °C; 1H NMR 
(300 MHz CDCl3): δ = 0.77-0.83 (m, 1 H, CHH, cyclopropane), 1.01-1.07 (m, 1 H, CHH, 
cyclopropane), 1.47-1.58 (m, 1 H, CHCH2O), 1.70-1.76(m, 1 H, CHCHCH2), 3.41 (dd, J = 
10.46, 6.96, Hz, 1 H, CHCH2O), 3.55 (dd, J = 10.46, 6.44, Hz, 1 H, CHCH2O), 4.53 (s, 2 H, 
CH2O), 6.56 (d, J = 1.37 Hz, Imi-5 H), 7.10-7.18 (m, 8 H, aromatic), 7.29-7. 37 (m, 12 H, 
aromatic); 13C NMR (75.5 MHz CDCl3): δ = 12.4 (-, CH2, cyclopropane), 15.3 (+, CH, 
cyclopropane), 20.5 (+, CH, cyclopropane), 71.5 (-, CHCH2O), 73.2 (-, CH2O), 75.2 (+, Cquat, 
CPh3), 117.1 (+, CH, Imi-C5), 120.5 (+ q, J = 256.9, CH, aromatic), 121.0 (+, q, J = 0.92, 
OCF3), 128.1 (+, CH, aromatic), 129.0 (+, CH, aromatic), 129.8 (+, CH, aromatic), 137.5 (+, 
Cquat, Imi-C4), 138.6 (+, CH, Imi-C2), 142.1 (+, Cquat, aromatic), 142.5 (+, Cquat, aromatic), 
148.64 (+, q, J = 0.92, Cquat, COCF3); IR (neat): ~ν  = 3050, 3223, 1492, 1445, 1359, 1229, 
1130, 1102, 1001, 821, 749, 701, 656 cm-1; MS (EI +VE): m/z (%) = 470.4 [M•+], 243.2, 
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(100) [CPh3+], 241.2 (14.6) , 228.2 (10.2), 165.1 (65.2), 91.1 (22.2); HRMS calcd for 
C33H30N2O, 470.2358. Found 470.2359. 
 
4-(2-((2,4,6-trimethyl)benzyloxy)methyl)cyclopropyl)-1-trityl-1H-imidazole (321):  
 
N
N
O
Ph3C
Me
Me Me
 
 
Stirred for 16 h, (38% yield); Rf  (EtOAc/hexanes 4:6) = 0.30; m.p. = 119-120 °C; 1H NMR 
(300 MHz CDCl3): δ = 0.77 (ddd, 1 H, J = 8.78, 5.23, 4.57 Hz CHH, cyclopropane), 0.98-
1.05 (m, 1 H, CHH, cyclopropane), 1.48-1.58 (m, 1 H, CHCH2O), 1.68-1.74 (m, 1 H, 
CHCHCH2), 2.23 (s, 3 H, CH3), 2.31 (s, 6 H, CH3), 3.40 (dd, J = 10.43, 6.91, Hz, 1 H, 
CHCH2O), 3.52 (dd, J = 10.43, 6.62, Hz, 1 H, CHCH2O), 4.49 (dd, J = 12.45, 10.43 Hz 2 H, 
CH2O), 6.53 (d, J = 1.37 Hz, Imi-5 H), 6.81 (bs, 2 H, aromatic), 7.09-7.15 (m, 6 H, aromatic) 
7.27 (d, J = 1.37 Hz, Imi-2 H), 7.28-7.32 (m, 9 H, aromatic); 13C NMR (75.5 MHz CDCl3): δ 
= 12.4 (-, CH2, cyclopropane), 15.2 (+, CH, cyclopropane), 19.5 (+, CH3), 20.5 (+, CH, 
cyclopropane), 20.9 (+, CH3), 66.3 (-, CH2O), 73.5(-, CHCH2O), 75.1 (+, Cquat, CPh3), 116.8 
(+, CH, Imi-C5), 127.9 (+, CH aromatic), 127.9 (+, CH, aromatic), 128.8 (+, CH, aromatic), 
129.8 (+, CH, aromatic), 131.4 (+, Cquat, aromatic), 137.4 (+, Cquat, Imi-C4), 137.8 (+, Cquat, 
aromatic), 138.2 (+, CH, Imi-C2), 142.1 (+, Cquat, aromatic), 142.5 (+, Cquat, aromatic); IR 
(neat): ~ν  = 3012, 2923, 2822, 2811, 1572, 1491, 1442, 1354, 1223, 1130, 1087, 1050, 1033, 
1004, 934, 851,819,  746, 697, 655, 638 cm-1; MS (EI +VE): m/z (%) = 512.1 (1.1) [M•+], 
270.3 (1.3) [M• - CPh3+], 243.0, (100) [CPh3+], 227.9 (3.9), 165.0 (14.6), 132.9 (13.4), 121.0 
(4.9), 28.1 (13.9); HRMS calcd for C36H36N2O, 512.2828. Found 512.2827. 
 
4-(2-((4-bromobenzyloxy)methyl)cyclopropyl)-1-trityl-1H-imidazole (312):  
 
N
N
O
Ph3C
Br
 
 
Stirred for 16 h, (79% yield); Rf (EtOAc/hexanes 1:1) = 0.31; m.p. = 139-141 °C; 1H NMR 
(300 MHz CDCl3): δ = 0.77 (ddd, 1 H, J = 8.74, 5.28, 4.63 Hz CHH, cyclopropane), 0.98-
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1.04 (m, 1 H, CHH, cyclopropane), 1.45-1.55 (m, 1 H, CHCH2O), 1.68-1.74(m, 1 H, 
CHCHCH2), 3.38 (dd, J = 10.44, 6.91, Hz, 1 H, CHCH2O), 3.50 (dd, J = 10.44, 6.46, Hz, 1 H, 
CHCH2O), 4.48 (s, 2 H, CH2O), 6.54 (d, J = 1.37 Hz, Imi-5 H), 7.09-7.15 (m, 6 H, aromatic), 
7.17-7.21 (m, 2 H, aromatic), 7.27-7.33 (m, 10 H, aromatic), 7.41-7.45 (m, 2 H, aromatic); 
13C NMR (75.5 MHz CDCl3): δ = 12.4 (-, CH2, cyclopropane), 15.3 (+, CH, cyclopropane), 
20.4 (+, CH, cyclopropane), 71.6 (-, CHCH2O), 73.6 (-, CH2O), 75.2 (+, Cquat, CPh3), 117.0 
(+, CH, Imi-C5), 121.4 (+, Cquat, C-Br), 128.1 (+, CH, aromatic), 129.4 (+, CH, aromatic), 
129.9 (+, CH, aromatic), 131.5 (+, CH, aromatic), 137.7 (+, Cquat, Imi-C4), 138.4 (+, CH, 
Imi-C2), 142.1 (+, Cquat, aromatic), 142.6 (+, Cquat, aromatic); IR (neat): ~ν  = 3010, 2820, 
1491, 1445, 1360, 1224, 1085, 1005, 805, 746, 700, 656 cm-1; MS (EI +VE): m/z (%) = 548.3 
[M•+], 244.2 (16.5), 243.1, (100) [CPh3+], 241.0 (7.7), 228.1 (4.5), 165.0 (33.7), 105.0 (13.2); 
HRMS calcd for C33H29BrN2O, 548.1463. Found 548.1456. 
 
4-(2-((4-iodobenzyloxy)methyl)cyclopropyl)-1-trityl-1H-imidazole (311):  
 
N
N
O
Ph3C
I
 
 
Stirred for 16 h, (79% yield); Rf = (EtOAc/hexanes 1:1) 0.32; m.p. = 159-161 °C; 1H NMR 
(300 MHz CDCl3): δ = 0.77 (ddd, 1 H, J = 8.75, 5.29, 4.67 Hz, CHH, cyclopropane), 0.98-
1.04 (m, 1 H, CHH, cyclopropane), 1.44-1.54 (m, 1 H, CHCH2O), 1.68-1.74(m, 1 H, 
CHCHCH2), 3.38 (dd, J = 10.46, 6.82, Hz, 1 H, CHCH2O), 3.49 (dd, J = 10.46, 6.55 Hz, 1 H, 
CHCH2O), 4.48 (s, 2 H, CH2O), 6.53 (d, J = 1.37 Hz, Imi-5H), 7.05-7.09 (m, 2 H, aromatic), 
7.11-7.15 (m, 6 H, aromatic), 7.27 (d, J = 1.37 Hz, Imi-2H), 7.29-7.34 (m, 9 H, aromatic), 
7.62-7.66 (m, 2 H, aromatic); 13C NMR (75.5 MHz CDCl3): δ = 12.4 (-, CH2, cyclopropane), 
15.3 (+, CH, cyclopropane), 20.4 (+, CH, cyclopropane), 71.7 (-, CHCH2O), 73.6 (-, CH2O), 
75.2 (+, Cquat, CPh3), 93.0 (+, Cquat, C-I), 117.0 (+, CH, Imi-C5), 128.1 (+, CH, aromatic), 
129.6 (+, CH, aromatic), 129.9 (+, CH, aromatic), 137.5 (+, Cquat, aromatic), 138.4 (+, Cquat, 
Imi-C4), 138.4 (+, CH, Imi-C2), 142.1 (+, Cquat, aromatic), 142.6 (+, Cquat, aromatic); IR 
(neat): ~ν  = 3012, 2853, 1483, 1442, 1343, 1276, 1224, 1127, 1081, 1036, 1006, 823, 792, 750, 
699, 657, 638 cm-1; MS (EI +VE): m/z (%) = 596.0 [M•+], 243.1, (100) [CPh3+], 239.1 (10.1), 
228.1 (7.7), 165.0 (48.5), 127.9 (3.8), 91.0 (2.7); HRMS calcd for C33H29IN2O, 596.1325. 
Found 596.1322. 
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4-(((2-(1-trityl-1H-imidazol-4-yl)cyclopropyl)methoxy)methyl)benzonitrile (313):  
 
N
N
O
Ph3C
CN
 
 
Stirred for 16 h, (34% yield); Rf  (EtOAc/hexanes 7:3) = 0.27; m.p. = 48-50 °C, (pail yellow 
foam); 1H NMR (300 MHz CDCl3): δ = 0.77-0.83 (m, 1 H CHH, cyclopropane), 1.00-1.07 
(m, 1 H, CHH, cyclopropane), 1.47-1.57 (m, 1 H, CHCH2O), 1.71-1.77(m, 1 H, CHCHCH2), 
3.44 (dd, J = 10.46, 6.82, Hz, 1 H, CHCH2O), 3.55 (dd, J = 10.46, 6.51, Hz, 1 H, CHCH2O), 
4.59 (s, 2 H, CH2O), 6.55 (d, J = 1.26 Hz, Imi-5H), 7.11-7.14 (m, 6 H, aromatic), 7.30-7.33 
(m, 10 H, aromatic), 7.42-7.48 (m, 2 H, aromatic), 7.59-7.62 (m, 2 H, aromatic); 13C NMR 
(75.5 MHz CDCl3): δ = 12.3 (-, CH2, cyclopropane), 15.3 (+, CH, cyclopropane), 20.4 (+, 
CH, cyclopropane), 71.4 (-, CH2O), 74.1 (-, CH2O), 75.3 (+, Cquat, CPh3), 111.2 (+, Cquat, 
aromatic), 117.0 (+, CH, Imi-C5), 119.0 (+, Cquat, CN), 127.7 (+, CH, aromatic), 128.1 (+, 
CH, aromatic), 129.9 (+, CH, aromatic), 132.2 (+, CH, aromatic), 138.4 (+, CH, Imi-C2), 
141.9 (+, Cquat, Imi-C4), 142.5 (+, Cquat, aromatic), 144.4 (+, Cquat, aromatic); IR (neat): ~ν  = 
3057, 2859, 2228, 1492, 1445, 1362, 1267, 1224, 1157, 1086, 1035, 819, 735, 700, 657 cm-1; 
MS (EI +VE): m/z (%) = 495.2 [M•+], 253.1 (1.3) [M- CPh3] 244.1, (40.3) 243.1 (100) 
[CPh3+], 241.1 (16.9), 239.1 (11.9), 228.2 (10.2), 165.1 (54.9), 152.1 (3.4), 116.0 (4.7), 94 
(3.3); HRMS calcd for C34H29N3O, 495.2311. Found 495.2306;  
 
General procedure for trityl deprotection of cyclopropanated ethers: To a solution of 
benzyl ether (0.25 mmol) in MeOH (2 mL) was added 2 M solution of HCl (2 mL) and 
reaction mixture was refluxed for 1.5 h. Most of the MeOH was evaporated in vacuo and 
aqueous phase was made strongly basic by adding solid K2CO3 and extracted in CH2Cl2 (4×8 
mL) dried (MgSO4). The solvent was removed in vacuo to leave the pure products as oils. 
 
4-(2-((benzyloxy)methyl)cyclopropyl)-1H-imidazole (314):  
 
N
N
H
O
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(91% yield); Rf  (SiO2, MeOH/EtOAc 1:9) = 0.32; thick oil; 1H NMR (300 MHz CDCl3): δ = 
0.76-0.82 (m, 1 H, CHH, cyclopropane), 0.94-1.00 (m, 1 H, CHH, cyclopropane), 1.39-1.50 
(m, 1 H, CHCH2O), 1.73-1.79 (m, 1 H, CHCHCH2), 3.40 (dd, J = 10.33, 6.96, Hz, 1 H, 
CHCH2O), 3.46 (dd, J = 10.33, 6.55, Hz, 1 H, CHCH2O), 4.52 (s, 2 H, CH2O), 6.67 (bs, Imi-
5H), 7.22-7.32 (m, 5 H, aromatic), 7.41 (bs, 1 H, Imi-2H), 9.76 (bs, 1 H, Imi-NH); 13C NMR 
(75.5 MHz CDCl3): δ = 12.0 (-, CH2, cyclopropane), 14.1 (+, CH, cyclopropane), 20.5 (+, 
CH, cyclopropane), 72.6 (-, CHCH2O), 73.5 (-, CH2O), 115.3 (+, CH, Imi-C5), 127.7 (+, CH, 
aromatic), 127.8 (+, CH, aromatic), 128.5 (+, CH, aromatic), 134.5 (+, CH, Imi-C2), 138.3 
(+, Cquat, aromatic), 138.7 (+, Cquat, Imi-C4); IR (neat): ~ν  = 3050, 3030, 2856, 1572, 1453, 
1361, 1210, 1071, 1027, 819, 734, 697, 660, 625 cm-1; MS (EI +VE): m/z (%) = 228.2 (15.4) 
[M•+], 198.2 (3.2), 187.2 (3.9), 137.1 (30.1), 122.1 (37.9), 107.1 (60.1), 94.1 (37.1), 91.1, 
(100) [C7H7+], 80.1 (32.7) HRMS calcd for C14H16N2O, 228.1263. Found 228.1266. 
 
4-(2-((4-(methyl)benzyloxy)methyl)cyclopropyl)-1H-imidazole (315):  
 
N
N
H
O
CH3
 
 
(88% yield); Rf  (SiO2, MeOH/EtOAc 1:9) = 0.28; thick oil; 1H NMR (300 MHz CDCl3): δ = 
0.76-0.83 (m, 1 H, CHH, cyclopropane), 0.94-1.00 (m, 1 H, CHH, cyclopropane), 1.39-1.49 
(m, 1 H, CHCH2O), 1.73-1.79 (m, 1 H, CHCHCH2), 2.33 (s, 3 H, CH3), 3.39 (dd, J = 10.29, 
6.93, Hz, 1 H, CHCH2O), 3.47 (dd, J = 10.29, 6.48, Hz, 1 H, CHCH2O), 4.50 (s, 2 H, CH2O), 
6.67 (bs, Imi-5H), 7.12-7.23 (m, 4 H, aromatic), 7.43 (bs, 1 H, Imi-2H), 9.22 (bs, 1 H, Imi-
NH); 13C NMR (75.5 MHz CDCl3): δ = 12.0 (-, CH2, cyclopropane), 14.1 (+, CH, 
cyclopropane), 20.5 (+, CH, cyclopropane), 21.2 (+, CH3), 72.6 (-, CHCH2O), 73.4 (-, 
CH2O), 115.5 (+, CH, Imi-C5, broad), 128.0 (+, CH, aromatic), 129.2 (+, CH, aromatic), 
134.5 (+, CH, Imi-C2, broad), 135.3 (+, Cquat, aromatic), 137.4 (+, Cquat, aromatic) 138.7 (+, 
Cquat, Imi-C4, broad); IR (neat): ~ν  = 3055, 3035, 2855, 1572, 1450, 1359, 1213, 1075, 939, 
803, 754, 659, 626 cm-1; MS (EI +VE): m/z (%) = 242.2 (15.4) [M•+], 201.0 (4.02), 212.2 
(5.9), 137.1 (21.6), 122.1 (35.8), 105.0 (100) [C8H9+] 93.9 (18.3), 77.0, (15.2), HRMS calcd 
for C15H18N2O, 242.1419. Found 242.1420;  
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4-(2-((4-(trifluoromethyl)benzyloxy)methyl)cyclopropyl)-1H-imidazole (316):  
 
N
N
H
O
CF3
 
 
(86% yield); Rf (SiO2, MeOH/EtOAc 1:9) = 0.30; thick oil; 1H NMR (300 MHz CDCl3): δ = 
0.79-0.85 (m, 1 H, CHH, cyclopropane), 0.97 - 1.03 (m, 1 H, CHH, cyclopropane), 1.42-1.53 
(m, 1 H, CHCH2O), 1.77-1.84 (m, 1 H, CHCHCH2), 3.43 (dd, J = 10.29, 6.79, Hz, 1 H, 
CHCH2O), 3.49 (dd, J = 10.29, 6.55, Hz, 1 H, CHCH2O), 4.57 (s, 2 H, CH2O), 6.74 (bs, Imi-
5H), 7.40-7.43 (m, 2 H, aromatic), 7.49 (bs, 1 H, Imi-2H), 7.55-7.57 (m, 2 H, aromatic), 
10.76 (bs, 1 H, Imi-NH); 13C NMR (75.5 MHz CDCl3): δ = 12.1 (-, CH2, cyclopropane), 14.2 
(+, CH, cyclopropane), 20.5 (+, CH, cyclopropane), 71.7 (-, CHCH2O), 73.8 (-, CH2O), 115.2 
(+, CH, Imi-C5, broad), 124.2 (+, q, J = 272.0, CF3), 125.3 (+, q J = 3.9, CHC-CF3, 
aromatic), 127.6 (+, CH, aromatic), 129.7 (+, q J = 32.2, C-CF3), 134.4 (+, CH, Imi-C2, 
broad), 138.9 (+, Cquat, Imi-C4, broad), 142.6 (+, Cquat, aromatic); IR (neat): ~ν  = 3058, 3038, 
2857, 1620, 1415, 1313, 1161, 1112, 1064, 1017, 943, 819, 757, 627 cm-1; MS (EI +VE): m/z 
(%) = 297.2/296.2 (5.4/33.6) [M•+], 277.2 (4.5) [M•+-F], 174.1/173.1 (4.7/13.0), 159.1 (100) 
[C8H9+], 137.1 (29.7), 122.1 (67.6), 119.1 (40.3), 107.1, (87.5), 94.1 (86.), 80.1 (49.6) HRMS 
calcd for C15H15F3N2O, 296.1136. Found 296.1134; 
 
4-(2-((4-(trifluoromethoxy)benzyloxy)methyl)cyclopropyl) -1H-imidazole (317):  
 
N
N
H
O
OCF3
 
 
(89% yield); Rf (SiO2, MeOH/EtOAc 1:9) = 0.30; thick oil; 1H NMR (300 MHz CDCl3): δ = 
0.79-0.85 (m, 1 H, CHH, cyclopropane), 0.97-1.03 (m, 1 H, CHH, cyclopropane), 1.42-1.53 
(m, 1 H, CHCH2O), 1.76-1.82 (m, 1 H, CHCHCH2), 3.43 (dd, J = 10.24, 6.84, Hz, 1 H, 
CHCH2O), 3.49 (dd, J = 10.24, 6.60, Hz, 1 H, CHCH2O), 4.53 (s, 2 H, CH2O), 6.74 (bs, Imi-
5H), 7.16-7.18 (m, 2 H, aromatic), 7.33-7.36 (m, 2 H, aromatic), 7.49 (bs, 1 H, Imi-2H), 8.68 
(bs, 1 H, Imi-NH); 13C NMR (75.5 MHz CDCl3): δ = 12.1 (-, CH2, cyclopropane), 14.2 (+, 
CH, cyclopropane), 20.5 (+, CH, cyclopropane), 71.7 (-, CHCH2O), 73.7 (-, CH2O), 115.1 (+, 
CH, Imi-C5, broad), 120.5 (+, Cquat, q, J = 256.9 Hz, CF3), 120.9 (+, q, J = 0.92, CHC-CF3, 
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aromatic), 121.1 (+, Cquat, q, J = 0.92, C-CF3), 134.5 (+, CH, Imi-C2, broad), 137.3 (+, Cquat, 
aromatic), 139.1 (+, Cquat, Imi-C4 broad), 148.7 (+, Cquat, q, J = 1.96 Hz, COCF3); IR (neat): 
~ν  = 3061, 3042, 2862, 1721, 1508, 1254, 1217, 1159, 1097, 1018, 815, 767, 708, 621 cm-1; 
MS (EI +VE): m/z (%) = 313.3/312.2 (2.8/18.8) [M•+], 190.1/189.1 (3.4/7.0), 175.1 (100) 
[C8H6F3+], 137.1 (28.4) [M•+ - C8H6F3+] 122.1 (46.5), 119.1 (20.3), 109.1, (26.7), 107 (56.2), 
94.1 (36.0.), 80.1 (26.5) HRMS calcd for C15H15F3N2O2, 312.1086. Found 312.1084. 
 
4-(2-((4-iodobenzyloxy)methyl)cyclopropyl)-1H-imidazole (312)  
 
N
N
H
O
I
 
 
(66% yield); Rf  (SiO2, MeOH/EtOAc 1:9) = 0.23; thick oil; 1H NMR (300 MHz CDCl3): δ = 
0.77-0.83 (m, 1 H, CHH, cyclopropane), 0.95-1.01 (m, 1 H, CHH, cyclopropane), 1.39-1.50 
(m, 1 H, CHCH2O), 1.74-1.80 (m, 1 H, CHCHCH2), 2.33 (s, 3 H, CH3), 3.39 (dd, J = 10.33, 
6.86, Hz, 1 H, CHCH2O), 3.46 (dd, J = 10.33, 6.51 Hz, 1 H, CHCH2O), 4.47 (s, 2 H, CH2O), 
6.71 (bs, Imi-5H), 7.04-7.08 (m, 2 H, aromatic), 7.46 (bs, 1 H, Imi-2H), 7.62-7.66 (m, 2 H, 
aromatic), 9.23 (bs, 1 H, Imi-NH); 13C NMR (75.5 MHz CDCl3): δ = 10.9 (-, CH2, 
cyclopropane), 13.0 (+, CH, cyclopropane), 19.4 (+, CH, cyclopropane), 70.8 (-, CHCH2O), 
72.5 (-, CH2O), 92.0 (+, Cquat, C-I), 114.1 (+, CH, Imi-C5 broad), 129.6 (+, CH, aromatic), 
137.5 (+, CH, aromatic), 133.4 (+, CH, Imi-C2 broad), 137.1 (+, Cquat, aromatic), 137.8 (+, 
Cquat, Imi-C4 broad); IR (neat): ~ν  = 3052, 2856, 1719, 1586, 1484, 1364, 1261, 1221, 1165, 
1088, 1007, 803, 749, 702, 659 cm-1; MS (EI +VE): m/z (%) = 354.0 (4.9) [M•+], 227.1 (5.9), 
216.9 (55.6), 137.1 (34.3), 122.1 (100), 107.0 (66.6) [C8H9+] 93.1 (12.3), 80.1, (23.9); HRMS 
calcd for C14H15IN2O, 354.0229. Found 354.0233. 
 
4-(2-((4-bromobenzyloxy)methyl)cyclopropyl)-1H-imidazole (319):  
 
N
N
H
O
Br
 
 
(78% yield); Rf  (SiO2, MeOH/EtOAc 1:9) = 0.25; thick oil; 1H NMR (300 MHz CDCl3): δ = 
0.77-0.83 (m, 1 H, CHH, cyclopropane), 0.96-1.02 (m, 1 H, CHH, cyclopropane), 1.39-1.50 
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(m, 1 H, CHCH2O), 1.74-1.80 (m, 1 H, CHCHCH2), 3.39 (dd, J = 10.36, 6.89 Hz, 1 H, 
CHCH2O), 3.47 (dd, J = 10.36, 6.52 Hz, 1 H, CHCH2O), 4.47 (s, 2 H, CH2O), 6.72 (bs, Imi-
5H), 7.17-7.21 (m, 2 H, aromatic), 7.41-7.45 (m, 2 H, aromatic), 7.46 (bs, 1 H, Imi-2H), 8.89 
(bs, 1 H, Imi-NH); 13C NMR (75.5 MHz CDCl3): δ = 12.0 (-, CH2, cyclopropane), 14.1 (+, 
CH, cyclopropane), 20.5 (+, CH, cyclopropane), 71.8 (-, CHCH2O), 73.6 (-, CH2O), 115.2 (+, 
CH, Imi-C5, broad), 121.5 (+, Cquat, C-Br), 129.4 (+, CH, aromatic), 131.5 (+, CH, aromatic), 
134.5 (+, CH, Imi-C2, broad), 137.5 (+, Cquat, aromatic), 138.9 (+, Cquat, Imi-C4, broad); IR 
(neat): ~ν  = 3060, 2854, 1722, 1592, 1486, 1402, 1211, 1088, 1069,1011, 941, 795, 757, 657, 
625 cm-1; MS (EI +VE): m/z (%) = 308.1/306.1 (4.6/4.8) [M•+], 227.1 (8.5), 170.9/169.0 
(62.5/62.0), 137.1 (48.8), 122.1 (92.6), 107.1 (100) [C8H9+] 94.1 (57.8), 80.1, (45.6), 53.1 
(14.6); HRMS calcd for C14H15BrN2O, 306.0368. Found 306.0362. 
 
4-(((2-(1H-imidazol-4-yl)cyclopropyl)methoxy)methyl)benzonitrile hydrochloride (320):  
 
N
N
H
O
CN.HCl
 
 
To a solution of 313 (45 mg 0.091 mmol) in EtOH (2 mL) at 0 °C was slowly added 2N HCl 
(2 mL). The reaction mixture was allowed to come to RT and stirred for 12 h. Ether (6 mL) 
was added and the reaction mixture was extracted in the (3 × 6 mL). The aqueous layer was 
concentrated to leave a hydrochloride salt as a white solid (92 %). 
Rf  (SiO2, MeOH/EtOAc/NH3 1:9:0.2) = 0.25; m.p. = 158-159 °C; 1H NMR (300 MHz 
CD3OD): δ = 1.01-1.11 (m, 2 H, CH2, cyclopropane), 1.51-1.62 (m, 1 H, CHCH2O), 1.94-
1.99 (m, 1 H, CHCHCH2), 3.49 (dd, J = 10.36, 6.86 Hz, 1 H, CHCH2O), 3.66 (dd, J = 10.36, 
5.90 Hz, 1 H, CHCH2O), 4.64 (s, 2 H, CH2O), 7.26 (d, J = 1.33 Hz, Imi-5H), 7.52-7.55 (m, 2 
H, aromatic), 7.69-7.72 (m, 2 H, aromatic), 8.74 (d, J = 1.33 Hz, Imi-2H); 13C NMR (75.5 
MHz CD3OD): δ =  12.0 (+, CH, cyclopropane), 12.5 (-, CH2, cyclopropane), 22.2 (+, CH, 
cyclopropane), 72.8 (-, CHCH2O), 73.9 (-, CH2O), 112.3 (+, Cquat, CCN), 115.8 (+, CH, Imi-
C5), 119.7 (+, Cquat, CN), 129.2 (+, CH, aromatic), 133.4 (+, CH, aromatic), 134.4 (+, CH, 
Imi-C2), 136.9 (+, Cquat, Imi-C4), 145.8 (+, Cquat, aromatic); IR (neat): ~ν  = 3144, 3092, 3006, 
2941, 2763, 2227, 1730, 1618, 1474, 1450, 1403, 1369, 1277, 1203, 1171, 1014, 840, 813, 
626 cm-1; MS (EI +VE): m/z (%) = 253.2 (25.5) [M•+], 137.1 (30.6) [M•+ – NC-C6H4-CH2•], 
122.1, (68.5), 116.1 (76.8) [NC-C6H4CH2+], 107.1 (100) [C6H7N2+, imidazole cyclopropyl], 
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94.1 (95.1), 80.0 (60.7), 53.0 (21.9); HRMS calcd for C15H15N3O, 253.1215. Found 
253.1216. 
 
Phenyl-N-((2-(1-trityl1H-imidazol-4-yl)cyclopropyl)methyl)methanamine (326):  
 
N
N
NH
Ph3C
 
 
To a solution of 325 (100 mg 0.263 mmol) together with powdered activated molecular sieves 
(100 mg) was added freshly distilled benzaldehyde (30.76 mg, 29.5 µL, 0.290 mmol). The 
reaction mixture was stirred overnight filtered and dissolved in MeOH (5 mL). The reaction 
mixture was cooled to 0 °C and NaBH4 (24.9 0.657 mmol) was added. The reaction mixture 
was allowed to come to RT and stirred further for 12 h. quenched with sat. ammonium 
chloride and the reaction mixture was extracted with CH2Cl2 (4 × 8 mL). Combined organic 
layers were washed with saturated aq NaHCO3 (5 mL) and brine (5 mL) dried over MgSO4. 
Filtration and evaporation of the solvent afforded the crude product was purified by column 
chromatography (CH2Cl2/MeOH 95:5) to obtain 326 ( 45 mg, 36%). 
Rf  (SiO2, EtOAc/hexanes 7:3) = 0.23; thick oil; 1H NMR (300 MHz CDCl3): δ = 0.68-0.75 
(m, 1 H, CHH, cyclopropane), 0.92-0.98 (m, 1 H, CHH, cyclopropane), 1.34-1.44 (m, 1 H, 
CHCH2O), 1.64-1.70 (m, 1 H, CHCHCH2), 2.66 (d, J = 6.96 Hz, 2 H, CHCH2N), 4.87 (bs, 3 
H, CH2N + NH), 6.51 (d, J = 1.30 Hz, Imi-5H), 7.08-7.15 (m, 6 H, aromatic), 7.24-7.37 (m, 
15 H, aromatic + Imi-2H); 13C NMR (75.5 MHz CDCl3): δ = 12.9(-, CH2, cyclopropane), 
16.0 (+, CH, cyclopropane), 20.4 (+, CH, cyclopropane), 52.6 (-, CH2N), 52.8 (-, CH2N), 75.2 
(+, Cquat, CPh3), 116.9 (+, CH, Imi-C5), 127.4 (+, CH, aromatic), 128.0 (+, CH, aromatic), 
128.1 (+, CH, aromatic), 128.6 (+, CH, aromatic), 128.7 (+, CH, aromatic), 129.9 (+, CH, 
aromatic), 138.3 (+, CH, Imi-C2), 138.5 (+, Cquat, Imi-C4), 142.2 (+, Cquat, aromatic), 142.5 
(+, Cquat, aromatic); IR (neat): ~ν  = 3359, 3061, 2927, 1468, 1489, 1445, 1285, 1223, 1156, 
1128, 1084, 1034, 907, 870, 825, 749, 700, 658 cm-1; MS (CI, NH3): m/z (%) = 470.2 (100) 
[M + H+], 386.0 (5.0), 243.1 (70.3) [CPh3+], 228.1 (53.4). 
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(2-(1H-imidazol-4-yl)cyclopropyl)-N-benzylmethanamine dihydrochloride (327):  
 
N
N
H
N
H
2HCl
 
 
To a solution of 326 (60 mg 0.128 mmol) in MeOH (2 mL) was added 2N HCl (2 mL). The 
reaction mixture was refluxed for 1.5 h. cooled to RT Ether (6 mL) was added and the 
reaction mixture was extracted in ether (3 × 6 mL). The aqueous layer was separated and 
concentrated to leave a hydrochloride salt as a white solid (96 %). 
Rf  (SiO2, MeOH/EtOAc/NH3 3:7:0.3) = 0.23; thick oil (hygroscopic); 1H NMR (300 MHz 
CD3OD): δ = 1.25 (m, 2 H, CH2, cyclopropane, broad), 1.67 (m, 1 H, CHCH2O, broad), 2.22 
(m, 1 H, CHCHCH2, broad), 3.19 (m, 2 H, CHCH2O, broad), 4.28 (m, 2 H, CH2O, broad), 
7.37 (bs, 1 H, Imi-5H), 7.44 (m, 3 H, aromatic, broad), 7.59 (m, 2 H, aromatic, broad), 8.79 
(bs, 1 H, Imi-2H); 13C NMR (75.5 MHz CD3OD): δ = 13.6 (+, CH, cyclopropane), 13.8 (-, 
CH2, cyclopropane), 18.3 (+, CH, cyclopropane), 51.9 (-, CHCH2O), 52.6 (-, CH2O), 116.9 
(+, CH, Imi-C5), 130.4 (+, CH, aromatic), 130.8 (+, CH, aromatic), 131.4 (+, CH, aromatic), 
132.6 (+, Cquat, Imi-C4), 134.9 (+, CH, Imi-C2), 135.6 (+, Cquat, aromatic); IR (Film): ~ν  = 
3382 (broad), 3099, 3003, 2957, 2798, 2612, 1625, 1494, 1454, 1206, 1175, 1085, 1019, 830, 
752, 700 cm-1; MS (EI +VE): m/z (%) = 227.1 (2.7) [M•+], 186.1 (14.6), 146.1 (6.6), 132.1 
(11.8), 122.1 (34.8) [M - C7H7N], 108.0 (10.9) [M - C6H9N], 106.0 (14.1), 95.0 (28.9), 91.0, 
(100) [C7H7+], 65.0 (13.1) HRMS calcd for C14H17N3, 227.1422. Found 227.1421. 
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4 Appendix of NMR and X-ray data 
 
 
4.1 NMRs 
 
 
1HNMR-Spectra   (top of the page) 
 
 
13CNMR-Spectra   (bottom of the page) 
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(E)-methyl 3-(1-((2methoxyethoxy)methyl)1H-Imidazol-4-yl)acrylate (171) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
CO2Me
MEM
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N-methoxy-N-methyl-3,3-diphenylpropanamide (174) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
172.5
(ppm)
0102030405060708090100110120130140150160170180190
 
 
O
N
O
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(E)-methyl3-(1-((2methoxyethoxy)methyl)-2-(3,3-diphenylpropanoyl)-1H-Imidazol-4-
yl)acrylate (175) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
CO2Me
O MEM
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(E)-methyl 3-(1-((2-methoxyethoxy)methyl)-2-(3,3-diphenylpropanoyl)-1H-imidazol-5-
yl)acrylate (176) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
O MEM
CO2Me
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Benzyl(1S,2S)-1-(methoxycarbonyl)-2-(1-((2-methoxyethoxy)methyl)-2-(3,3-
diphenylpropanoyl)-1H-imidazol-4-yl)-2-hydroxyethylcarbamate (183) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
CO2Me
O MEM
OH
NHCbz
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Benzyl (1R,2S)-2-(methoxycarbonyl)-1-(1-((2-methoxyethoxy)methyl)-2-(3,3-
diphenylpropanoyl)-1H-imidazol-4-yl)-2-hydroxyethylcarbamate (184) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
CO2Me
O MEM
NHCbz
OH
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Methyl3-(1-((2-methoxyethoxy)methyl)-2-(3,3-diphenylpropanoyl)-1H-imidazol-4-yl)-2-
amino-3-hydroxypropanoate (183-a) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
CO2Me
O MEM
OH
NH2
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Tert-butyl (1S,2S)-1-(methoxycarbonyl)-2-(1-((2-methoxyethoxy)methyl)-2-(3,3-
diphenylpropanoyl)-1H-imidazol-4-yl)-2-hydroxyethylcarbamate (189) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
CO2Me
O MEM
OH
NHBoc
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(2S,3S)-methyl3-(2-(3,3-diphenylpropanoyl)-1H-imidazol-4-yl)-2-amino-3-
hydroxypropanoatedihydrochloride (191) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
H
NH2
Ph
OPh
OH
CO2Me
2HCl
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 (E)- 3-(1-((2-methoxyethoxy)methyl)-1H-Imidazol-4-yl)prop-2-en-1-ol (177) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
MEM
OH
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1-((2-methoxyethoxy)methyl)-4-((E)- 3-(benzyloxy)prop-1-enyl)-1H-Imidazole (178) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
MEM
OBn
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1-(1-((2methoxyethoxy)methyl)4-((E)-3-(benzyloxy)prop-1-enyl)-1H-Imidazol -2-yl)3,3-
diphenylpropan-1-one (179) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
MEM
OBn
O
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Compound (180) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
MEM
OTBDMS
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Compound (181) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
MEM
OTBDMS
O
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1-(1-((2-methoxyethoxy)methyl)-4-((E)-3-hydroxyprop-1-enyl)-1H-imidazol-2-yl)-3,3 
diphenylpropan-1-one (182) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
MEM
OH
O
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Compound (194) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
MEM
OH
O
OH
NHBoc
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1-(4-((1S,2R)-2-amino-1,3-dihydroxypropyl)-1H-imidazol-2-yl)3,3-diphenylpropan-1-
onedihydrochloride (196) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
H
OH
O
NH2
HO
2HCl
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methyl3-(1-((2methoxyethoxy)methyl)-2-(3,3-diphenylpropanoyl)-1H-Imidazol-4 
yl)propanoate (197) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
CO2Me
O MEM
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3-(1-((2methoxyethoxy)methyl)-2-(3,3-diphenylpropanoyl)-1H-Imidazol-4-
yl)propanoicacid (198) 
 
(ppm)
910
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
CO2H
O MEM
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benzyl2-(1-((2methoxyethoxy)methyl)-2-(3,3-diphenylpropanoyl)-1H-imidazol-4-
yl)ethylcarbamate (199) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
NHCbz
O MEM
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1-(1-((2methoxyethoxy)methyl)-4-(2-aminoethyl)-1H-Imidazolyl)-3,3-diphenylpropan-1-
one (200) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
NH2
O MEM
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1-(4-(2-aminoethyl)-1H-Imidazolyl)-3,3-diphenylpropan-1-onedihydrochloride (201) 
 
(ppm)
2.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
H
NH2
O
2HCl
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1,3-bis(2-(1-((2methoxyethoxy)methyl)-2-(3,3-diphenylpropanoyl)-1H-imidazol-4-
yl)ethyl)urea (203) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
H
N
Ph
Ph
O
H
N
O N
N
Ph
Ph
O
MEM MEM
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1,3-bis(2-(2-(3,3-diphenylpropanoyl)-1H-imidazol-4-yl)ethyl)urea (204) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
HN
H
N
Ph
Ph
O
H
N
O NH
N
Ph
Ph
O
Appendix H1 and H3-Receptor 175 
  
tert-butyl 2-(1-((2-methoxyethoxy)methyl)-2-(3,3-diphenylpropanoyl)-1H-imidazol-4-
yl)ethylcarbamate (212) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
NHBoc
O MEM
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tert-butyl 2-(1-((2-methoxyethoxy)methyl)-2-(1-hydroxy-3,3-diphenylpropyl)-1H-
imidazol-4-yl)ethylcarbamate (217) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
NHBoc
OH MEM
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1-(1-((2-methoxyethoxy)methyl)-4-(2-aminoethyl)-1H-imidazol-2-yl)-3,3-
diphenylpropan-1-ol hydrochloride (218) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
NH2
OH MEM
.HCl
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tert-butyl 2-(1-((2-methoxyethoxy)methyl)-2-(4,4-diphenylbut-1-en-2-yl)-1H-imidazol-4-
yl)ethylcarbamate (213) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
NHBoc
CH2 MEM
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2-((4-(2-aminoethyl)-2-(4,4-diphenylbut-1-en-2-yl)-1H-imidazol-1-yl)methoxy)ethanol 
hydrochloride (215)) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
NH2
Ph
Ph CH2
HCl
O
OH
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tert-butyl 2-(1-((2-methoxyethoxy)methyl)-2-(4,4-diphenylbutan-2-yl)-1H-imidazol-4-
yl)ethylcarbamate (214) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
NHBoc
CH3 MEM
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methyl 3-(1-((2-methoxyethoxy)methyl)-2-(4,4-diphenylbut-1-en-2-yl)-1H-imidazol-4-
yl)propanoate (211) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
CO2Me
CH2 MEM
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methyl 3-(1-((2-methoxyethoxy)methyl)-2-(3,3-diphenylpropanoyl)-1H-imidazol-5-
yl)propanoate (205) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
O MEM
O
O
Appendix H1 and H3-Receptor 183 
  
3-(1-((2-methoxyethoxy)methyl)-2-(3,3-diphenylpropanoyl)-1H-imidazol-5-yl)propanoic 
acid (206) 
 
(ppm)
10.5
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
O MEM
OH
O
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benzyl 2-(1-((2-methoxyethoxy)methyl)-2-(3,3-diphenylpropanoyl)-1H-imidazol-5-
yl)ethylcarbamate (207) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
O MEM
NHCbz
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tert-butyl 2-(1-((2-methoxyethoxy)methyl)-2-(3,3-diphenylpropanoyl)-1H-imidazol-5-
yl)ethylcarbamate (208) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
O MEM
NHBoc
Appendix H1 and H3-Receptor 186 
  
tert-butyl 2-(1-((2-methoxyethoxy)methyl)-2-(1-hydroxy-3,3-diphenylpropyl)-1H-
imidazol-5-yl)ethylcarbamate (209) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
OH MEM
NHBoc
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tert-butyl 2-(1-((2-methoxyethoxy)methyl)-2-(2-methyl-3,3-diphenylpropanoyl)-1H-
imidazol-5-yl)ethylmethylcarbamate (223) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
2530354045
(ppm)
156
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
O
N
Boc
CH3
CH3MEM
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2-methyl-1-(4-(2-(methylamino)ethyl)-1H-imidazol-2-yl)-3,3-diphenylpropan-1-one 
dihydrochloride (224) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
H
H
N
O
CH3 CH3
2HCl
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tert-butyl 2-(2-(3,3-diphenylpropanoyl)-1H-imidazol-4-yl)ethylcarbamate(219) 
 
(ppm)
1112
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
N
N
H
NHBoc
O
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tert-butyl 2-(2-(1-hydroxy-3,3-diphenylpropyl)-1H-imidazol-4-yl)ethylcarbamate (220) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
H
NHBoc
OH
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1-(4-(2-aminoethyl)-1H-imidazol-2-yl)-3,3-diphenylpropan-1-ol dihydrochloride (221) 
 
(ppm)
15.0
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
H
NH2
OH
2HCl
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1-(4-((E)-3-(1-trityl-1H-imidazol-4-yl)allyloxy)phenyl)ethanone (285) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
O
Ph3C
O
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1-(4-((E)-3-(1H-imidazol-4-yl)allyloxy)phenyl)ethanone (287) 
 
(ppm)
12.0
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
H
O
O
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1-(4-((E)-3-(1H-imidazol-4-yl)allyloxy)phenyl)ethanone oxime (293) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
H
O
N OH
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1-(4-(prop-2-ynyloxy)phenyl)ethanone (290) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
O
O
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1-(4-(3-(1-trityl-1H-imidazol-4-yl)prop-2-ynyloxy)phenyl)ethanone (291) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
O
O
N
N
Ph3C
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1-(4-(3-(1H-imidazol-4-yl)prop-2-ynyloxy)phenyl)ethanone (292) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
O
O
N
HN
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1-(4-(3-(1H-imidazol-4-yl)prop-2-ynyloxy)phenyl)ethanone (294) 
 
(ppm)
12.0
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
O
N
N
HN
OH
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1-(4-((Z)-3-(1H-imidazol-4-yl)allyloxy)phenyl)ethanone (295) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
H
O
O
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1-(4-(1-(1-trityl-1H-imidazol-4-yl)but-3-enyloxy)phenyl)ethanone (301) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
O
O
Ph3C
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1-(4-(1-(1H-imidazol-4-yl)but-3-enyloxy)phenyl)ethanone (302) 
 
(ppm)
9.6
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
H
O
O
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4-(3-(4-iodobenzyloxy)propyl)-1-trityl-1H-imidazole (304) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
O
Ph3C
I
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4-(3-(4-iodobenzyloxy)propyl)-1H-imidazole or (iodoproxyfan)(248) 
 
(ppm)
11.4
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
H
O
I
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4-((E)-3-(4-iodobenzyloxy)prop-1-enyl)-1-trityl-1H-imidazole (305) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
O
Ph3C
I
Appendix H1 and H3-Receptor 205 
  
4-((E)-3-(4-iodobenzyloxy)prop-1-enyl)-1H-imidazole (306) 
 
(ppm)
9.810.0
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
H
O
I
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(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
4-(2-((benzyloxy)methyl)cyclopropyl)-1-trityl-1H-imidazole (307) 
 
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
 
N
N
O
Ph3C
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4-(2-((4-(methyl)benzyloxy)methyl)cyclopropyl)-1-trityl-1H-imidazole (308) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
O
Ph3C
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4-(2-((4-(trifluoromethyl)benzyloxy)methyl)cyclopropyl)-1-trityl-1H-imidazole (309) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
O
Ph3C
CF3
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4-(2-((4-(trifluoromethoxy)benzyloxy)methyl)cyclopropyl)-1-trityl-1H-imidazole (310) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
O
Ph3C
OCF3
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4-(2-((2,4,6-trimethyl)benzyloxy)methyl)cyclopropyl)-1-trityl-1H-imidazole (321) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
O
Ph3C
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4-(2-((4-bromobenzyloxy)methyl)cyclopropyl)-1-trityl-1H-imidazole (312) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
O
Ph3C
Br
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4-(2-((4-iodobenzyloxy)methyl)cyclopropyl)-1-trityl-1H-imidazole (311) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
O
Ph3C
I
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4-(((2-(1-trityl-1H-imidazol-4-yl)cyclopropyl)methoxy)methyl)benzonitrile (313) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
O
Ph3C
CN
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4-(2-((benzyloxy)methyl)cyclopropyl)-1H-imidazole (314) 
 
(ppm)
9.510.0
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
H
O
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4-(2-((benzyloxy)methyl)cyclopropyl)-1H-imidazole (314) 
 
(ppm)
9.09.5
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
(ppm)
120130140
 
 
N
N
H
O
Appendix H1 and H3-Receptor 216 
  
4-(2-((4-(trifluoromethyl)benzyloxy)methyl)cyclopropyl)-1H-imidazole (316) 
 
(ppm)
11.0
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
H
O
CF3
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4-(2-((4-(trifluoromethoxy)benzyloxy)methyl)cyclopropyl) -1H-imidazole (317) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
H
O
OCF3
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4-(2-((4-iodobenzyloxy)methyl)cyclopropyl)-1H-imidazole (312) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
H
O
I
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4-(2-((4-bromobenzyloxy)methyl)cyclopropyl)-1H-imidazole (319) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
H
O
Br
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4-(((2-(1H-imidazol-4-yl)cyclopropyl)methoxy)methyl)benzonitrile hydrochloride (320) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
H
O
CN
.HCl
Appendix H1 and H3-Receptor 221 
  
Phenyl-N-((2-(1-trityl1H-imidazol-4-yl)cyclopropyl)methyl)methanamine (326) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
N
H
Ph3C
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(2-(1H-imidazol-4-yl)cyclopropyl)-N-benzylmethanamine dihydrochloride (327) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
N
N
H
N
H
2HCl
Appendix H1 and H3-Receptor 223 
  
4.2 X-ray crystallographic data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(E)-methyl3-(1-((2methoxyethoxy)methyl)-2-(3,3-diphenylpropanoyl)-1H-Imidazol-4-
yl)acrylate (175): 
CCDC 606450 
 
 
 
 
 
 
 
 
 
 
(E)-methyl 3-(1-((2-methoxyethoxy)methyl)-2-(3,3-diphenylpropanoyl)-1H-imidazol-5-
yl)acrylate (176): 
CCDC 606449 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tert-butyl (1S,2S)-1-(methoxycarbonyl)-2-(1-((2-methoxyethoxy)methyl)-2-(3,3-
diphenylpropanoyl)-1H-imidazol-4-yl)-2-hydroxyethylcarbamate (189): 
CCDC 286008
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